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Cognitive decline and dementia
With the improvements in medical care and the increase in life expectancy, the older 
population is expanding, especially the group of  the oldest-old (aged>85 years).1 The 
expansion in the number of  older adults will consequently result in an increase in age-related 
health problems and diseases).1 One of  the functions that gradually declines during normal 
aging is cognitive function.2 
Cognitive function refers to the processes involved in receiving, processing, storing, 
and using information that enters the brain via sensory input, and the complex mental 
functions that enable individuals to exert control over their environment.3 Cognitive 
functions are often grouped as cognitive domains, including memory, learning, attention 
and concentration, language, executive functions (i.e. higher-order cognitive functions, 
such as planning, self-monitoring, problem solving), and visual and spatial skills. Growing 
old is regularly accompanied by problems related to speed of  processing, solving complex 
problems, and remembering new information.4 However, not all cognitive functions are 
affected; those requiring higher mental effort, speed demands, novelty, and information 
complexity deteriorate more than functions related to behavioural patterns and previously 
acquired routines and expertise.2, 5 The rate of  decline differs between people.6 Mild cognitive 
impairment (MCI) is a rate of  decline that goes beyond the range of  the normal aging 
process, and may eventually convert to dementia,7 as is illustrated in Figure 1. Within 5 years 
after diagnosis, approximately half  of  the diagnosed MCI patients develop dementia.
Dementia refers to the progressive deterioration of  cognitive functions and loss of  
functional independence as a result of  neuronal loss or damage to the connections between 
neurons.8 Other neuropsychiatric symptoms may be present as well, such as apathy, agitation, 
Figure 1 Illustration of  decline in cognitive functioning and brain volume, which is different between individuals 
(not based on absolute numbers)(figure adapted from Dik, 2002)9 
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and depression. Prevalence of  dementia is around 0.5% in the worldwide population, and 
total numbers are expected to nearly double from 35.6 million people in 2011 to 65.7 million 
in 2030, and to around 115 million in 2050.10 The presence of  dementia increases after the 
age of  85 years; 22% of  the 85-years and older and even 43% of  the 90-years old suffer 
from dementia.10 In the Netherlands, around 260.000 people are diagnosed with dementia.11 
Dementia is a major cause of  disability and dependency among elderly people and has an 
enormous impact on the quality of  life of  the patient, caregivers and family. In addition, 
the costs of  the disease are huge, reaching €177 billion per year in Europe.12 The present 
medications focus on slowing down declining processes and the effectiveness is uncertain.10 
Although research in finding a cure for dementia is progressing and new therapies are being 
tested in various clinical trial stages, a long journey is still ahead.
Dementia subtypes
Dementia subtypes are based on different pathologies and symptoms. Alzheimer’s 
disease (AD) is the most diagnosed type of  dementia, responsible for 60-70% of  the 
dementia cases.10 Other major subtypes are vascular dementia, Lewy body dementia and 
frontotemporal dementias. 
• AD is characterized by extra-neuronal β-amyloid plaques, which are abnormal protein 
deposits, and intra-neuronal neurofibrillary tangles, which consist of  phosphorylated tau 
fibers. While the disease can start many years before symptoms are apparent, the disease 
often manifests at an older age (late onset dementia). The first symptoms are usually 
related to memory problems and acquiring new information, which are especially related 
to damage in the hippocampus.13 
• Vascular dementia is related to a reduced or blocked blood flow to the brain. The brain 
is one of  the most perfused organs and is sensitive to changes in blood flow, influencing 
the supply of  oxygen and nutrients to brain cells. Small strokes or transient ischemic 
attacks can therefore cause damage to the brain. Vascular dementia often starts in the 
prefrontal area, causing particularly problems with higher-order cognitive functions.14 
• Lewy body dementia is characterized by so-called Lewy bodies and is closely related 
to Parkinson’s disease. Lewy bodies are abnormal circular protein structures and are 
associated with the depletion of  the neurotransmitters dopamine and acetylcholine, 
resulting in problems with thinking, executive functions, and behaviour.15
• Frontotemporal dementias affect mainly the frontal and temporal lobes and therewith 
disturb social behaviour and personality; onset often appears to be at a younger age, 
around 40 to 65 years.16
Often a mixture of  pathologies is seen in a brain autopsy,17, 18 which makes the contribution 
of  different pathologies to the total number of  dementia patients somewhat ambiguous. 
Although mixed dementia is often suspected, diagnosis whilst the patient is alive is 
infrequent.19,10
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Neuropsychological assessment 
Cognitive performance comprises many different functions and can be measured by 
neuropsychological tests. These measure cognitive processes that are important for functions 
in daily life and should be able to distinguish different states and individuals’ competencies.3, 
20, 21 In almost all studies discussed in this thesis, widely used and well-validated classic paper-
pencil tests were administered. In addition, computer tests were used to measure reaction 
times. Cognitive domains that are represented are episodic memory, attention and working 
memory, information processing speed, and executive functions. Table 1 gives an overview 
of  all neuropsychological tests that were used in the research described in this thesis and 
which cognitive function domain they cover.
Structural MRI
In addition to the cognitive function tests, we used another non-invasive method as a 
measure of  brain health; brain volume was assessed by Magnetic Resonance Imaging 
(MRI). MRI scanners use a strong magnetic field and radiofrequencies to obtain images 
of  the body, based on hydrogen atoms that generate a signal that is different for various 
bodily tissues. Structural brain scans give information on the volumes of  grey and white 
matter and cerebrospinal fluid of  the total brain and of  more specific brain regions. Grey 
matter predominantly contains neuronal bodies, whereas white matter contains mainly long 
myelinated axons. Whole brain atrophy is an obvious prominent change during normal aging 
that already starts slowly around the age of  30.5, 22 Hippocampal and total brain atrophy can 
be valid markers for the progression of  AD.23 Associations or effects of  nutrients observed 
in structural MRI scans may be expected to have long-term consequences on central nervous 
system functions.24
13
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Table 1 Overview of  neuropsychological tests that were used in this thesis
Domains and 
tests
Explanation Scoring Chapter
Global cognitive function
Mini-Mental State 
Examination 31
Basic screening tool with a variety of  questions and tasks. Number of  correct 
answers, max 30 
points. 
6
Episodic memory The ability to encode and retrieve events and experiences with a specific temporal or spatial 
context
RAVLT, direct 
recall 32
Recall as many words from a 15-word list that is read 
aloud to the participant. This is repeated five times (three 
times in Chapter 3)
Number of  correct 
reproduced words, 
max 75 (and 45 in 
chapter 3)
3, 4, 5, 6
RAVLT, delayed 
recall 
Twenty minutes after the last repetition of  RAVLT, the 
participant is asked to recall the words again. 
Number of  correct 
reproduced words, 
max 15 points
3, 4, 5, 6
RAVLT, delayed 
recognition
Recognize words from a list with words of  the RAVLT 
and other words.
Number of  correct 
words recognized, 
max 30 points
4, 5, 6
Story Recall, direct 
recall
Recall as many details of  short story that is read aloud to 
the participant.
Number of  correct 
sentences reproduced, 
max 21 points
3
Story recall, delayed 
recall
After a 20-25 minutes delay, the participant is asked to 
recall as many details of  the story again.
Number of  correct 
sentences reproduced, 
max 21 points
3
Paired Associate 
Learning (associate 
memory)
A list of  word pairs is read out by the examiner. This is 
followed by the examiner reading the first word of  the 
pair, which the participant has to complete with the other 
word of  the pair. 
Number of  correct 
pairs formed, max 21 
points
3
Attention and 
Working memory
Resembles the ability of  online maintenance of  information for a brief  period of  time
Digit Span forward 
(attention) 33
The examiner verbally presents a series of  digits, and 
the participant has to repeat the digits verbatim. The 
series of  digits increases by one, until the participant 
consecutively fails two trials of  the same digit span 
length.
Number of  correct 
recalls, max 16 points
3, 4, 5, 6
Digit Span 
backward (working 
memory)
The same as the Digit Span forward test, but now the 
participant has to repeat the digits in reversed order.
Number of  correct 
recalls, max 14 points
3, 4, 5, 6
Information 
processing speed
The ability to process information and to respond accurately under time pressure
Symbol-Digit 
and Letter-Digit 
Substitution Test 34
Nine different symbols are assigned a unique digit 
(1–9), presented in a key at the top of  the test form. 
The participants are presented with a random series 
of  symbols in cells and are instructed to add the 
corresponding digit to the symbols. In Chapter 3, letters, 
not symbols, had to be recoded into digits.
The number of  
correctly copied 
corresponding digits 
in 90 seconds (60 
seconds in Chapter 
3) will be recorded, 
max 125
3, 6
Table continues on the next page
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Domains and 
tests
Explanation Scoring Chapter
Trail Making Test 
part A 35
Participant has to connect shuffled numbers in ascending 
order.
Time (s) needed to 
finish the task, lower 
scores indicate better 
performance
3, 4, 5, 6
Stroop part I and 
II 36
Part I consists of  reading a card with the words of  colors 
“red”, “blue”, “yellow” and “green” as fast as possible. 
Part II consists of  naming strips of  these colors. 
Time (s) needed to 
finish the task, lower 
scores indicate better 
performance
3, 4, 5, 6
TAP – alertness 
(computer task) 37
The participant has to react as fast as possible when the 
stimulus (an ‘X’) appears on the computer screen. Prior 
to half  of  the stimuli, a beep was played
Time to react (ms). 
Lower scores indicate 
better performance
3
TAP – Letters and 
digits (computer 
task)
Per trial, a letter and a digit appear on both sides of  the 
computer screen. The participant has to react as fast as 
possible on the side where the stimulus (either a letter or 
a digit) appears on the computer screen. 
Time to react (ms). 
Lower scores indicate 
better performance
3
Reaction time test 
(computer task) 38
This test was a four-choice reaction task, with index and 
middle fingers of  both hands operating four response 
keys. Goal was to react as quickly and accurately as 
possible to a single plus-sign on the screen, matching one 
of  the four fingers.
Time to react (ms). 
Lower scores indicate 
better performance
4, 5
Executive 
functions
Resembling the higher-order functions that are needed for among others planning, organizing, 
strategizing, and problem solving
Trail Making 
Test part B 
(concept shifting 
interference)
Participant has to connect numbers and letters in 
alternating order (1-A-2-B etcetera)
Time (s) needed to 
finish the task, lower 
scores indicate better 
performance
3, 4, 5, 6
Stroop III 
(susceptibility 
to behavioral 
interference) 
Names of  colors are printed in a different color of  ink, 
interchangeably. The participant has to name the colors 
of  the ink, instead of  reading the words, which lead to a 
so called “color-word interference effect”.
Time (s) needed to 
finish the task, lower 
scores indicate better 
performance. 
3, 4, 5, 6
Verbal Fluency 
(language) 39
Participants have to name as many words as possible in 
1 minute, starting with a specific letter, or words of  a 
specific category.
Number of  correct 
words
3, 4, 5, 6
TAP-alternating 
(computer task) 
(flexibility)
Per trial, a letter and a digit appears on both sides of  the 
computer screen. The participant has to react as fast as 
possible alternating on the side of  the letter and on the 
side of  the digit. This involves both reaction time and 
attention.
Time to react (ms). 
Lower scores indicate 
better performance
3
Notes: RAVLT, Rey Auditory Verbal Learning Test; TAP, Test for Attentional Performance battery.
Table 1 Overview of  neuropsychological tests that were used in this thesis (continued)
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Risk factors for dementia and 
cognitive decline
Dementia is a major challenge of  this century and it is therefore of  great importance to 
identify risk factors for dementia that can be modified. It has been suggested that an array 
of  interrelated mechanisms between genetics and environment are the cause of  the multi-
factorial disease dementia.25 Several factors have been proposed to influence the risk of  
dementia and cognitive decline (Figure 2). Many of  those factors are based on the cognitive 
reserve theory. This theory suggests that a reserve capacity can be built during life, with 
more brain volume and neuronal connections that can be used later in life to compensate 
for cognitive decline, and with a better resilience (coping with stressors or adverse events). 
Environmental factors during specific periods of  the lifespan may, for instance, stimulate 
the production of  new neurons, which can be sustained when one gets older.2, 26 The reserve 
theory may explain why some people with pathologies of  dementia do not experience 
cognitive complaints, whereas others already manifest many cognitive deficits with only few 
pathologies.26 
Endogenous factors
Endogenous factors for cognitive decline and dementia include age and being female. The 
incidence of  AD is 1.5-3 times higher in women than in men,27 and especially women after 
the age of  80 years have a higher risk compared to men (hazard ratio of  1.7).28 Having the 
apolipoprotein E-ε4 allele increases the risk for dementia, in particular AD, ranging from an 
odds ratio (OR) of  2.6 with one copy of  the ε4 allele to an OR of  14.9 with two copies.29, 30 
Figure 2 Risk and protective factors for cognitive decline and dementia. Round shapes are non-modifiable factors, 
square shapes are modifiable, and triangles are the proxy measures and outcome.
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Socio-demographic factors
Socio-demographic factors include marital status, living situation, and social contacts.40, 41 
Married men and women 40, 42 and people who live together 43 have a lower risk of  developing 
dementia. It has been suggested that being surrounded by other people enhances socially 
and mentally stimulating activities, and that these stimulating activities may be protective 
for neuronal degeneration by maintenance or even an increase of  growth of  neurons.42, 44 In 
addition, high education, high IQ, and occupational attainment can increase brain reserve 
and therewith decrease the risk on dementia.26
Lifestyle-related factors
Vascular health may affect cerebral blood flow and brain health, and therefore, 
cardiovascular risk factors also affect the risk of  cognitive decline and dementia. These 
factors include midlife hypertension, diabetes, hypercholesterolemia, atherosclerosis, and 
hyperhomocysteinemia.14, 45, 46 Age-related differences in risk size have been shown.47 For 
instance, hypertension in midlife confers a higher risk for dementia than hypertension in late 
life.48 Other risk factors include smoking, midlife overweight and obesity, physical activity, 
stress and depression.49, 45 Heavy alcohol use increases the risk on dementia,50 whereas 
moderate alcohol use may be protective.51 A recent report showed that half  of  the dementia 
patients can be explained by lifestyle-related factors, including diabetes, hypertension, obesity, 
depression, physical inactivity, smoking, and cognitive inactivity/education.45 
Nutrition
Nutrition is another lifestyle factor that may be important for cognitive development and 
cognitive decline and is the main focus of  this thesis. Epidemiological studies have shown 
possible beneficial associations between fish intake and omega-3 fatty acids (EPA, DHA 
and α-linoleic acid), B-vitamins, vitamin D, iron, anti-oxidants such as flavonoids, vitamin 
C and E, magnesium, selenium, zinc, and copper with cognitive performance or decline.52, 
53 54 Negative associations have been shown for high caloric intake and high intake of  
saturated fatty acids.55, 56 However, these observational data have not yet been confirmed 
by randomized controlled trials (RCTs) because the trials are heterogeneous, often of  
short duration, include small numbers of  participants, and therefore rarely show significant 
beneficial effects on cognitive performance.
Possible mechanisms of  nutritional factors 
Nutrients pass the blood-brain barrier by active transport, facilitated diffusion, binding 
receptors, and ion channels, in order to achieve homeostasis in the brain.57 Nutritional 
factors may alter brain function and cognitive decline in different ways, and mechanisms are 
assumed to be different for various nutrients. The basic mechanisms are energy provision 
(glucose), building blocks (e.g. lipids and amino acids), delivery of  essential micronutrients 
for enzymatic and endocrine processes (e.g., B-vitamins, iron), and as a source of  bio- or 
psychoactive molecules, such as neurotransmitters, synaptic transmission, membrane fluidity, 
17
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and signal-transduction pathways.20, 58 Other mechanisms may act on:59-61 
• Vascular health and cerebral blood flow
• Metabolic health, e.g., diabetes, insulin insensitivity, high blood glucose levels, and 
obesity
• Oxidation: anti-oxidants can remove free radicals from the blood
• Inflammation: specific nutrients (e.g. B-vitamins) may reduce levels of  the pro-
inflammatory cytokine interleukin-1, whereas omega-3 unsaturated fatty acids may 
stimulate the production of  the anti-inflammatory cytokine interleukin-10 
• Atrophy: nutrition may play a role in the loss of  brain tissue by influencing the capacity 
of  neurogenesis in the hippocampal area
• β-amyloid and phosphorylated tau deposition: the production, accumulation, and 
clearance of  those proteins may be influenced by nutrition. 
Nutritional factors and their role in 
cognitive performance 
In the current thesis, different nutrients that might enhance cognitive performance or slow 
down cognitive decline have been investigated. These nutritional factors include glucose and 
sucrose, protein and resistance-type exercise with or without protein, and vitamin B12 and 
folic acid. Their possible role in cognitive performance will be introduced separately. 
Glucose and sucrose 
Glucose is the main fuel for many processes in the body through the generation of  
adenosine triphosphate (ATP). Pure glucose is directly absorbed into the bloodstream, 
starting already in the mouth. Sucrose can be absorbed after hydrolysis into glucose and 
fructose. In the cytosol of  a cell, glucose is broken down via glycolysis to pyruvate, which 
goes to the mitochondria where it is broken down to acetyl-coenzyme-A and ATP. The brain 
uses approximately 20% of  glucose in the body, despite the fact that the brain constitutes 
just 2% of  the total body weight.62 In the brain, only a limited amount of  glucose can be 
stored as glycogen in astrocytes, and a constant supply of  glucose is needed to cover the 
needs of  metabolic processes in the brain. The importance of  a good glucose supply to the 
brain is reflected in the associations between low and high blood glucose levels and negative 
outcomes on cognitive performance in diabetic patients.63 In rats, it has been shown that 
performing a difficult task increases glucose utilization in the brain,64 and glucose availability 
can then become a limiting factor.65 It has been suggested that the supply of  extra glucose 
inhibits this decrease and improves cognitive functioning. A glucose load has shown to 
improve cognitive performance in humans as well (summarized by Smith et al.).66 Elderly 
people may especially benefit from extra glucose. The decrease in extracellular glucose, 
mainly in the hippocampus – an important brain structure for episodic memory - is larger in 
18
older rats compared to younger rats.67 Furthermore, peripheral glucose regulation can change 
with aging.68
To obtain an overview of  studies that have investigated the effects of  a glucose load on 
cognitive performance in elderly populations, we executed a comprehensive literature review 
(Chapter 2), and the mechanisms are described in depth. Based on the research gap that we 
identified, we then designed and performed an intervention study examining the acute effects 
of  glucose and sucrose on various cognitive functions (Chapter 3).
Protein intake and exercise training
Dietary protein
Proteins consist of  amino acids, which are essential compounds for several functions in 
the body, as structural components and for different processes related to, among others, 
enzymes or hormones. Amino acids and small proteins are absorbed in the small intestine. 
The recommended dietary allowance for protein intake in the Netherlands is 0.8 g per kg 
bodyweight per day for adults.69 Around 3-10% of  community-dwelling elderly who are 
older than 70 years consume less than the average requirements (0.66 g per kg bodyweight 
per day) for protein.70, 71 Low intakes of  protein may negatively affect all sorts of  functions 
in the body, such as the loss of  skeletal muscle mass, weight management, bone health,72 
and possibly also cognitive functions. Elderly people are especially vulnerable to the possible 
negative health effects of  low dietary protein intake, due to their relatively low body protein 
stores compared to younger adults.73, 74 
A potential effect of  protein intake on cognitive performance may be attributed to the 
effects that single amino acids can have on the production of  neurotransmitters. A 
continuous supply of  amino acids is essential for the rate of  synthesis and release of  
neurotransmitters.75, 76 In older age, the production and release of  neurotransmitters may be 
hampered, which calls for extra amino acids at the possible site of  action.77, 78 Tryptophan 
and tyrosine are of  special interest, as these are precursors for serotonin (tryptophan), 
epinephrine, norepinephrine, and dopamine (tyrosine). Studies have shown that tryptophan 
loading improved memory performance, but worsened speed and motor performance, 
presumable because of  sleep promotion effects.79 Tyrosine administration counteracted the 
detrimental effects of  stressed conditions on cognitive performance, especially working 
memory. Other extra dietary amino acids, in particular L-cysteine, L-glutamic acid, and 
glycine, may increase the production of  glutathione,61, 80 which is an enzyme that may protect 
against the damage of  reactive oxygen species. Furthermore, low protein intake is associated 
with an increased risk of  frailty,81 and frailty on the other hand is associated with an increased 
on dementia.82-84 
The effects of  protein intake on brain functions have hardly been studied. Results thus far 
are mainly based on observational studies and are inconclusive.79 The number of  RCTs is 
limited, with only two studies observing an acute enhancing effect of  protein intake on 
cognitive performance,85, 86 and one showing a beneficial effect on reaction time after a 
period of  a high protein diet in young men.87 A possible role for dietary protein in cognitive 
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performance needs to be further investigated, especially in frail individuals.
Resistance-type exercise
Physically activity is one of  the suggested modifiable protective factors for cognitive 
decline and dementia, from observations in cross-sectional, prospective, and retrospective 
studies.49, 88 In addition, evidence from RCTs investigating the effects of  physical exercise on 
cognitive performance is accumulating.89, 90 However, results are not consistent due to the 
heterogeneity between studies and the different types of  training that have been investigated, 
e.g., aerobic, resistance type, balance, and flexibility training, or a combination of  two 
or more.89, 90 Several mechanisms have been proposed for physical activity and cognitive 
functioning. First, better cardiorespiratory health due to the (mainly aerobic) physical exercise 
has been suggested to be an important mechanism behind the positive effect on cognitive 
function. Other possible mechanisms include indirect pathways, e.g., via sleep or stress, social 
engagement, insulin sensitivity, or reducing heart disease.89, 91 Evidence for possible direct 
effects are mainly derived from animal studies and includes the induction of  angiogenesis, 
neurogenesis, neural cell proliferation, synaptogenesis, changes in neurotransmitter systems, 
and changes in the growth factors brain-derived neurotrophic factor 92 and insulin-like 
growth factor-1.89 
Although the underlying mechanisms of  resistance-type exercise training on brain health are 
not fully understood, this type of  exercise is receiving more attention nowadays as it appears 
to be a promising means to promote cognitive performance. Resistance-type exercise training 
combined with a nutritional intervention has not been performed up till now. Because 
protein supplementation is suggested to benefit cognitive performance, the combination of  
resistance-type training with protein supplementation may have a synergistic enhancing effect 
on cognitive performance. Studying this in frail individuals, with an often low physical activity 
level,93 low protein intake and a higher risk for dementia, would be interesting. We therefore 
investigated first the single effects of  protein supplementation (Chapter 4), followed by the 
effects of  resistance-type training with and without protein supplementation (Chapter 5) in a 
frail elderly population.
Vitamin B12, folate and folic acid
Vitamin B12
Vitamin B12 is an essential co-factor for two enzymes that are important for the formation 
of  red blood cells and for the nervous system: methionine synthase and methylmalonyl 
coenzyme A mutase.94 In the Netherlands, the recommended dietary daily intake is 2.8 µg for 
adults. Prevalence of  vitamin B12 deficiency increases with age and is common among older 
adults; 6% of  the 60 years and older population suffer from a deficiency (serum vitamin B12 
<148 pmol/L) and >20% have suboptimal levels of  vitamin B12 (148-221 pmol/L).
95 The 
two main causes of  vitamin B12 deficiency are inadequate intake and malabsorption, but 
malabsorption is the main cause of  deficiency in older adults. Due to atrophy of  the gastric 
mucus layer and a decrease of  gastric acid that accompanies aging, the absorption of  vitamin 
B12 becomes impaired. Hence, vitamin B12 is primarily absorbed through passive diffusion in 
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the small intestine. Suboptimal levels of  vitamin B12 are related to fatigue, malaise, vertigo, 
and memory problems.96 Severe deficiency is characterized by pernicious anaemia, nerve 
damage in the spinal cord as a results of  failure of  methylation (myelopathy), and peripheral 
neuropathy.97 
Folate
Folate is a carrier of  one-carbon fragments for a variety of  reactions, and is essential for 
DNA methylation and synthesis. Folate is absorbed in the jejunum, mostly after reduction 
and methylation in the intestinal mucosa. Subsequently, 5-methyltetrahydrofolate is the 
compound that enters the blood stream and is the most important substrate for body tissues. 
In the Netherlands, the recommended daily folate intake is 300 µg. Folate deficiency is mainly 
a result of  poor intake, but it can also be caused by the use of  certain medications or alcohol 
abuse. Around 10-20% of  people aged >65 years are deficient, identified by <10 nmol/L 
serum folate or 340 nmol/L red blood count folate.96 Folate deficiency is characterized by 
megaloblastic anaemia. Supplementation with folic acid, the oxidized and synthetic form of  
folate, decreases the risk on congenital neural tube defects, and therefore fortification of  
flour with folic acid is mandatory in some countries. However, high intake of  folic acid can 
mask vitamin B12 deficiency and its neurological consequences by preventing the production 
of  megaloblasts. 
Interplay between vitamin B12 and folate
Observational studies have shown associations between a higher folate and vitamin B12 status, 
improved cognitive function and lower cognitive decline; however, these associations are not 
consistent among studies.53 A poor vitamin B12 status has also been associated with less brain 
volume, cross-sectionally 98, 99 and prospectively,100 and with brain integrity.101 An important 
intermediate in the possible associations between B-vitamin status, cognitive decline and 
brain volume is the amino acid homocysteine. Low vitamin B12 or folate intake or status can 
increase levels of  homocysteine.94 High homocysteine levels are associated with negative 
health outcomes, in particular cardiovascular disease 102 and fracture risk.103 In addition, 
cross-sectional and prospective studies have shown rather consistent associations between 
homocysteine, cognitive decline, dementia, and brain volume.46, 104, 105, 106 107 
There are different pathways by which vitamin B12, folate and homocysteine may influence 
brain health, as shown in Figure 3. Elevated homocysteine levels may negatively affect 
vascular lesions, may increase phosphorylated tau,108 and high homocysteine and low 
S-adenosylmethionine levels appear to be neurotoxic 109 and can damage white matter 
integrity.110 Vitamin B12 and folate by itself  may influence methylation reactions in the central 
nervous system,111 and consequently affect the methylation of  myelin and damage white 
matter.110-112
Supplementation with folic acid and vitamin B12 decreases homocysteine levels, and may 
therefore be beneficial for cognitive performance. Evidence for a beneficial effect of  
B-vitamin supplementation derived from intervention studies, however, is limited,113 with 
only a few studies observing beneficial effects, whereas most of  the studies did not observe 
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any effect at all. The studies up till now were predominantly done in small study populations 
and often with follow-up times of  only one year or shorter. To induce a beneficial effect of  
lowering homocysteine, longer studies are warranted in larger study populations, preferably 
in populations who would benefit the most, e.g. people with low vitamin B12 or folate status, 
or with elevated homocysteine levels. Therefore, we investigated the effects of  vitamin B12 
and folic acid supplementation on cognitive functioning by performing a large, two-year 
intervention study in elderly people with elevated homocysteine levels (Chapter 6). We 
furthermore investigated the associations of  folate, vitamin B12 status, and brain volumes 
(Chapter 7). 
Figure 3 Vitamin B12 is needed for the two enzymes involved in the conversion of  methylmalonyl-CoA into 
succinyl-CoA (mehtylmalonyl coenmzyme A mutase) and for the remethylation of  homocysteine into methionine (me-
thionine synthase). For this last conversion, folate is required as a methyl donor. Low levels of  methionine result in low 
levels of  S-adenosylmethionine (SAM), which is important for methylation reactions in the central nervous system,111 
and consequently affects the methylation of  myelin and damage to white matter.110-112 High levels of  methylmalonyl-
CoA might substitute malonyl-CaO in fatty acid metabolism, which might result in abnormal fatty acids in neural 
membranes.114
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Rationale and outline of this thesis
The general objectives of  this thesis are to investigate the short-term (glucose and sucrose), 
median long-term (protein and exercise training with and without protein supplementation), 
and long-term effects (vitamin B12 and folic acid) of  different nutrients on cognitive 
performance in cognitively healthy, community-dwelling elderly people. Table 2 gives an 
overview of  the studies that address the aim to investigate these effects. Chapter 2 and 
3 cover the research area of  the short-term effects of  glucose and sucrose by means of  a 
comprehensive literature overview and a cross-over intervention study. In Chapter 4 and 
5, the results derived from the ProMuscle study are described. This was an RCT primarily 
designed to investigate the effects of  protein supplementation, with or without resistance-
type exercise training, on muscle mass and muscle function, but with cognitive performance 
as a secondary outcome. Chapter 4 focuses solely on the effect of  protein supplementation, 
whereas in Chapter 5 the effects of  combined protein supplementation and exercise training 
are described. In Chapter 6 and 7 results of  the B-PROOF study are presented, a 2-year 
intervention study that was primarily designed to examine the efficacy of  vitamin B12 and 
folic acid supplementation on fracture incidence. An extensive neuropsychological test 
battery was included, enabling us to investigate the effects of  the B-vitamin supplementation 
on cognitive performance (Chapter 6). After two years of  supplementation, brain MRI 
measures were done to study cross-sectionally the associations between vitamin B12 and 
folate status with brain MRI volume (Chapter 7). In Chapter 8, the Discussion, all results 
that are presented in this thesis will be discussed and are put in a broader perspective. 
Table 2 Overview of  used projects in this thesis
Chapter Project Study 
design
Nutrient Measurements Study population
2 Sweet 
Thoughts
Literature 
review
Glucose and sucrose Neuropsychological 
tests
Studies selected that were 
done in elderly people
3 Sweet 
Thoughts
Cross-over, 
acute
Glucose and sucrose Neuropsychological 
test battery
43 elderly individuals (≥65 
yrs) with light self-reported 
memory complaints
4 ProMuscle Intervention, 
24 wks
Protein 
supplementation
Neuropsychological 
test battery
65 frail and pre-frail elderly 
individuals (≥65 yrs)
5 ProMuscle Intervention, 
24 wks
Exercise training 
with and 
without protein 
supplementation
Neuropsychological 
test battery
62 and 65 frail and pre-
frail elderly individuals 
(≥65 yrs)
6 B-PROOF Intervention, 
2 yrs
Vitamin B12 and 
folic acid
Neuropsychological 
test battery
2,919 elderly people (≥65 
yrs) with slightly elevated 
Hcy levels
7 B-PROOF Cross-
sectional 
Vitamin B12 and 
folic acid, and blood 
markers for vitamin 
B12 status and folate 
status
MRI brain volumes 218 elderly people (≥65 
yrs) with slightly elevated 
Hcy levels
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Abstract
Glucose is the main fuel for the brain and as such, manipulation of  glucose supply may 
affect brain function. The main objective of  this review was to give an overview of  studies 
that investigated the acute effects of  a glucose load on memory and other cognitive 
functions in elderly people. Furthermore, the effects of  sucrose on cognition and suggested 
mechanisms are described.
In total, twenty studies met our inclusion criteria. The majority of  studies investigated 
episodic memory and suggested a beneficial role for glucose in that specific cognitive 
domain. Other cognitive domains, e.g. working memory, semantic memory, visual memory, 
information processing speed, attention, executive functions, and visual/spatial function, 
have been studied less frequently and evidence for a beneficial effect of  glucose was 
equivocal. Mechanisms are mainly based on the fact that glucose is needed as metabolic 
substrate for physiological mechanisms in both central as peripheral processes. 
Effects of a glucose load 
on cognitive functions in 
elderly people: A literature 
review
Nikita L. van der Zwaluw, Ondine van de Rest, Roy P.C. Kessels, and Lisette C.P.G.M. de Groot. Effects 
of  a glucose load on cognitive functions in elderly people: A literature review. Nutrition Reviews, in press.
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2Review: glucose and cognitive performance 
Introduction
Glucose is the main source for metabolic processes in the brain and therefore, it is important 
to have a constant supply. As such, manipulation of  the glucose supply may play a role in 
the modulation of  cognitive processes. An increasing number of  studies has been published 
about the effects of  a glucose load on cognitive functions in different study populations, 
such as young adults, patients with Alzheimer’s Disease (AD) and healthy older adults 
(summarized by Smith et al.).1 
Aging is accompanied with cognitive decline, resulting in memory loss and a decline in 
attention, processing speed and executive functions.2, 3 This suggests that elderly people have 
more room for cognitive improvement compared to younger adults. Moreover, elderly people 
often have an impaired glucose metabolism, which includes a reduced ability to normalize 
elevated blood glucose levels and a decreased peripheral and central glucose utilization.4, 5 
A poor glucose regulation is associated with memory impairment and age-related cognitive 
deficits;6 people with diabetes showed to have more difficulties with attention, speed of  
information processing and memory tasks and they performed worse on verbal fluency tasks 
than healthy older adults.6, 7 Also individuals without diabetes, but with a poorer glucose 
regulation performed worse on cognitive performance tests compared to those with a better 
regulation.8, 9 Individual differences in glucose regulation as well as in baseline cognitive 
performance may influence the effects of  a glucose load on cognitive functions. These may 
partly explain differences in results between young, elderly, and cognitively impaired people.1 
Also mechanisms underlying the effect of  glucose may differ between young and older 
adults. 
Many studies have been conducted regarding the beneficial effect of  a glucose load on 
cognitive functions in older adults. In this review we will give an overview of  studies that 
investigated the facilitating effect of  glucose on memory and other cognitive functions, 
performed in healthy older adults, and elderly people with mild cognitive impairment (MCI) 
and AD. Moreover, the effects of  fructose and sucrose will be discussed, as well as possible 
underlying mechanisms. 
Methods
Medline databases were searched for suitable articles up to May 2013. Combinations of  
the following search terms were used: glucose, sugar, carbohydrates, sucrose, fructose, 
brain, memory, attention, cognition, cognitive, mental performance. Titles, abstracts and 
keywords were carefully examined to select articles. Furthermore, reference lists of  identified 
publications were checked. Only papers covering original research, placebo-controlled, 
written in the English language and performed in elderly people were included. Selected 
outcome measures were performance on cognitive function tasks after a glucose or sucrose 
drink compared to a placebo drink. 
In accordance with our inclusion criteria, 42 studies were excluded because they were not 
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performed in older populations (34 studies in younger or middle-aged adults, eight studies in 
children or adolescents), and four studies because these focused on cognitive deficits other 
than age-related cognitive decline (for instance, patients with schizophrenia). In total, twenty 
studies were included, of  which nineteen studies investigated glucose and memory functions, 
and fifteen studies investigated glucose in relation to other, non-memory cognitive functions. 
Results
Glucose and memory in elderly people
A detailed overview of  studies addressing the effect of  a glucose drink compared to a 
placebo drink on different aspects of  memory in elderly people is given in Table 1.9-27 Per 
study, often more than one memory task was administered in order to capture different 
aspects of  memory function. Although the effects varied among studies, the majority of  
studies showed a positive effect of  glucose on at least one memory task.10-12, 14, 16-19, 21-24, 26 
Contrarily, all studies with more than one test reported also no effects of  glucose on other 
memory tasks that were performed, and five studies reported no beneficial effects of  glucose 
on any of  the performed memory tasks.9, 13, 15, 25, 27
The domain of  episodic memory was studied most frequently, which is the memory for 
events and experiences with a specific temporal or spatial context. The majority of  studies 
showed an improvement in one of  the episodic memory tasks, most often tested with story 
recall, paired associate learning, or word-list learning tests. There were no clear differences 
in effects on performance on long-term episodic memory, that is, tasks with a delay between 
presentation and test, or immediate recall (presentation directly followed by the test); some 
studies showed a larger effect on long-term memory,10, 14, 23, 24 others on immediate recall.11, 
18, 22 Riby et al. showed that task difficulty played a role in glucose facilitation; only the 
easier tasks improved after glucose.11 In contrast to these free- or cued-recall tests, however, 
performance on recognition tests (‘yes/no’ decisions about previously presented stimuli) did 
not improve.10, 12 This is probably because recognition tests are not very sensitive and ceiling 
performances were present. When tests are too difficult, though, a glucose load may be 
insufficient to improve performance.11 
Two studies showed that only individuals with a poorer glucose regulation improved their 
episodic memory performance; differences in memory function between people with 
poorer and better glucose regulations became smaller after glucose ingestion,13, 15 mainly 
in the older participants and only in some of  the tests.13 Another study though, showed 
that glucose impaired performance of  episodic memory in better glucose regulators.17 
Two studies showed that a smaller peak change in glucose levels was associated with larger 
memory improvement after glucose,23, 24 whereas two other studies did not observe such 
an association.19, 22 Together with glucose regulation, baseline performance might also play 
a role. Healthy participants with a poorer baseline performance and with a poorer β-cell 
function were more sensitive for the facilitating effects of  glucose.15 Craft et al. observed 
similar beneficial effects in patients with mild AD, who had a poorer glucose recovery,20 but 
35
2Review: glucose and cognitive performance 
baseline performance did not always play a role.21 
Another memory domain that was investigated is working memory, the memory related to 
the online maintenance of  information for a brief  period of  time, after which it will not be 
stored into long-term memory. In the studies discussed here, working memory was mostly 
measured by digit span forward and backward tests (brief  maintenance of  sequences of  
digits which increase in length). Overall, working memory performance was not affected 
after glucose intake. One study showed a beneficial effect on the digit span forward 
in women with a poor glucose regulation, but women with a better glucose regulation 
performed worse.17 Another study observed a lower score on the digit span backwards test 
after glucose.27 
Visual memory was not extensively examined, and only one study showed a beneficial effect 
on the delayed Rey/Taylor Complex Figure test.26 Also the domain of  semantic memory, that 
is, memory for general knowledge in which the spatial or temporal context of  learning has 
been lost, did not improve after glucose intake. One study showed significant improvements 
after glucose on verbal fluency 26 and one study on word-stem completion task,19 but these 
effects can also be a result of  a general improvement in information processing, which may 
have resulted in a quicker response. An explanation for the lack of  effect of  glucose may 
be because abilities for verbal reasoning and semantic memory are not heavily affected by 
normal aging.28
Two of  the discussed studies included younger participants as well 11, 24 and one of  them 
showed a more pronounced effect of  glucose in the older participants compared to the 
youngsters.24 The studies that have investigated the differences between healthy elderly versus 
cognitively impaired older people showed mixed results. One study showed a difference 
between early-stage AD and healthy older adults with respect to the effect of  glucose 
administration in relation to their glucose recovery; in healthy participants episodic memory 
improved in those individuals with a better glucose recovery, while in people with a poor 
recovery memory was impaired. This pattern was reversed in the AD patients.20 In another 
study the enhancing effects of  glucose were not more pronounced in patients with MCI 
compared to healthy elderly people.10
In sum, based on the results of  nineteen studies, it may be concluded that a glucose load 
selectively enhances performance on episodic memory, but results on other memory 
functions are inconclusive. In general, it seems that glucose ingestion is more effective 
on sensitive cognitive tests with a certain level of  task complexity, although the effects of  
glucose may be limited to a certain extent. 
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Table 1 Overview of  studies investigating the effect of  glucose on memory functions in elderly people 
Reference Population description: N, 
age (mean±SD (range)); 
and study design
Cognitive tests Results
Episodic memory
Van der 
Zwaluw et al. 
(2014)27 
N=43, 78±8 yrs (range >65). 
50 g glucose, 100 g sucrose vs. 
placebo
Word list recall immediate 
(RAVLT)
∆gl-plac = 0.1, n.s.
Word list recall delayed (RAVLT) ∆gl-plac = -0.4, n.s.
Story recall immediate (RBMT) ∆gl-plac = -0.5, n.s.
Story recall delayed (RBMT) ∆gl-plac = -0.6, n.s.
PAL easy (WMS-R) ∆gl-plac = 0, n.s.
PAL difficult (WMS-R) ∆gl-plac = -0.2, n.s.
Compound score ∆gl-plac = -0.12, n.s.
Messier et al. 
(2010)9
N=93, 70.1±8.3 yrs (range 55-
88). 50 g glucose vs. placebo
Story recall immediate (WMS-
III)
n.s.
Story recall delayed (WMS-III) n.s. 
Verbal free recall n.s.
Order recall n.s. 
Riby et al. 
(2009)10
N=24 patients with MCI, 
73±5.4 yrs; N=24 healthy 
elderly, 71±5.6 yrs. 25 g 
glucose vs. placebo
Story recall immediate (RBMT) MCI: ∆gl-plac = 0.0; 
Healthy: ∆gl-plac = 0.9; n.s.
Story recall delayed (RBMT) MCI: ∆gl-plac = 0.8; Healthy: 
∆gl-plac = 1.5; p<0.05
Picture recognition delayed 
recognition
MCI: ∆gl-plac = 0.1; 
Healthy:∆gl-plac = -0.6; n.s.
Riby et al. 
(2006)11
N=13 elderly, 68±5.9 yrs.a 25 g 
glucose vs. placebo
PAL, easy and difficult, direct 
recall
Easy: ∆gl-plac = 0.8, p<0.05; 
Difficult: ∆gl-plac = -0.1, n.s.
PAL, easy and difficult, delayed 
recall
Easy: ∆gl-plac = -0.3, n.s.; 
Difficult: ∆gl-plac = -0.4, n.s.
Word learning, easy and difficult, 
immediate recall
Easy: ∆gl-plac = 1.6, p<0.05; 
Difficult: g-∆p = -0.4, n.s.
Word learning, easy and difficult, 
delayed recall
Easy: ∆gl-plac = 1.7, p<0.05; 
Difficult: ∆gl-plac = 0.0, n.s.
Riby et al. 
(2004)12
N=20, 68.8±6 yrs (range 60-
80). 25 g glucose vs. placebo
PAL, easy and difficult, 
immediate recall
Easy: ∆gl-plac = 1.3; 
Difficult: ∆gl-plac = 1.3; n.s. 
overall, but 2(drink)x2(delay)
x2(difficulty)ANOVA 
showed greater recall after 
glucose (p<0.05)
PAL, easy and difficult, around 
30 min delayed recall
Easy: ∆gl-plac = 0.4; 
Difficult: ∆gl-plac = -0.3; n.s.
PAL recognition, easy and 
difficult, around 30 min delayed
Easy: ∆gl-plac = -0.2; 
Difficult: ∆gl-plac = -0.2; n.s.
PAL recognition, easy and 
difficult, 1 week delayed
Easy: ∆gl-plac = -1.7; 
Difficult: ∆gl-plac = -0.9; n.s.
Table continues on the next page 
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Reference Population description: N, 
age (mean±SD (range)); 
and study design
Cognitive tests Results
Messier et al. 
(2003)13
N=57, 71.9±7.2 yrs (range 55-
84). 50 g glucose vs. placebo
Story recall immediate (WMS-
III)
n.s.
Story recall delayed (WMS-III) n.s.
Verbal free recall n.s.
Order reconstruction recall n.s.
Kaplan et al. 
(2001)14
N=22, 71.2±1.3 yrs (range 
61-79). 50 g glucose vs. fat, 
protein, and placebo.
Word list recall (RAVLT) p=0.03, impaired 
performance after glucose 
in men (n.s. with Bonferroni 
correction)
Story recall immediate (WMS-R) p=0.02
Story recall delayed  (WMS-R) p=0.001
Kaplan et al. 
(2000)15
N=20, 72.3±1.4 yrs (range 60-
82). 50 g glucose vs. mashed 
potatoes, barley, and placebo
Word list recall (RAVLT) n.s.
Story recall immediate (WMS-R) n.s. overall, but people with 
poor GR performed better 
after glucose intake, while 
good GR performed worse.
Story recall delayed (WMS-R)
Manning et al. 
(1998)16
N=20, 67 yrs (range 60-83). 
50 g glucose vs., placebo. 
Pre-training: glucose on day 1; 
pre-testing: glucose on day 2
Story recall, 24h delay (WMS-R) F(1.19)=11.60, p<0.01 
overall. Pre-training glucose 
gave better recall than pre-
testing glucose.
Messier 
(1997)17
N=15, 62.3±6.5 yrs (range 
≥55). 50 g glucose vs. placebo
Story recall immediate (WMS-R) n.s. Tendency for better 
recall after glucose, but worse 
in men with poor GR
Story recall delayed (WMS-R) n.s.
PAL (WMS-R) n.s.
Word recall (ADAS) Glucose improved 
performance in better 
recovery males
Word recognition (ADAS) n.s.
Craft et al. 
(1993)18
N=20 patients with very mild 
to mild AD, 69.1±6.5 yrs. 
N=12 age- and sex matched 
healthy controls 65.3±10.5 yrs. 
Intravenous raise in glucose 
levels to 9,7 mmol/L, or 12,5 
mmol/L
Story recall immediate (WMS-R) Significant effect in the 12,5 
mmol/L condition, especially 
seen in the very mild AD 
patients
Story recall delayed (WMS-R) n.s.
PAL immediate (WMS-R) n.s.
PAL delayed (WMS-R) n.s.
Manning et al. 
(1993)19
N=23 patients with AD, 82 yrs 
(range 68-94). 75 g glucose vs. 
placebo
Story recall (WMS-R) ∆gl-plac=1.18, p=0.001
Word list learning (modified 
RAVLT)
∆gl-plac=2.53, p=0.003
Table 1 Overview of  studies investigating the effect of  glucose on memory functions in elderly people (continued)
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Reference Population description: N, 
age (mean±SD (range)); 
and study design
Cognitive tests Results
Craft et al. 
(1992)20
N=21 mild and very mild 
patients with AD, 71.5±8.5 yrs; 
N=14 age- and sex matched 
controls, 73.5±4.7 yrs. 50 g 
glucose vs. placebo
Story recall immediate (WMS-R) Treatment n.s.
Story recall delayed (WMS-R) Treatment n.s.
PAL immediate (WMS-R) Healthy: ∆gl-plac = 2.4, AD: 
∆gl-plac = 1.6. Treatment 
n.s.
PAL delayed (WMS-R) Healthy: ∆gl-plac = 0.4, AD: 
∆gl-plac = 0.7, treatment n.s.
Manning et al. 
(1992)21
N=22, 67 yrs (range 60-81). 50 
g glucose vs. placebo ingested 
before or after cognitive test
Story recall delayed (24h) 
(WMS-R)
F(2.42)=6.7, p<0.01
Parsons and 
Gold (1992)22
N=10, 67.6 yrs (range 60-82). 
10, 25 and 50 g glucose vs. 
placebo.
Story recall 5-min delay 
(WMS-R)
25g glucose: t=3.44, p<0.01. 
N.s. effects after 10 g and 50 
g glucose
Story recall 40-min delay 
(WMS-R)
25g glucose: t=2.27, p<0.05. 
N.s. effects after 10 g and 50 
g glucose
Manning et al. 
(1990)23
N=17, 73 yrs (range 62-84). 50 
g glucose vs. placebo
Word list learning immediate 
(Selective Reminding test)
∆gl-plac = 0.75, n.s
World list learning delayed 
(Selective Reminding test) 
∆gl-plac = 8.63, p=0.05
Story recall immediate (WMS-R) ∆gl-plac = 2.12, p=0.004
Story recall delayed (WMS-R) ∆gl-plac = 2.75, p=0.002
Hall et al. 
(1989)24
N=11 elderly, 67.4 yrs (range 
58-77).b 50 g glucose vs. 
placebo
PAL easy and difficult, 
immediate (WMS-R)
n.s.
PAL 24h-delayed (WMS-R) n.s.
Story recall delayed (WMS-R) ∆gl-plac = 2.0, p=0.024
Working memory
Van der 
Zwaluw et al. 
(2014)27 
N=43, 78±8 yrs (range >65). 
50 g glucose, 100 g sucrose vs. 
placebo
Digit span forward (WAIS-III) ∆gl-plac = -0.1, n.s.
Digit span backward (WAIS-III) ∆gl-plac = -0.6, p<0.05
Messier et al. 
(2010)9
N=93, 70.1±8.3 yrs (range 55-
88). 50 g glucose vs. placebo
Digit span forward (WMS-R) n.s.
Digit span backward (WMS-R) n.s. 
Arithmetic (WAIS-III) n.s.
Letter-number sequencing 
(WAIS-III)
n.s.
Modified Brown-Peterson n.s.
Riby et al. 
(2004)12
N=20, 68.8±6 yrs (range 60-
80). 25 g glucose vs. placebo
Digit span forward (WMS-III) ∆gl-plac = 0.0, n.s.
Digit span backward (WMS-III) ∆gl-plac = 0.0, n.s.
Table 1 Overview of  studies investigating the effect of  glucose on memory functions in elderly people (continued)
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Reference Population description: N, 
age (mean±SD (range)); 
and study design
Cognitive tests Results
Messier et al. 
(2003)13
N=57, 71.9±7.2 yrs (range 55-
84). 50 g glucose vs. placebo
Digit span forward (WAIS-III) n.s.
Digit span backward (WAIS-III) n.s.
Arithmetic (WAIS-III) n.s.
Letter-number sequencing 
(WAIS-III)
n.s.
Modified Brown-Peterson n.s.
Knott et al. 
(2001)25
N=10, 63±5 yrs. 50 g glucose 
vs. placebo
Sternberg memory scanning – 
accuracy
n.s.
Memory scanning – reaction 
time
n.s.
Messier et al. 
(1997)17
N=15, 62.3±6.5 yrs (range 
≥55). 50 g glucose vs. placebo
Digit Span forward (WMS-R) Women with poor GR 
improved performance after 
glucose, while performance 
in women with good GR was 
impaired.
Digit Span backward (WMS-R) n.s.
Manning et al. 
(1990)23
N=17, 73 yrs (range 62-84). 50 
g glucose vs. placebo
Digit span forward (WAIS-R) ∆gl-plac = -0.33, n.s.
Digit span backward (WAIS-R) ∆gl-plac = -0.14, n.s.
Hall et al. 
(1989)24
N=11 elderly, 67.4 yrs (range 
58-77).b 50 g glucose vs. 
placebo
Digit span forward (WMS-R) n.s.
Digit span backward (WMS-R) n.s.
Visual Memory
Messier et al. 
(2010)9
N=93, 70.1±8.3 yrs (range 55-
88). 50 g glucose vs. placebo
Rey/Taylor complex figure test 
immediate recall
n.s.
Rey/Taylor complex figure test 
delayed recall
n.s.
Spatial span forward (WMS-III) n.s.
Spatial span backward (WMS-
III)
n.s.
Messier et al. 
(2003)13
N=57, 71.9±7.2 yrs (range 55-
84). 50 g glucose vs. placebo
Spatial span forward (WMS-III) n.s.
Spatial span backward (WMS-
III)
n.s.
Messier et al. 
(1997)17
N=15, 62.3±6.5 yrs (range 
≥55). 50 g glucose vs. placebo
Visual memory span forward 
(WMS-R)
n.s.
Visual memory span backward 
(WMS-R)
n.s.
Allen et al. 
(1996)26
N=28, 73 yrs (range 61-87). 50 
g glucose vs. placebo
Rey/Taylor Figure, delayed ∆gl-plac = 3.42, p<0.001
Table 1 Overview of  studies investigating the effect of  glucose on memory functions in elderly people (continued)
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Reference Population description: N, 
age (mean±SD (range)); 
and study design
Cognitive tests Results
Craft et al. 
(1992)20
N=21 mild and very mild 
patients with AD, 71.5±8.5 yrs; 
N=14 age- and sex matched 
controls, 73.5±4.7 yrs.  50 g 
glucose vs. placebo
Pattern recall immediate Healthy: ∆gl-plac = 0.2; AD: 
∆gl-plac = 1.0, Treatment 
n.s.
Pattern recall delayed Healthy: ∆gl-plac = 0.0; AD: 
∆gl-plac = 0.8, Treatment 
n.s.
Pattern recall recognition Healthy: ∆gl-plac = -0.6; AD: 
∆gl-plac = -0.4, Treatment 
n.s.
Manning et al. 
(1990)23
N=17, 73 yrs (range 62-84). 50 
g glucose vs. placebo
Rey Complex figure test ∆gl-plac = -0.06, n.s.
Hall et al. 
(1989)24
N=11 elderly, 67.4 yrs (range 
58-77).b 50 g glucose vs. 
placebo
Visual memory test (WMS-R) n.s.
Semantic memory/Verbal fluency
Van der 
Zwaluw et al. 
(2014)27 
N=43, 78±8 yrs (range >65). 
50 g glucose, 100g sucrose vs. 
placebo
Verbal Fluency ∆gl-plac = 1.4, n.s.
Riby et al. 
(2006)11
N=13 elderly, 68±5.9 yrs.a 25 g 
glucose vs. placebo
Verbal fluency, easy and difficult 
letters
Easy: ∆gl-plac = -1.0, n.s.
Difficult: ∆gl-plac = 0.9, n.s.
Category fluency, easy and 
difficult
Easy: ∆gl-plac = -2.6, n.s.
Difficult: ∆gl-plac = -1.9, n.s.
Computerized semantic 
verification task accuracy, easy 
+ hard
Easy: ∆gl-plac = 0.13, n.s.
Difficult: ∆gl-plac = 0.08, n.s.
Categorical verification response 
time, easy + hard
Easy: ∆gl-plac = 29, n.s.
Difficult: ∆gl-plac = 36, n.s.
Riby et al. 
(2004)12
N=20, 68.8±6 yrs (range 60-
80). 25 g glucose vs. placebo
Category fluency ∆gl-plac = 2.9, n.s.
Allen et al. 
(1996)26
N=28, 73 yrs (range 61-87). 50 
g glucose vs. placebo
Verbal fluency ∆gl-plac = 1.68, p<0.01
Boston naming test ∆gl-plac = -0.14, n.s.
Manning et al. 
(1993)19
N=23 patients with AD, 82 yrs 
(range 68-94). 75 g glucose vs. 
placebo
Priming: word-stem completion 
task, recognition
∆gl-plac = 1.63, p=0.002
Priming: word-stem completion 
task, completion
∆gl-plac = 0.52, n.s.
Notes: ∆gl-plac, difference in performance after glucose and placebo drink; n.s., no significant differences between 
glucose and placebo drink; PAL, Paired Associate Learning; MCI, mild cognitive impaired; WMS(-R), Wechsler 
Memory Scale (Revised); (S)DAT, (Senile) dementia of  the Alzheimer type. a n = 14 young, 30±5 yrs, only results in 
older participants are shown here;  b n = 12 young, 20 yrs (range 18-23), only results in older participants are shown 
here. 
Table 1 Overview of  studies investigating the effect of  glucose on memory functions in elderly people (continued)
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Glucose and other non-memory cognitive functions in elderly people
Less research has been done on the influence of  glucose on cognitive functions other than 
memory. Fifteen studies investigated the effects of  glucose on various other cognitive 
functions and we divided the performed neuropsychological tests into the following cognitive 
domains: information processing speed, executive function, attention, visual/spatial function, 
and other functions (Table 2).9, 10, 12-15, 17, 19, 20, 22, 23, 26, 27, 29 Seven studies showed a positive effect 
of  glucose on various tasks in different cognitive domains.14, 17, 19, 20, 26, 27, 29
Information processing speed and executive functioning were mostly measured with 
different parts of  the trail making test, letter symbol digit test, or Stroop color word test, 
and performance was improved in three studies.14, 27, 29 In one study, the improvements in 
performance after glucose were only seen in men.14 Glucose improved divided attention, 
measured by a computerized dual reaction time task,29 but episode-watching, another 
attention test, did not improve. Visual/spatial function was determined with a facial 
recognition task, Rey Taylor figure test, figural fluency, or a one-feature target detection task, 
and three studies observed glucose-enhancing effects,19, 20, 26 although one study only showed 
improvement in participants with AD.20 AD patients also improved their performance on an 
orientation task after a glucose load.19 
Poor β-cell function was associated with higher improvements in the trail making test, 
whereas participants with better β-cell function performed worse.15 In a study of  our own 
research group we likewise observed an improvement in information processing speed only 
in participants with a poorer glucose regulation and not in those with a better regulation.27 
The same effect was seen in a study of  Messier et al.17
Due to the limited number of  studies and the variety of  tests covering different cognitive 
domains we are unable to draw any conclusions regarding a possible facilitating effect of  
glucose on other domains than memory. The higher-order executive functions, which are 
mainly controlled processes such as activation, inhibition and switching, are influenced by 
normal aging and require more mental effort. Glucose may mediate the processes, but more 
research in larger samples is needed to replicate the results.  
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Table 2 Overview of  studies investigating the effect of  glucose on other cognitive functions in elderly people
Reference Population description: N, 
age (mean ±SD (range); 
and study design
Cognitive tests Results
Information processing speed
Van der 
Zwaluw et al. 
(2014)27 
N=43, 78±8 yrs (range >65). 
50 g glucose, 100 g sucrose vs. 
placebo
Stroop reading and color naming ∆gl-plac = -0.9, n.s.
Letter digit substitution test ∆gl-plac = 1.1, p=0.04
TAP Flexibility, letters ∆gl-plac = -4, n.s.
TAP Flexibility, digits ∆gl-plac = -11, n.s.
Compound scores ∆gl-plac = -0.1, n.s.
Gagnon et al. 
(2010)29
N=44, 67.7±5 yrs (range 60-
80). 50 g glucose vs. placebo
TMT A F(1, 41)=6.81, p<0.05
Stroop reading F(1,41)=3.64, n.s.
Stroop color naming n.s.
Messier et al. 
(2010)9
N=93, 70.1±8.3 yrs (range 
55-88). 50 g glucose vs. 
placebo
Digit symbol-coding (WAIS-III) n.s.
Symbol search (WAIS-III) n.s.
Riby et al. 
(2004)12
N=20, 68.8±6 yrs (range 60-
80). 25 g glucose vs. placebo
Digit symbol substitution test 
(WAIS-III)
∆gl-plac = 1.5, n.s.
Messier et al. 
(2003)13
N=57, 71.9±7.2 yrs (range 
55-84). 50 g glucose vs. 
placebo
Digit symbol-coding (WAIS-III) n.s.
Symbol search (WAIS-III) n.s.
Kaplan et al. 
(2001)14
N=22, 71.2±1.3 yrs (range 
61-79). 50 g glucose vs. fat, 
protein and placebo.
TMT A p=0.02 in men
Messier et al. 
(1997)17
N=15, 62.3±6.5 yrs (range 
≥55). 50 g glucose
Digit symbol-coding (WAIS-R) n.s.
Cancellation H test Improved by glucose, but 
not in men with a good GR.
Allen et al. 
(1996)26
N=28, 73 yrs (range 61-87). 
50 g glucose vs. placebo
TMT A ∆gl-plac = -9.4, n.s.
Grooved pegboard ∆gl-plac = 1.2, n.s.
Manning et al. 
(1990)23
N=17, 73 yrs (range 62-84). 
50 g glucose vs. placebo
Finger Oscillation Test ∆gl-plac = -1.72, n.s.
Executive function
Van der 
Zwaluw et al. 
(2014)27 
N=43, 78±8 yrs (range >65). 
50 g glucose, 100 g sucrose vs. 
placebo
Stroop interference ∆gl-plac = 2.3, n.s.
TAP Flexibility ∆gl-plac = 27, n.s.
Compound scores ∆gl-plac = -0.02, n.s.
Gagnon et al. 
(2010)29
N=44, 67.7±5 yrs (range 60-
80). 50 g glucose vs. placebo
TMT B ratio ((B-A)/A) F(1, 41)=0.15, n.s.
Stroop  inhibition F(1, 39)=4.61, p<0.05
Stroop switching F(1, 41)=10.47, p<0.01
Table continues on the next page 
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Reference Population description: N, 
age (mean ±SD (range); 
and study design
Cognitive tests Results
Kaplan et al. 
(2001)14
N=22, 71.2±1.3 yrs (range 
61-79). 50 g glucose vs. fat, 
protein, and placebo.
TMT A+B p=0.02 in men
Kaplan et al. 
(2000)15
N=20, 72.3±1.4 yrs (range 
60-82). 50 g glucose vs. 
mashed potatoes, barley, and 
placebo
TMT B n.s. overall, but carbohydrate 
intake improved perfor-
mance in those with a poor 
β cell function and impaired 
in those with better β cell 
function
Allen et al. 
(1996)26
N=28, 73 yrs (range 61-87). 
50 g glucose vs. placebo
TMT B ∆gl-plac = -15.1, n.s.
Attention
Van der 
Zwaluw et al. 
(2014)27 
N=43, 78±8 yrs (range >65). 
50 g glucose, 100 g sucrose vs. 
placebo
TAP Alertness, simple RT ∆gl-plac = -6, n.s.
TAP Alertness, cued RT ∆gl-plac = -10, n.s.
Gagnon et al. 
(2010)29
N=44, 67±5 yrs (range 60-
80). 50 g glucose vs. placebo
Computerized dual-task – RT F(1, 38)=8.49, p<0.01
Computerized dual-task - ac-
curacy
F(1, 38)=4.61, p<0.05
Riby et al. 
(2009)10
N=24 patients with MCI, 
73±5.4 yrs; N=24 healthy el-
derly, 71±5.6 yrs. 25 g glucose 
vs. placebo
SART hit rate MCI: ∆gl-plac = 0.03; 
Healthy: ∆gl-plac = -0.02; 
n.s.
SART reaction time MCI: ∆gl-plac = -0.03; 
Healthy: ∆gl-plac = 0.00; n.s.
SART false alarm rates MCI: ∆gl-plac = 0.04; 
Healthy: ∆gl-plac = -0.01; 
n.s.
Kaplan et al. 
(2001)14
N=22, 71.2±1.3 yrs (range 
61-79). 50 g glucose vs. fat, 
protein and placebo.
Episode-watching (sustained 
attention)
n.s.
Kaplan et al. 
(2000)15
N=20, 72.3±1.4 yrs (range 
60-82). 50 g glucose vs. 
mashed potatoes, barley, and 
placebo
Episode-watching (sustained 
attention)
n.s.
Allen et al. 
(1996)26
N=28, 73 yrs (range 61-87). 
50 g glucose vs. placebo
Dichotic listening ∆gl-plac = -0.15, n.s.
Visual/spatial function
Messier et al. 
(2010)9
N=93, 70.1±8.3 yrs (range 
55-88). 50 g glucose vs. 
placebo
Rey/Taylor complex figure test 
copy
n.s.
Table continues on the next page 
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Reference Population description: N, 
age (mean ±SD (range); 
and study design
Cognitive tests Results
Allen et al. 
(1996)26
N=28, 73 yrs (range 61-87). 
50 g glucose vs. placebo
Meier visual test ∆gl-plac = -0.79, n.s.
Rey/Taylor Complex Figure test, 
copy
∆gl-plac = 0.74, n.s.
Figural fluency ∆gl-plac = 1.43, p<0.05
Craft et al. 
(1992)20
N=21 mild and very mild pa-
tients with AD, 71.5±8.5 yrs; 
N=14 age- and sex matched 
controls, 73.5±4.7 y. 50 g 
glucose vs. placebo
One-feature target detection and 
localization task
Healthy: ∆gl-plac = 0.4; 
AD: ∆gl-plac = 3.7, in AD 
significant improvement 
after glucose
Two-feature target detection and 
localization task
Healthy: ∆gl-plac = -2.36; 
AD: ∆gl-plac = -0.58, n.s.
Manning et al. 
(1990)23
N=17, 73 yrs (range: 62-84). 
50 g glucose vs. placebo
Letter Cancellation Test ∆gl-plac = -4.29, n.s.
Other
Riby et al. 
(2004)12
N=20, 68.8±6 yrs (range: 60-
80). 25 g glucose vs. placebo
Mental control test (WMS III) ∆gl-plac = 0.8, n.s.
Manning et al. 
(1993)19
N=23 patients with AD, 82 
yrs (range 68-94). 75 g glucose 
vs. placebo
Randt Memory test - Orientation ∆gl-plac = 0.91, p=0.045
Parsons and 
Gold (1992)22
N=10, 67.6 yrs (range 60-82). 
10, 25 and 50 g glucose vs. 
placebo
Ammons Quick test - Intelligence n.s.
Manning et al. 
(1990)23
N=17, 73 yrs (range 62-84). 
50 g glucose vs. placebo
Ammon’s Quick Test - Intel-
ligence
∆gl-plac = 2.00, n.s.
Notes: ∆gl-plac, difference in performance after glucose and placebo drink; n.s., no significant differences between 
glucose and placebo drink; MCI, mild cognitive impaired; TAP, Test for Attentional Performance; TMT, Trail Making 
Test; RT, reaction time; SART, Sustained Attention to Response Task; WMS, Wechsler Memory Scale; AD Alzheimer 
dementia.
Table 2 Overview of  studies investigating the effect of  glucose on other cognitive functions in elderly people 
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Fructose, sucrose and cognitive performance
Fructose is, just like glucose, a mono-saccharide and together with glucose it forms sucrose. 
Only two studies were found that investigated the effects of  sucrose on cognitive functions 
in an adult human population.27, 33 In a study of  our group, we showed that after a sucrose 
drink elderly participants performed better on speed of  information processing tasks 
compared to a placebo drink.27 Another study showed that sucrose in combination with 
nicotine may be beneficial for performance on a continuous performance task in young 
adults.33 
Studies performed in rats showed that fructose can improve memory performance, although 
extrapolating results from animal studies to humans has to be done with caution. In a series 
of  rat experiments of  Messier and White 31 both glucose and fructose enhanced memory 
with the same dose and also Rodriguez et al. showed that peripheral injected fructose may 
affect cognitive functioning.34 Another study observed that a combination of  fructose and 
glucose affected memory less than a single dose of  one of  these mono-saccharides.35 This 
might be a result of  the hepatic output of  glucose, which may be attenuated when both 
fructose and glucose are administered.36 White 37 only observed an effect of  fructose after 
a higher dose (2 g/kg), and not after a smaller dose (100 mg/kg), whereas two other studies 
showed an improvement after 100 mg/kg.34, 35 In contrast to glucose, fructose cannot cross 
the blood-brain barrier,30 does not raise blood glucose levels, and is metabolized by the liver. 
This can indicate that there are other mechanisms responsible than raised glucose levels to 
enhance cognition, probably of  a peripheral nature.31, 32 
Due to the limited amount of  studies done in human and the equivocal results of  rat 
studies, no conclusions can be drawn about the effects of  fructose and sucrose on cognitive 
functions in older humans. 
Methodological issues
Study design
All studies but one 29 used a repeated-measures design to minimize the influence of  
substantial variability in memory function of  elderly people on test scores, which is probably 
the most optimal study design for this research area that focuses on acute effects. To 
counteract the risk of  learning effects in such a design, the order of  test drinks was mostly 
counterbalanced, and parallel versions for cognitive tests sensitive for learning effects 
were used. Other inter-individual variability, such as glucose recovery abilities, stress, sex 
and baseline performance may still have influenced the results.15 The majority of  studies 
was done in the morning, after an overnight fast, to control for circadian rhythm, but this 
questions the usability of  a glucose load in daily life.12 In younger adults it has already been 
shown that a glucose-enhancing effect already is present after only two hours of  fasting,38 
but in elderly people this has not been investigated yet. 
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Neuropsychological testing
A variety of  neurocognitive tests was used, and the number of  different tests within a study 
was sometimes large, which may have increased the risk of  chance findings. Nevertheless, 
the effect of  glucose on episodic memory was present in most of  the studies, indicating that 
glucose may be beneficial for improving episodic memory. It has been discussed that level 
of  task difficulty is important to show an enhancing effect of  glucose; an often mentioned 
assumption is that tasks have to be difficult enough to detect a glucose effect. Arguments 
that may confirm this thought are results in which delayed recall tasks profit more from 
glucose than immediate recall tasks.10, 14, 23 However, Riby et al. 11 observed a beneficial effect 
in the easier task only, and not under high-demanding conditions. The authors suggested 
that the capacity of  an individual is limited when the conditions are too demanding, and that 
glucose would not be able to counteract these high costs. Nonetheless, what exactly can be 
labeled as ‘cognitively demanding’ has not been clearly defined, as both duration and task 
complexity play a role in this.
Test conditions and glucose dose
All studies used glucose dissolved in water, compared to a placebo solution (250 ml) that 
contained saccharine, aspartame, or a combination of  artificial sweeteners, and cognitive 
testing started around 5-15 minutes after ingestion. Drinks were matched for sweetness and 
taste by adding a lemon or orange flavor to the drink. Artificial sweeteners are assumed not 
to alter blood glucose levels and thus that they would not affect cognition. However, small 
effects of  saccharin on several brain regions have been shown,39 which can be explained by 
the effect of  taste on memory processes, as activated taste receptors produce small amounts 
of  insulin.32, 40 No difference, though, was observed when a saccharin solution was compared 
to water.41 One study in young adults only observed a beneficial effect of  glucose when 
participants were told that they received the glucose drink and not when was told that they 
drank the placebo drink.42 
A discrepancy between studies was the used dosage of  glucose; either 25 g or 50 g of  glucose 
was used for the glucose drinks, and once a dose of  10 g (no effect) 22 and a dose of  75 g 
was used (which was beneficial in AD patients).19 For memory functions, it was shown that 
all studies using a dose of  25 g glucose showed a positive effect on episodic memory, where 
three-quarter of  the studies that used a dose of  50 g showed a positive effect. In the non-
memory cognitive domains the opposite was shown; in the studies that used a dose of  25 g 
glucose, only three though, no facilitating effects were observed,10, 12, 22 whereas the studies 
using a dose of  50 g glucose did show effects on different cognitive functions. It is plausible 
that the optimum glucose dose differs for different cognitive functions. In rats it has been 
shown that every brain region differs in extracellular glucose level.43, 44 Glucose transporters 
are not homogeneously distributed throughout the brain and this may suggest that the 
effects of  glucose vary between brain regions.45-47 Moreover, brain regions may vary in the 
degree of  increasing glucose metabolism to the maximum capacity.48 Furthermore, because 
every individual has a different body weight, the amount of  glucose per kilogram body 
weight was different, which may, partly, explain the different results.38 Dose-response studies 
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in young and older adults showed that the effect of  glucose follows an inverted U-shaped 
dose-response function indicating 25 g as the most optimum dose,22, 38, 49 which is comparable 
to what was found in a rat study.50 The optimum blood glucose concentration to facilitate 
memory lay between 8 to 10 mmol/L, around 8.9 mmol/L in healthy elderly individuals. 
In patients with AD, higher concentrations are probably warranted to induce an enhancing 
effect of  glucose; Craft et al. showed that 75 g of  glucose was needed to reach an optimal 
blood glucose level of  225 mg/dL (12.5 mmol/L).18
The optimal dose may also depend on peripheral glucose regulation, but results are 
inconclusive. The different findings may be explained by the mostly used method, a median 
split, to divide the study population into better and poorer glucose recoverers. This is based 
on the study population and not on a reference value, and therefore, reliable determination 
of  poor glucose regulators classified as such in a different study population has been 
questioned. Nevertheless, possible explanations for the effect of  glucose regulation are 
present for both better and poorer glucose recovery conditions. The improvements for the 
better regulators could be that a good glucose regulation is needed to use the extra glucose 
in an effective way. Insulin sensitivity is probably also better, and consequently it may have 
its effects on the brain. On the other hand, people with a poorer glucose regulation perform 
worse and thus have more room for improvements.1 
Possible mechanisms for the effect of 
glucose on cognitive functions 
Glucose enters the brain through the blood-brain barrier by using GLUT1 glucose 
transporters, which are located in the endothelial cells of  blood vessels.51 A concentration 
gradient drives glucose to the extracellular fluid of  the brain, and therefore extracellular 
glucose levels fluctuate slightly with blood glucose levels, whereas intracellular levels are more 
controlled.52 Only a limited amount of  glucose can be stored as glycogen in astrocytes, but 
not in neurons.53, 54 When a deficit of  neuronal glucose occurs, lactate, derived from glycogen, 
goes from the astrocytes to the extracellular fluid to the neurons, where it can be used as 
energy substrate. This drive of  lactate is dependent on the level of  adenosine triphosphate 
(ATP) within the neuron: low levels of  ATP increase the transport.32 
Several possible neurochemical systems have been implicated underlying the glucose 
facilitating effect on cognition. Mechanisms are mainly based on the rationale that glucose 
is needed as metabolic substrate for physiological mechanisms in both central as peripheral 
processes, such as ion pumps involved in neurotransmission, cell mechanisms, and for the 
synthesis of  the neurotransmitters serotonin, noradrenalin, glutamate, gamma-aminobutyric 
acid (GABA) and acetylcholine (ACh).43 
A general proposed mechanism is that the supply of  a glucose load may prevent the 
depletion of  brain glucose levels when performing a cognitive task;55 because of  the limited 
storage capacity of  glucose in the brain, a continuous peripheral supply of  glucose is 
48
necessary.56 Increased neural activity is associated with increased use of  glucose in localized 
brain areas,44 resulting in a decrease of  glucose in extracellular brain areas after learning a 
task. Particularly more difficult tasks may lead to more depleted storages of  glucose and 
supply of  extra glucose may counteract these depletion effects especially when astrocytes 
cannot deliver enough lactate. Recently, suggestions have been put forward that effects 
of  glucose on cognitive performance are mediated by the control of  metabolic substrates 
by astrocytes.54 In normal conditions, glucose is taken up by astrocytes to form glycogen. 
During learning or a cognitive task, glycogenolysis and production of  lactate are induced 
by activation of  membrane receptors on astrocytes. Glucose is then mainly taken up by 
astrocytes rather than neurons.57 This may indicate that lactate from astrocytes may provide 
an additional energy substrate, next to glucose.54, 58 
An important brain area regarding the glucose-facilitating effects is the hippocampus. This is 
a key structure in learning and memory modulation and is especially important in mediating 
episodic memory function. As we concluded from the discussed study results, performance 
on episodic memory benefitted the most from glucose ingestion. When learning a new 
task, hippocampal activity increases and extra glucose can help sustain hippocampal activity, 
which may lead to a better storage of  new memories.59 Hippocampal extracellular glucose 
levels fluctuate depending on cognitive demands;55 levels decrease during memory tasks, as 
is shown in rats, and these changes appeared to be larger in older than in younger rats.60 A 
functional magnetic resonance imaging (fMRI) study in patients with schizophrenia showed 
that glucose ingestion was associated with greater parahippocampal activation during verbal 
encoding.61 These results indicate that the medial temporal region may be involved in 
memory facilitating due to glucose.
In the hippocampus, another possible mechanism can be identified; the neurotransmitter 
ACh is produced in the hippocampus and is part of  the cholinergic system, a 
neurotransmitter system involved in the regulation of  memory and learning.62 The release 
of  ACh is partly regulated by glucose availability. In rat studies, a relationship has been 
shown between glucose availability and brain ACh levels; intra-hippocampal and intra-septal 
glucose injections increased ACh release and improved alternation scores in rats.63, 64 In highly 
demanding situations, such as difficult memory tasks, increased glucose levels may enhance 
the production of  acetyl coenzyme A and therewith facilitate the production of  ACh.65 ACh 
also plays a role in prefrontal lobe functioning 66 and as such, the increase of  ACh following 
a glucose load may explain the possible effects of  glucose on executive function and 
attention.67
Throughout the brain, although not homogenously, insulin receptors are found, with higher 
concentrations of  receptors in, among others, the hippocampus.68, 69 This indicates another 
possible site of  action of  glucose intake because of  a glucose-mediated secretion of  insulin. 
Insulin can enter the brain by receptor-mediated transport in the blood-brain barrier. Via 
insulin receptors, insulin may be important in memory formation by activating specific 
signaling pathways that may modulates synaptic plasticity, density, and neurogenesis.70, 71 It 
has been shown that intra-nasal infusion with insulin improves memory in patients with 
AD.72 Under euglycemic hyperinsulinemic conditions, insulin has shown to improve verbal 
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memory and selective attention.73 However, when an oral glucose load is given, it is difficult 
to discriminate between the possible mechanism of  the glucose-mediated insulin secretion 
and pure sole glucose effects, because of  the narrow relationship between an increase in 
glucose levels and the subsequent increase in insulin levels. 
Another possible mechanism of  glucose facilitation is via ATP-sensitive potassium channels, 
which seems to be sensitive for glucose metabolism. The presence of  glucose is needed to 
increase intra-neuronal ATP levels, which results in depolarization of  neurons. This again 
mediates the release of  neurotransmitters (nicely explained by Stefani et al.),74 which can then 
alter cognitive performance. 
The action of  glucose seems not only to occur in the central nervous system, but also in 
the peripheral nervous system.43 Peripheral mechanisms might go via the gut hormone 
cholecystokinin and its receptors in the celiac ganglion.15, 32 In addition, glucose may also 
affect cognition via the liver, where a mechanism may send a neural signal by stimulating 
the vagus nerve, to the central nervous system to influence the physiological processes 
underlying memory.32 Findings in vagotomized rats substantiate that there is a peripheral 
mechanism as well; L-glucose, which does not cross the blood-brain barrier, enhanced task 
performance in healthy rats, but not in vagotomized rats.75 This may also explain the possible 
effects of  fructose, which does not cross the blood-brain barrier but has been shown to 
enhance memory in rats. The metabolite pyruvate, a common metabolite of  glucose and 
fructose, may be a key in this mechanism of  improving memory.35 Pyruvate can cross the 
blood-brain barrier in a substantial amount. In the brain, pyruvate undergoes reversible 
carboxylation and can then act as an energy substrate for neurons in case of  energy 
deficiency.76
The facilitating effects of  glucose on memory and partly on other cognitive functions are 
shown in younger and older populations, but the effects seem to be more pronounced in 
older individuals.24 Underlying causes of  aging can be changes in neuron components in a 
structural, chemical, or in an electrical way.56 Moreover, neuroendocrine regulation may be 
changed whereby key hormones involved in memory storage are disturbed, as well as the 
age-related impairments in glucose metabolism.51 Circulating blood glucose levels increase 
with age while overall cerebral glucose metabolism decreases with age, and insulin sensitivity 
decreases. Aged rats showed a larger decrease in extracellular hippocampal glucose during 
training than younger rats 60, 77 and extracellular glucose levels in the hippocampal areas are 
lower compared to younger rats,77 which may, partly, explain why the effect of  glucose is 
larger in elderly people. Furthermore, insulin receptors in the brain may change due to aging 
and might play a role in memory formation.78 
Mechanisms that explain the glucose-enhancing effects by the raise in blood glucose levels 
have been contradicted by a few studies. Kaplan et al. investigated the effects of  other 
nutrients besides glucose on cognition and showed that protein 14 and barley,15 which have 
low glycemic indexes, also improved cognition. Blood glucose levels rose minimally and 
it was suggested that the supply of  energy may be more important to enhance cognitive 
functions, pointing to other possible evolutionary mechanisms. Furthermore, Manning et al. 
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showed a beneficial effect of  glucose at a 24-hour delayed recall, when glucose levels were 
already at normal levels again.21 This indicates that once the memory has been formed, this 
outlasts the acute effects of  glucose on the brain. 
Summary and conclusions
In this review we discussed the effects of  a glucose load on various cognitive functions in 
healthy elderly people and patients with MCI and AD. Based on the selected studies, we 
conclude that glucose may improve episodic memory in elderly people. On other cognitive 
domains, however, the beneficial effect was doubtful; effects have been studied less abundant 
with only a few studies that observed beneficial effects on different cognitive domains. 
The limited number of  studies is surprisingly, because attentional functions and higher 
executive functions are particularly vulnerable for decline due to aging.79 Nevertheless, it is 
also possible that glucose has domain-specific actions and thus, may only slightly improve 
functions other than episodic memory. Fructose and sucrose might also improve cognitive 
performance, but most evidence was derived from studies in rats and it has hardly been 
investigated in humans. 
To the best of  our knowledge, we collected all available studies performed in elderly 
individuals concerning the glucose effects on cognitive performance. Our focus was on 
studies done in the elderly, because it is assumed that elderly people have more room for 
improvements than younger individuals and therefore might benefit more from glucose. 
Furthermore, it has been suggested that elderly people have different needs because 
their brain metabolic rate is different than younger adults.56 Also dysfunction of  neurons 
containing ACh, especially in the hippocampus, as a result of  aging supports the interest in 
the glucose-enhancing effects in older individuals.66 A review done in 2011 discussed results 
not only in older populations, but also in younger individuals, and concluded that glucose 
can have beneficial effects in younger populations as well.1 Also in younger populations, the 
focus was mainly on episodic memory, and especially when there was a divided attention 
condition by dual tasking, glucose improved memory performance.1 Glucose may also have 
an effect on non-memory functions, but tasks have to be challenging. In a study done in both 
elderly and younger participants, the facilitating effect of  glucose was more pronounced in 
the older adults,24 but contradictory results were found in a meta-analysis, showing a smaller 
effect size in older adults than in younger adults. The authors, however, mentioned to treat 
the effects with caution, as the studies in both populations were heterogeneous and more 
effect sizes were available from studies done in younger populations.12 By focusing on only 
the elderly population in the current review, we were able to discuss the results extensively, 
and by showing the broad spectrum of  neuropsychological tests that were done in those 
studies, we had a distinctive look at the results of  all cognitive functions that were examined.  
In conclusion, a glucose load seems to improve episodic memory in elderly people, but 
limited evidence is available for the effects of  glucose on other cognitive domains. The 
effects of  fructose or sucrose on cognitive functioning have hardly been studied and 
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therefore no conclusions can be made. Recommendations for the regular dietary use of  
pure glucose, sucrose, or products containing high amounts of  added sugars, are, however, 
hard to make due to the negative health effects it has on the long term, as is also stated in 
the guidelines for healthy nutrition for American people.80 In addition, a recent draft report 
of  the World Health Organization proposes to reconsider the guidelines for free sugar 
use, as limiting the consumption of  free sugars may reduce the risk of  obesity and dental 
caries.81 For difficult memory tasks, though, extra glucose might be a useful tool to improve 
performance. A quick rise in glucose levels may be beneficial, but on the longer-term stable 
glucose levels are warranted. To get a more complete picture, future research has to focus 
on a better understanding of  the mechanism behind the effect of  glucose and sucrose on 
cognitive performance, which would also be useful in understanding neurological processes. 
Neuroimaging studies will be of  great use for determining specific brain regions involved in 
the enhancing effects of  glucose, whereas animal models can be useful in entangling different 
mechanisms of  neuronal functions. 
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Abstract
Objective: In this study we determined the short-term effects of  a glucose drink and a 
sucrose drink compared to a placebo on cognitive performance and mood in elderly people 
with subjective, mild memory complaints using a randomized crossover study design. 
Methods: In total, 43 non-diabetic older adults with self-reported memory complaints were 
included. Drinks consisted of  250 mL with dissolved glucose (50 g), sucrose (100 g), or a 
mixture of  artificial sweeteners (placebo). Multiple neuropsychological tests were performed 
and combined by means of  Z-scores into four cognitive domains: episodic memory, working 
memory, attention and processing speed, and executive functioning. Mood was assessed with 
the s-POMS questionnaire. Blood glucose concentrations were measured at five time points 
to divide participants into those with a better or poorer blood glucose recovery. 
Results: Performance on the domain of  attention and information processing speed was 
significantly better after consuming the sucrose drink (domain score of  0.06 ± 0.92) than 
after the placebo drink (-0.08 ± 0.91, p = 0.04). Sucrose had no effect on the other three 
domains, and glucose had no effect on any of  the domains compared to the placebo. When 
dividing participants into poorer or better glucose recoverers, the beneficial effect of  sucrose 
on attention and information processing speed was only seen in participants with a poorer 
recovery. After sucrose consumption, depressive feelings and tension were slightly higher 
than after the placebo. 
Conclusions: To conclude, 100 g sucrose, but not 50 g glucose, optimized attention 
and information processing speed on the short-term in this study in elderly people with 
subjective, mild memory complaints.
Short-term effects of glucose 
and sucrose on cognitive 
performance and mood in 
elderly people
Nikita L. van der Zwaluw, Ondine van de Rest, Roy P.C. Kessels, and Lisette C.P.G.M. de Groot. Short-
term effects of  glucose and sucrose on cognitive performance and mood in elderly people. Journal of  
Clinical and Experimental Neuropsychology, 2014, 36(5); 517-527.
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Introduction 
Glucose is the main metabolic fuel for the brain and as such, it plays a role in the modulation 
of  cognitive processes. In rats, it has been shown that the use of  brain glucose is enhanced 
when neural activity related to high cognitive demands increases.1 Brain glucose availability 
can then become a limiting factor for optimal brain functioning.2  In rats, it has also been 
shown that blood glucose concentrations and glucose levels in extracellular brain fluid 
change with aging.3 Aging is accompanied with cognitive decline and neuro-endocrine 
dysregulation, which includes a disturbed regulation of  key hormones and neurotransmitters 
that are involved in glucose regulation and memory storage, such as adrenalin and 
acetylcholine.4 Therefore, elderly people are a highly relevant population to study the effects 
of  manipulating blood glucose concentration on cognitive performance.
The amount of  evidence that the intake of  a glucose load may have beneficial effects on 
cognitive performance is growing, in particular on the domain episodic memory. In rodents 
and human populations with cognitive deficits (i.e., Alzheimer’s disease, Down syndrome 
and schizophrenia) enhancing effects of  glucose on episodic memory have been consistently 
demonstrated (see Smith et al. for review),4 and also in relatively healthy elderly people 
beneficial effects have been observed. Aging also affects attentional mechanisms,5 but the 
few studies that focused on the effect of  glucose on this cognitive domain showed mixed 
results. Enhancing effects of  glucose on attention have been reported in younger 6, 7 and in 
older populations,8 but other studies, did not find effects.9, 10
Next to cognitive performance, blood glucose concentrations may influence behavioral 
functions and mood, such as for instance a less energetic feeling when blood glucose levels 
decrease.11 Glucose intake can increase the synthesis of  the neurotransmitter serotonin, 
which is involved in mood regulation and sedation.12 Evidence on the effect of  a glucose 
load on mood is, however, limited and inconsistent, with only a few studies that reported 
inconsistent and small effects,13, 14 and others that did not find an effect.15
Whether sucrose, which consists of  half  glucose and half  fructose, has the same effect on 
cognitive performance as glucose, has hardly been investigated in older adults. Sucrose in 
combination with nicotine may be beneficial for performance on a continuous performance 
task 16 and in rodents, a positive effect of  fructose on memory performance has been 
demonstrated.17, 18 In contrast to glucose, fructose cannot cross the blood-brain barrier 
and only slightly raises blood glucose concentrations.18 Thus, it has to act through another 
mechanism, probably of  a peripheral nature,19 like via the gut hormone cholecystokinin and 
its receptors in the celiac ganglion.20 Because sucrose may have a direct effect on the brain 
via glucose, as well as an effect on a peripheral mechanism via fructose, we hypothesized that 
sucrose may have a stronger effect than only glucose on cognitive performance and mood. 
The objectives of  the current study were to investigate the short-term effects of  glucose 
and sucrose on cognitive performance and mood in healthy elderly people with self-reported 
mild memory complaints. Furthermore, we studied whether there was a differential effect 
of  glucose and sucrose on cognitive performance between participants who had a better or 
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poorer glucose recovery, since the ability to normalize blood glucose concentrations after a 
glucose load depends on an individual’s glucose recovery abilities. 
Methods
Participants 
Participants were recruited in the area of  Wageningen, the Netherlands, by sending an 
invitation letter to volunteers from an existing database. Potentially eligible participants 
were invited for a screening session at the Wageningen University. Inclusion criteria were: 
elderly men and women (≥70 years), non-diabetic (fasting blood glucose <7.0 mmol/L),21 
non-depressed (score on the Center for Epidemiologic Studies Depression Scale (CES-D) 
≤16, range 0-60; a higher score indicates more depressive symptoms),22 non-demented 
(Mini-Mental State Examination (MMSE) score >25, range 0-30; a lower score indicates 
more cognitive impairment),23 and mild memory complaints. The latter was specified by the 
Cognitive Failure Questionnaire (CFQ),24 that assesses self-reported memory complaints. 
The total score ranges from 0-100 and a higher score indicates more memory complaints. An 
individual was included when the CFQ score was >21, and when the participant reported to 
experience memory complaints and was hampered by those complaints.25 Exclusion criteria 
were pharmacological antidepressants or suffering from liver disease, Parkinson’s disease or 
Phenylketonuria. This study was approved by the Wageningen University Medical Ethical 
Committee. Written informed consent was obtained from all participants. This trial was 
registered in the NIH clinical trial database (ClinicalTrials.gov number NCT01427231).
The required sample size was calculated based on the results on the Paired Associate 
Learning task after 50 g of  glucose and a placebo drink in elderly participants.26 The 
calculated effect size was 0.40,27 and with a power of  80% and a significance level (α) of  0.05, 
a sample size of  at least 41 participants was required to find a difference between glucose 
and placebo drink, as was calculated by the program G*Power 3.0.10.28
In total, 311 volunteers were invited of  which 119 were interested to receive more 
information, 79 did not respond to the invitation letter, and 113 were not interested in 
participating. Of  the 80 volunteers who returned the medical questionnaire, 71 were screened 
and 45 fulfilled the inclusion criteria. In the end, 43 participants were included in the study. 
Only one woman withdrew from the study, because of  dizziness and heart palpitations after 
consuming the test drinks.
Design and procedure
A randomized repeated-measures crossover design was used. Each participant consumed 
three test drinks on three different moments, with at least one week in between to minimize 
carryover effects. The order of  drinks was randomized. Test sessions took place during the 
morning after an overnight fast (10-12h).
During each test session, blood glucose response was measured using a finger prick 
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(HemoCue Glucose 201) at t=0 (fasting), t=15, t=30, t=60, and t=90 minutes. Immediately 
after the first blood glucose measurement, the participant had to consume the test drink, 
which had to be finished within five minutes. Cognitive testing was started fifteen minutes 
after consumption of  the test drink, allowing a good absorption of  the sugar into the blood 
stream.
Materials 
All three test beverages were presented in a non-transparent cup, in a serving of  250 mL 
that contained either 50 g of  glucose, 100 g of  sucrose (consisting of  50 g glucose and 50 
g fructose), or a mixture of  artificial sweeteners as placebo condition (see Supplementary 
Table 1 for all ingredients). All drinks were matched for color, flavor and sweetness (by 
adding artificial sweeteners) and were lemon-flavored to mask differences in taste. Drinks 
were provided by United Soft Drinks (Utrecht, the Netherlands). 
After each test drink, participants completed a questionnaire on sensory properties to assess 
differences in taste. Pleasantness, sweetness, lemon taste, sourness, viscosity, pleasantness of  
the after taste, artificial taste, and hunger and thirst were rated on 10-point scales (e.g. 1 = 
‘‘totally not pleasant’’ and 10 = ‘‘totally pleasant’’).
Cognitive performance
Cognitive performance was measured using an extensive battery of  neuropsychological tests, 
which was performed in a quiet room by well-trained research assistants who followed a 
strict protocol. In 74% (n = 31) of  the participants, all three test sessions were performed 
by the same research assistant. Tests were always performed in the same order. To minimize 
learning effects, parallel versions were used for the tests measuring episodic memory (Rey 
Auditory Verbal Learning Test (RAVLT), Story recall, Paired Associate Learning (PAL) test 
and for the Verbal Fluency).
A test session started with the RAVLT direct recall (three-trial version) to measure episodic 
memory.29 Twenty minutes later, RAVLT delayed recall was tested. In between, Wechsler’s 
Digit Span Task forward and backward were performed to measure working memory and 
attention.30 Furthermore, Letter Digit Substitution Test (LDST) 31 and the Alertness subtest 
from the Test for Attentional Performance (TAP) were performed to measure information 
processing speed and reaction time.32 After the RAVLT delayed recall, the TAP subtest 
Flexibility was done measuring complex reaction times (parts Letters and Digits), and 
mental flexibility (Letter-Digit Alternation) as part of  executive function. This was followed 
by another episodic memory test: the Story Recall subtest of  the Rivermead Behavioral 
Memory Tests direct recall and delayed recall (approximately 20 minutes after direct recall).33 
The Stroop Color-Word Test was used to measure response inhibition as part of  executive 
function.34 For Verbal Fluency three different letter combinations were used for each test 
session; ‘D-A-T’, ‘K-O-M’ and ‘P-G-R’. This test measures semantic memory and language 
production.35 Each test session was finished with the PAL test to assess associative memory 
(see Supplementary Table 2 for the order of  cognitive tests).36 To control for the effect of  
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motor speed on performance we calculated an interference measure for Stroop part 3 (Time 
needed for Stroop part 3 – (mean time needed for Stroop part 1 and 2)).
Mood 
Mood was assessed immediately after consuming the test drink and after each test session 
by the short Profile Of  Mood Status (s-POMS) questionnaire. The s-POMS focuses on 
how participants are feeling at that particular moment. It consists of  32 items, covering five 
components of  mood: depression, fatigue, anger, tension, and vigor.37 
Other measurements 
Information about smoking habits, alcohol use, marital status and highest education level 
was obtained using a questionnaire. Education was categorized according to Statistics 
Netherlands (CBS; low, moderate, or high educated). During the first test session, body 
weight was measured to the nearest 0.1 kg with a digital scale (Seca Delta-707), with 
participants wearing light clothes and without shoes. Body height and waist circumference 
were measured to the nearest 0.1 cm. Furthermore, a fasting blood sample was collected 
in an EDTA-tube to determine plasma insulin concentrations. Insulin was analyzed by 
radioimmunoassay (Insulin RIA Kit; LINCO Research Inc, St Charles, MO). 
Statistics 
Data are expressed as n (%), means ± SD, or as median [interquartile range (IQR)] for non-
normal distributed data. Repeated-measures ANOVA was used to determine differences in 
effect of  the three test drinks on cognitive test scores and mood scores at t=0 and t=90. 
Cognitive test scores acted as dependent factor, whereas drinks and time (test day) were set 
as fixed variables. Tukey post-hoc tests were used to compare mean scores between the three 
drinks and to correct for multiple testing. 
To compare the results of  individual cognitive test scores and to limit the number of  
dependent variables, individual cognitive tests were transformed into Z-scores and clustered 
into compound scores for four neuropsychological domains: episodic memory; working 
memory; attention and information processing speed; and executive functioning.
Episodic memory = (ZRAVLT, direct + ZRAVLT, delayed + ZPAL + ZStory recall, direct + ZStory recall, delayed)/5 
Working memory = (ZDigitSpan forward + ZDigitSpan backward)/2 
Attention and information processing speed = (-ZStroop mean part 1+2 + ZLDST + -ZTAP Flexibility 
letters + -ZTAP Flexibility digits + -ZTAP Alertness simple + -ZTAP Alertness cued)/6
Executive functioning = (-ZStroop (part 3-(part 1+part 2)/2) + ZVerbal Fluency Letters + ZTAP Flexibility letter-digit 
alternating)/3
Previous research showed that facilitating effects of  glucose may be influenced by blood 
glucose recovery. We therefore determined the rate at which blood glucose concentrations 
returned to baseline level, by calculating the incremental area under the curve (AUC) for 
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each participant.38 A median split divided the study population into two groups; participants 
with a better or poorer glucose recovery. Participants with values above the median split were 
indicated as having a poorer recovery, whereas participants with values below the median 
split were classified as having a better recovery.
A two-sided p-value of  0.05 was used to determine statistical significance. All statistical 
analyses were performed using SPSS Statistics v19 (SPSS Inc. Chicago, IL). 
Results
Participants 
Baseline characteristics of  the 43 participants can be found in Table 1. Mean age was 78 ± 
6 years and slightly more women (63%) than men participated in the study. Median MMSE 
score was 29 (IQR 28-30, range 26-30). 
Table 1 Characteristics of  Dutch older adults with subjective, mild memory complaints (n = 43)
Characteristic
Age (yrs)a 77.7 ± 5.6
Sex, menb 16 (37%)
BMI (kg/m2) 25.6 ± 2.9
Waist circumference (cm) 92 ± 13
Education low / middle / high 3 (7%) / 20 (47%) / 20 (47%)
Smokers 3 (7%)
Number of  cigarettes/cigars per dayc 4.5 ± 0.7
Alcohol consumers 31 (72%)
Alcohol consumption (glasses/ week)d 8.1 ± 7.1
MMSEe 29 [28-30]
CES-D 7.7 ± 4.2
CFQ 33.2 ± 8.8
Baseline glucose (mmol/L) 5.2 ± 0.7
Baseline insulin (mU/L) 4.8 ± 2.4
HOMA Insulin resistance 1.1 ± 0.7
HOMA beta cell function 66.9 ± 37.6
AUC better glucose recoveryf 332 ± 52
AUC poorer glucose recoveryg 168 ± 57
Notes: BMI, Body Mass Index; MMSE, Mini-Mental State Examination; CES-D, Center for Epidemiologic Studies 
Depression Scale; CFQ, Cognitive Failure Questionnaire; HOMA, Homeostasis Model Assessment; AUC, incremental 
Area Under the Curve. a mean ± SD (all such values); b n (%)(all such values); c Mean use in smokers only; d Mean use in 
alcohol consumers only; e median [IQR]; f  n = 21; g n = 22. 
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Cognitive performance 
Almost all test scores, except for the working memory tasks and three tasks of  the TAP, 
improved significantly over time (p < 0.01), which indicates there was a learning effect. Post-
hoc analyses showed that the largest improvement was seen at test day 2 compared to test 
day 1 (data not shown).  
Table 3 presents the scores of  the cognitive performance tests and the scores for the four 
cognitive domains per drink. After the sucrose drink, the cognitive domain attention and 
information processing speed was significantly better (mean 0.06 ± 0.92) than after the 
placebo drink (mean -0.08 ± 0.91, p = 0.04). Within this domain, performance of  the TAP 
Flexibility-letters test was best after the sucrose drink (mean 541 ± 89 ms) compared to the 
placebo drink (mean 566 ± 92 ms, p = 0.01) and compared to the glucose drink (mean 562 ± 
100 ms, p = 0.04). Furthermore, LDST score was better after the sucrose drink (mean 30.4 ± 
6.8) and after the glucose drink (mean 30.6 ± 7.6) compared to the placebo drink (mean 29.3 
± 5.5, p = 0.10 and p = 0.04 respectively). 
No other differences were observed between the glucose or sucrose drink compared to the 
placebo drink. Working memory, however, was better after sucrose compared to glucose 
(p = 0.04), due to better performances on the Digit Span Test forward and backward after 
Sensory properties 
Sensory properties of  the three test drinks are shown in Table 2. Participants rated the 
glucose drink as most pleasant (5.8 ± 2.0) and the placebo drink as least pleasant (4.8 ± 
2.2), p<0.01 with Tukey’s post-hoc test) on a palatability scale 1 (not at all pleasant) to 10 
(very pleasant). The sucrose drink was rated as sweeter (7.7 ± 1.7) compared to the placebo 
drink (6.6 ± 2.3, p = 0.02). Other sensory aspects did not differ between test drinks and 
participants were equally hungry and thirsty at all test days.
Table 2 Sensory properties of  three test drinks, and feelings of  hunger and thirst (n = 43, mean values ± SD)
Variable Glucose (50 g) Sucrose (100 g) Placebo 
(n = 42)
(df) F-ratio p
Pleasantness 5.8 ± 2.0a 5.5 ± 2.2 4.8 ± 2.2a (2,81) 6.00 <0.01
Sweetness 7.3 ± 1.9 7.7 ± 1.7b 6.6 ± 2.3b (2,81) 3.92 0.02
Lemon taste 5.1 ± 2.2 5.0 ± 2.3 4.8 ± 2.5 (2,81) 0.39 0.68
Sourness 3.7 ± 2.3 3.8 ± 2.1 3.8 ± 2.4 (2,81) 0.06 0.93
Viscosity 2.9 ± 1.9 3.5 ± 2.1 3.2 ± 2.1 (2,81) 2.29 0.11
Pleasantness aftertaste 5.5 ± 1.8 5.1 ± 2.1 4.7 ± 2.2 (2,81) 2.49 0.09
Artificial taste 4.2 ± 2.3 4.2 ± 2.4 4.7 ± 2.6 (2,81) 1.20 0.31
Hunger 4.1 ± 2.0 4.0 ± 2.3 3.6 ± 2.0 (2,81) 1.38 0.26
Thirst 4.1 ± 2.3 3.5 ± 2.2 3.8 ± 2.4 (2,81) 1.15 0.32
Notes: Differences between the three test conditions were measured with repeated-measures ANOVA. All scores were 
on a scale of  1-10, whereas a higher score indicates a stronger sensory property. a, b Within a row, groups with differing 
superscripts differ at p < 0.05, tested with Tukey post-hoc test 
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sucrose. Executive function was also slightly better after the sucrose drink (mean 0.09 ± 0.81) 
compared to the glucose drink (mean -0.02 ± 1.03), but this difference was not significant (p 
= 0.08). Episodic memory performance did not differ between test drinks. 
Table 3 Performance on cognitive tests and domain scores of  43 Dutch older adults with subjective, mild memory 
complaints after three test drinks (mean ± SD)
Cognitive measures Glucose 
(50 g)
Sucrose
 (100 g) 
Placebo# (df) 
F-ratio
p
Episodic memory
RAVLT, immediate recall, max. 45 
words*
21.4 ± 7.6 21.4 ± 7.0 21.3 ± 6.1 (2,79) 0.14 0.87
RAVLT, delayed recall, max. 15 words* 6.4 ± 3.1 6.0 ± 2.8a 6.8 ± 3.0a (2,79) 3.00 0.06
Story recall, immediate recall, max. 21 
points*
9.8 ± 3.6 10.2 ± 3.5 10.3 ± 3.6 (2,79) 0.84 0.44
Story recall, delayed recall, max. 21 
points*
8.2 ± 3.7 9.0 ± 3.2 8.8 ± 4.3 (2,76) 0.69 0.50
PAL easy, max. 9 points* 8.0 ± 1.2 7.9 ± 1.6 8.0 ± 1.3 (2,79) 0.10 0.90
PAL difficult, max. 12 points* 5.4 ± 3.0 5.9 ± 3.2 5.6 ± 3.3 (2,79) 1.13 0.33
Working memory
Digit Span Forward, max. 16 points* 8.1 ± 2.0 8.6 ± 1.8 8.2 ± 1.5 (2,79) 1.41 0.25
Digit Span Backward, max. 14 points* 5.8 ± 1.8b 6.1 ± 1.9 6.4 ± 2.0b (2,79) 1.81 0.17
Attention and information processing speed
Stroop Color Word Test I (s)† 52.0 ± 11.1 52.3 ± 12.2 52.9 ± 11.5 (2,81) 0.35 0.71
Stroop Color Word Test II (s)† 64.3 ±14.9 64.9 ± 17.6 65.4 ± 14.6 (2,79) 0.31 0.74
Letter Digit Substitution test 30.6 ± 7.6c 30.4 ± 6.8 29.3 ± 5.5c (2,81) 2.61 0.08
TAP Alertness, simple RT (ms)† 280 ± 47 279 ± 63 286 ± 64 (2,81) 0.59 0.56
TAP Alertness, cued RT (ms)† 279 ± 59 276 ± 62 289 ± 69 (2,81) 1.77 0.18
TAP Flexibility, letters (ms)† 562 ± 100d 541 ± 89d,e 566 ± 92e (2,81) 4.30 0.02
TAP Flexibility, digits (ms)† 571 ± 118 559 ± 96 560 ± 108 (2,81) 0.88 0.42
Executive functioning
Stroop Color Word Test interference (s)† 48.2 ± 21.0f 43.5 ± 16.3f 45.9 ± 19.9 (2,81) 4.85 0.01
TAP Flexibility, letter-digit alternating 
(ms)†
915 ± 405 871 ± 322 888 ± 298 (2,79) 1.44 0.24
Word fluency (total words) 41.9 ± 13.6 41.4 ± 12.7 40.5 ± 12.3 (2,81) 0.42 0.66
Domain scores
Episodic memory 0.03 ± 0.96 0.15 ± 0.91 0.15 ± 0.94 (2,76) 0.37 0.69
Working memory -0.11 ± 1.09g 0.15 ± 1.00g 0.10 ± 0.89 (2,79) 1.23 0.30
Attention and information processing 
speed
0.02 ± 0.91 0.06 ± 0.92h -0.07 ± 0.91h (2,81) 2.31 0.11
Executive functioning -0.02 ± 1.03 0.09 ± 0.81 -0.00 ± 0.85 (2,79) 2.23 0.11
Notes: Differences between the three test conditions were measured with repeated-measures ANOVA. 
RAVLT, Rey Auditory Verbal Learning Test; PAL, Paired Associate Learning; TAP, Attention Test Battery; RT, reaction 
time. # n = 42; * n = 42 for the glucose and sucrose condition because of  one participant with hearing difficulties, in the 
placebo condition n = 41; † A higher score indicates more time was needed to complete the task, indicating a poorer 
performance. a-h Within a row, groups with differing superscripts differ at p < 0.05, tested with Tukey post-hoc test.
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Figure 1 Mean (SD) blood glucose response in mmol/L for three test drinks measured at five time points
Glucose recovery 
Blood glucose response is presented in Figure 1. Baseline blood glucose concentrations were 
similar for all test drinks. As expected, plasma glucose concentrations did not increase after 
the placebo drink, whereas the glucose drink and sucrose drink caused an increase in the 
first 30-60 minutes, followed by a decrease during the next 30 minutes. No differences were 
observed between the glucose recovery rate of  glucose and sucrose. 
Domain scores for participants with a better or poorer glucose recovery are shown in Table 
4. Participants with a better glucose recovery tended to have an enhanced performance 
than poorer glucose recoverers on all but one domain after the placebo drink; attention and 
information processing speed was better in participants with a poorer glucose recovery. 
In the group with a poor glucose recovery, attention and information processing speed 
improved significantly after glucose (mean 0.13 ± 0.87, p = 0.04) and sucrose (mean 0.15 
± 0.96, p = 0.02) compared to the placebo (mean -0.06 ± 1.09). The facilitating effects of  
glucose or sucrose on this domain were not observed in participants with better glucose 
recovery. 
Mood 
Five components of  mood were measured right after consumption of  the test drink (t=0), 
and again after the cognitive tests (t=90, Table 5). After sucrose consumption, negative 
feelings were higher than after the placebo drink at t=90 (depression p = 0.03; tension p 
= 0.03). Mood components after glucose consumption were not different than after the 
placebo drink at t=0 or at t=90. Compared to sucrose, however, mood components vigor at 
t=0 (p = 0.02) and at t=90 (p = 0.05), and depression at t=0 (p = 0.02) were better after the 
glucose drink. 
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Table 4 Performance per cognitive domain, measured in 43 Dutch older adults with subjective, mild memory 
complaints, split up by glucose recovery index (mean ± SD)
Cognitive domains Glucose (50g) Sucrose (100g) Placebo (df) F-ratio p
Better glucose recovery*
Episodic memory 0.07 ± 0.97 0.12 ± 0.73 0.21 ± 0.89 (2,37) 0.51 0.60
Working memory -0.08 ± 1.25a 0.25 ± 1.11a 0.19 ± 0.97 (2,38) 0.68 0.51
Attention and information 
processing speed
-0.07 ± 0.95 -0.03 ± 0.89 -0.08 ± 0.74 (2,40) 0.42 0.66
Executive functioning -0.03 ± 0.80b 0.15 ± 0.71b 0.02 ± 0.78 (2,38) 4.15 0.02
Poorer glucose recovery†
Episodic memory -0.02 ± 0.97 0.17 ± 1.09 0.09 ± 1.02 (2,35) 0.02 0.98
Working memory -0.15 ± 0.92 0.04 ± 0.89 -0.00 ± 0.81 (2,37) 0.99 0.38
Attention and information 
processing speed
0.13 ± 0.87c 0.15 ± 0.96d -0.06 ± 1.09c,d (2,37) 3.25 0.05
Executive functioning -0.01 ± 1.12 0.03 ± 0.92 -0.03 ± 0.93 (2,37) 0.00 1.00
Notes: Differences between the three test conditions were measured with repeated-measures ANOVA.
* n = 22, but n = 21 for the placebo condition; † n = 21, but n = 20 for episodic memory because of  one participant 
with hearing difficulties. a-d Within a row, groups with differing superscripts differ at p < 0.05, tested with Tukey post-
hoc test. 
Table 5 Mood scores per component measured by the s-POMS in 43 Dutch older adults, immediately measured 
after consuming the test drink (t=0) and after the cognitive functioning tests (t=90) (mean values ± SD)
Mood 
factors
Glucose (50 g) Sucrose (100 g) Placebo# (df) 
F-ratio
p (df) 
F-ratio
p
t=0 t=90 t=0 t=90 t=0 t=90 t=0 t=0 t=90 t=90
Depres-
sion
1.4 ± 3.4a 1.8 ± 4.1 2.7 ± 4.6a 2.6 ± 4.6b 2.3 ± 4.8 1.3 ± 3.1b (2,79) 
4.6
0.01 (2,76) 2.3 0.11
Anger 1.0 ± 2.1 1.4 ± 3.4 1.5 ± 3.0 1.6 ± 3.8 1.2 ± 3.2 1.0 ± 2.9 (2,81) 
0.8
0.46 (2,75) 
1.0
0.37
Fatigue 2.9 ± 4.1 5.0 ± 5.4 3.8 ± 4.9 4.7 ± 5.1 2.7 ± 4.0 4.2 ± 4.3 (2,80) 
3.3
0.04 (2,76) 
0.7
0.48
Tension 2.5 ± 3.4 2.3 ± 3.9 2.9 ± 3.9 3.0 ± 4.3c 2.9 ± 3.7 1.9 ± 2.6c (2,81) 
1.1
0.34 (2,76) 
2.8
0.07
Vigor 12.1 ± 3.7d 11.5 ± 4.0 10.4 ± 4.5d 10.3 ± 4.2 11.0 ± 4.3 10.9 ± 4.2 (2,81) 
3.9
0.02 (2,76) 
3.6
0.03
Notes: Per component, differences between the three test conditions were measured with repeated-measures ANOVA. 
Higher scores mean stronger feelings of  that mood component. # n = 42. a-d Within a row, groups with differing super-
scripts differ at p < 0.05, tested with Tukey post-hoc test.
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Discussion
In this study, short-term effects of  glucose and sucrose on cognitive performance in healthy 
elderly men and women with mild, self-reported memory complaints were investigated. 
Our findings showed that a sucrose drink had a beneficial effect on attention and 
information processing speed in this study population, whereas glucose improved attentional 
performance only in participants having a poorer glucose recovery. In contrast to previous 
studies, no beneficial effects of  glucose or sucrose were observed on episodic memory 
function.
One of  the strengths of  this study was the use of  an extensive neuropsychological test 
battery to measure cognitive performance, with sufficiently challenging tests to be able to 
detect subtle changes. Moreover, the tests we used have been applied in other studies as well 
(e.g. 8, 39). We clustered data of  individual test scores into four cognitive domains - episodic 
memory, working memory, attention and information processing speed, and executive 
function - to obtain more robust cognitive scores. The number of  dependent variables was 
thereby limited and the possibility of  chance findings is decreased. By assessing the four 
cognitive domains, we were able to investigate the effect of  glucose and sucrose on a broad 
spectrum of  cognitive functions that decline with aging.
Another strength was the crossover design, which was used to minimize the influence of  
substantial variability in memory function of  elderly people on test scores.40, 41 Test days were 
at least one week apart to minimize carryover effects, as was done in other studies applying 
a similar design (e.g. 42-44). Furthermore, validated parallel versions were used for those 
cognitive tests that are prone to learning effects, and by randomizing the order of  the drinks, 
a time effect was supposed to be diminished. However, still an effect over time was seen 
as participants improved performance on most tests after the first test day, independently 
of  the test drink. Although the tests were carefully explained and most tests were practiced 
beforehand, it would have been better to include a complete training session for all tests. 
Unlike many previous studies (reviewed by Smith et al.),41 we did not observe a beneficial 
effect of  glucose on episodic memory. Comparable to other studies, cognitive tests were 
always started fifteen minutes after consuming the test drink, assuming that this time interval 
would be sufficient to elevate glucose concentrations.44 After fifteen minutes, blood glucose 
concentrations were indeed elevated, but most optimal blood glucose concentrations for 
achieving cognitive effects, which lay between 8 and 10 mmol/L,45 were found after 30-60 
minutes. Because a test session always started with a memory test, it might be that glucose 
concentrations at that time point were not sufficiently elevated to enhance memory function. 
Next to the timing, the used glucose dose can be discussed. We assumed 50 g glucose to 
be the proper dose for older adults to enhance memory based on previous studies,39, 40, 45-47 
but studies using 25 g of  glucose also observed a facilitating effect on memory.9, 45, 48 This 
suggests that other factors than dose may play a role;45 body size for instance, may influence 
circulating blood volume and differences in glucose utilization as an energy substrate, 
which may affect the quantity of  glucose delivered to the brain.41, 49 It is also possible 
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that the optimum dose differs for different cognitive tasks; in rats it has been shown that 
brain regions differ in extracellular glucose levels.2 The dose to improve memory might 
be somewhat lower than 50 g, which may explain why we did not find any positive effects 
of  glucose and sucrose on memory, but that we did find a positive effect on attention and 
information processing speed. 
The dose of  100 g sucrose was chosen to have an equal amount of  glucose in the glucose 
and in the sucrose drink (in both test drinks 50 g of  glucose). In the total study population, 
we observed a small effect of  sucrose, but not of  glucose, on attention and information 
processing speed. This may indicate that the combination of  glucose and fructose is a better 
enhancer for this cognitive domain, but we should take into account that the sucrose drink 
contained a double amount of  energy as the glucose drink. It is therefore not possible to 
assign the beneficial effect of  sucrose only to fructose. To investigate the exclusive effect 
of  fructose, an extra treatment group investigating 50 g of  fructose should have been 
included. Due to limitations in organizational aspect and to keep the burden for participants 
acceptable, we decided to only investigate the 100 g sucrose. Moreover, other studies that 
investigated the effects of  glucose also encountered the aspect of  energy differences, since 
the placebo drinks almost never contained any calories. 
The positive effects of  glucose and sucrose on attention and information processing speed 
were shown in particular in participants having a poorer glucose regulation. This finding is 
in accordance with a study of  Kaplan et al.,44 in which older adults with a poorer glucose 
recovery had worse cognitive abilities, which was counteracted by the ingestion of  glucose. 
People with a poorer glucose regulation tend to score worse on cognitive tests,19 so it is 
plausible that more effect can be achieved in these persons. Other studies, though, have 
shown a stronger beneficial effect in better than in poorer glucose recoverers.43, 50 This 
discrepancy may be due to the commonly used method of  dividing a study population by 
a median split, which is rather arbitrary, since it depends on a particular study population. 
Furthermore, it has been suggested that younger adults with a poorer glucose regulation have 
a similar response as elderly people with a better glucose regulation.4 
By including older individuals with self-reported memory complaints, we aimed to include a 
study population that would be sensitive for changes in cognitive functioning. MMSE scores, 
however, were still high, which may be partly due to the fact that we excluded real cognitively 
impaired (MMSE ≤25) participants. MMSE, however, is a global measure for cognitive 
performance and impairments may only be picked up in a later stage, while memory 
complaints are usually the first signs of  cognitive decline. Mol et al. showed that people 
with subjective memory complaints had a lower score on information processing speed.51 
However, other causes than a poor cognitive performance are also known for reporting 
memory complaints, such as anxiety, depression,52 low self-esteem and neuroticism.53 
We did not find a clear effect of  glucose or sucrose on mood. Carbohydrates can increase 
brain serotonin concentrations and therewith decrease stressed feelings.11 In our study, mood 
was worst after the sucrose drink, the drink with the highest amount of  carbohydrates, which 
can be attributed to the low score on pleasantness of  the sucrose drink. The few studies 
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that are known, reported inconsistent and small effects of  a glucose drink on mood.11 In a 
study of  Bentone & Owen,14 a very small effect was observed in a large study population, 
and the authors already mentioned that it would be difficult to replicate these subtle findings 
in a smaller study population. In our study, mood was a secondary outcome, and as such, 
the study population was probably too small to observe an effect. Also the timing of  the 
questionnaires could have played a role in that serotonin concentration was not elevated 
enough at the first time point of  measurement, and that it was maybe depleted at the second 
time point.11 However, it was also suggested that mood would be more influenced by the 
supply of  glucose when performing cognitively demanding tasks, as this will increase brain’s 
need for glucose.11 We therefore expected a positive effect of  glucose or sucrose on mood 
after the cognitive tests. 
The best-known mechanism of  the glucose facilitating effect on memory is the possible 
effect on the hippocampus, which is the key structure in mediating episodic memory. Due 
to fluctuations in hippocampal extracellular glucose concentrations after a high-demanding 
cognitive task, replenishing these glucose concentrations could be beneficial to optimize 
performance. Also, insulin can play a role on the hippocampus; its receptors are densely 
concentrated in the hippocampus. In the absence of  a raise in plasma glucose, it has been 
found that insulin has a direct effect on memory.43 However, after a glucose load, it is 
difficult to distinguish between the effects of  a raise in blood glucose concentrations and the 
effects of  insulin. Other mechanisms that may play a role in the possible facilitating effect of  
glucose on cognitive performance may be related to the effect on neurotransmitters, such as 
epinephrine, glutamate, serotonin and acetylcholine, all involved in cognitive functioning.19, 
54 Synthesis of  acetylcholine is dependent on glucose and in rats, improved memory was 
shown after glucose ingestion together with an increase in hippocampal neurotransmitter 
acetylcholine synthesis.55 
A limitation of  this study was the lack of  an extra arm of  fructose drink. Another important 
consideration of  glucose use and the consecutive elevated blood glucose levels points to 
the negative long-term effects on neurons, and cognitive decline and dementia.56 As such, 
recommendations to take extra glucose are hard to make, but in case of  a high-demanding 
task, it might be useful to raise your glucose levels to improve performance. 
To conclude, a sucrose drink - which contained twice as much energy as the glucose 
drink - optimized attention and information processing speed on the short-term in elderly 
participants with mild memory complaints. Glucose also showed a beneficial effect on 
attention and information processing speed, but this effect was only observed in people with 
poorer glucose recovery. 
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Supplementary material
Supplementary Table 2 Order of  measurements on a test day 
Time Measurements
Blood glucose measurement
t=0 Drink
Questionnaire sensory properties
s-POMS
t=15 Blood glucose measurement
RAVLT
Digit Span
LDST
t=30 Blood glucose measurement
TAP-Alertness
Delayed recall RAVLT 
TAP-Flexibility 
Story Recall
t=60 Blood glucose measurement
Stroop-Color Word test
Letter Fluency
Delayed recall Story recall
PAL
t=90 Blood glucose measurement
s-POMS
Notes: s-POMS, short-Profile Of  Mood Status; RAVLT, Rey Auditory 
Verbal Learning Test; LDST, Letter-Digit Substitution Test; TAP, Test 
for Attentional Performance; PAL, Paired Associate Learning.
Supplementary Table 1 Ingredients (in g) per 250 mL test drink
Test drink Sucrose Dextrose Sodium 
cyclamate
Aspartame Acesulfame 
potassium
Citric acid 
Anhydrous
Sucrose drink 100 - - - - 1.00
Glucose drink - 50 0.04 0.10 0.10 0.75
Placebo drink - - 0.10 0.25 0.25 0.44
Notes: To all drinks potassium sorbate (0.15 g), drink essence (0.30 g), and ascorbic acid (0.10 g) was added.
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Abstract
Objective: Maintenance of  cognitive abilities is important for elderly to stay independent. 
With the aging of  the population, the call for modifiable factors is emerging. Dietary protein 
might improve cognitive performance; however, this has hardly been studied. Therefore, we 
studied the impact of  24 weeks dietary protein supplementation on cognitive performance in 
pre-frail and frail elderly people. 
Methods: Pre-frail and frail elderly subjects, according to the Fried-criteria, randomly 
received a protein drink containing 15 g protein or a non-caloric placebo drink twice a day. 
Cognitive performance was measured at baseline and after 24 weeks by means of  a sensitive 
neuropsychological test battery. In addition, reaction time was assessed after both 12 and 24 
weeks of  intervention. Domain scores were calculated for the domains episodic memory, 
attention and working memory, information processing speed, and executive functioning. 
ANCOVA was used to determine differences between groups. Linear Mixed Models were 
used to determine differences in reaction time over time and per treatment.
Results: In total, 65 subjects (79 ± 8 years) with a median MMSE score of  28 (interquartile 
range 26-30) were included. Reaction time improved more in the protein group (68 ms) than 
in the placebo group (18 ms, p = 0.03). Dietary protein had no significant effect on any of  
the cognitive domain scores. 
Conclusions: Protein supplementation might improve reaction time performance in pre-
frail and frail elderly, but did not improve other cognitive functions. 
Protein supplementation 
and cognitive performance 
in frail elderly people
Nikita L. van der Zwaluw, Ondine van de Rest, Michael Tieland, Jos J. Adam, Gert Jan Hiddink, Luc 
J.C. van Loon, and Lisette C.P.G.M. de Groot. The impact of  protein supplementation on cognitive 
performance in frail elderly. European Journal of  Nutrition, 2014, 53; 803-812
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Introduction
The prevalence and incidence of  dementia is an increasing problem worldwide. Almost 66 
million people will suffer from dementia in the year 2030, and this number will nearly be 
doubled till 115 million in 2050.1 Cognitive decline, which usually accompanies aging, is 
associated with loss of  independency and autonomy.2, 3 Maintaining or improving cognitive 
performance is therefore of  major importance to elderly. With the aging population, the call 
for modifiable factors to stay cognitive healthy, such as nutrition, is emerging.4, 5
The recommendations for protein intakes are based on short-term nitrogen balance. 
However, in order to create an optimum for a long-term health and well-being, these 
recommendations are nowadays being discussed.6 A possible beneficial role of  protein on 
several health outcomes, such as sarcopenia, weight management and bone health, has been 
suggested by an increasing number of  studies.7-10 The effect of  protein intake on cognitive 
performance, however, has barely been studied. A few observational studies reported an 
association between protein intake and cognitive performance. Goodwin and colleagues 
showed that older adults with lower protein intakes had a lower score on verbal memory 
tests and nonverbal abstract reasoning than adults who were better nourished.11 Positive 
correlations between protein intake and several cognitive tests were also found by La Rue et 
al. 12 and Roberts et al. 13 showed that higher protein intakes were associated with a decreased 
risk on mild cognitive impairment or dementia 3.7 years later. Furthermore, acute beneficial 
effects of  high protein intake on memory functions compared to a high-carbohydrate meal 
14 and compared to a placebo 15 were observed. A high-protein diet improved cognitive 
performance in healthy young men after three weeks of  intervention,7 but the authors 
suggested that the beneficial effect also may have been due to elevated levels of  vitamin 
D, B2, B6 and B12 intake compared to the control group.7 On the other hand, an 8-weeks 
intervention trial with exercise training and whey-protein and leucine supplementation did 
not show any difference between the protein and the placebo group.16 
Acute beneficial effects were also found of  the single amino acid tyrosine on cognitive 
performance in a stressful condition.17 Tyrosine is a precursor for the neurotransmitters 
dopamine, norepinephrine and epinephrine 18 and its dietary intake influences the synthesis 
and release of  neurotransmitters. As such, it may alter brain functions.19 Also the presence 
of  the amino acid tryptophan, the precursor for serotonin, may be influenced by diet and 
can affect cognitive performance.19-21 Tryptophan loading may have a detrimental effect on 
psychomotor speed, but it has also been shown to improve memory, especially in stress-
vulnerable or depressed participants who have suboptimal levels of  serotonin.22, 23 Also 
elderly may have suboptimal serotonin activity.24 The effect and uptake into the brain of  both 
tryptophan and tyrosine, however, is dependent on other amino acids, because they share and 
compete for a transporter in the blood brain barrier. 
Cognitive performance is positively related to physical fitness.25 Physical frailty on the other 
hand is a predictor for cognitive decline and Alzheimer’s disease.26-28 Frailty comes with age 
and is seen as a biological syndrome associated with decreased reserves and resistance to 
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stressors, which increases the risk of  adverse health outcomes, such as the onset of  disability, 
morbidity, and institutionalization.29, 30 Beasley et al. showed that higher protein intakes are 
associated with a lower risk of  frailty, which suggests a preventive role of  protein on frailty.10 
Furthermore, previous work of  our group showed that protein supplementation might be a 
promising nutritional strategy to improve functional performance.31  
We hypothesized that frail elderly are susceptible to a possible beneficial effect of  protein 
supplementation on cognitive performance. Because no long-term studies have been 
conducted about the effect of  protein on cognition in elderly, our aim was to investigate the 
effect of  24 weeks protein supplementation on cognitive performance in frail and pre-frail 
elderly. 
Methods
Participants
Participants were men and women who participated in the ProMuscle study, a study that 
investigated the effect of  protein supplementation on muscle mass and muscle strength.31 
Subjects’ selection and attrition have extensively been described elsewhere.31 In short, 
subjects were recruited through an existing database of  volunteers, distribution of  
information flyers and letters, and local information meetings. Inclusion criteria were: being 
≥65 years old and being pre-frail or frail according to the criteria from Fried et al.32 The 
five criteria to define frailty were: [1] unintentional weight loss, [2] weakness (low handgrip 
strength), [3] self-reported exhaustion, [4] slow walking speed, and [5] low physical activity. 
Pre-frailty was classified when one or two of  these criteria were present, and frailty was 
classified when three or more criteria were present. Exclusion criteria were diabetes mellitus 
type I or II (as measured by a fasted plasma glucose level ≥7,0 mmol/L),33 cancer, COPD, 
participation in any structured exercise training program in the past two years, and/or renal 
failure (estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73 m2).34 All subjects 
gave their written informed consent and the study was approved by The Wageningen 
University Medical Ethical Committee.
Study design
After enrollment, subjects were randomized to receive either the protein supplementation or 
the placebo for a period of  24 weeks. Randomization was done by an independent person by 
means of  computer-generated random numbers in stratified permuted blocks of  size four, 
stratified by gender. All outcome measures were collected at baseline, after 12 weeks (except 
most cognitive function tests) and after 24 weeks of  intervention.
Protein supplementation
During the intervention period, volunteers either received a 250 mL protein-supplemented 
beverage that contained 15 g protein (MPC80; milk protein concentrate), 7.1 g lactose, 0.5 
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g fat, and 0.4 g calcium, or a non-caloric placebo supplement that contained no protein 
(FrieslandCampina Consumer Products Europe, the Netherlands). All beverages were in 
a non-transparent package and were vanilla flavored to mask the contents of  the drinks. 
Participants were instructed to consume one beverage after their breakfast and one beverage 
after their cold lunch meal (time depended on timing of  lunch: ~12:00 p.m. or ~18:00 p.m.). 
Compliance was judged by returned ticked calendars and non-consumed beverages. Staff  
members and participants were blinded towards treatment allocation until completion of  
data analyses.
Cognitive performance
At baseline, the Mini-Mental State Examination (MMSE) was performed to assess overall 
cognitive status.35 Cognitive performance was measured at baseline and after the 24-week 
intervention period by well-trained research assistants. Reaction time test was also performed 
after 12 weeks. 
An extensive neuropsychological test battery was used to cover four cognitive domains: 
episodic memory, attention and working memory, information processing speed, and 
executive functioning. To measure episodic memory, Word Learning Test (WLT) was used, 
consisting of  fifteen words that were read aloud for five times. To assess direct recall, the 
participant had to recall as many words as possible after every trial; WLT delayed recall and 
WLT recognition were measured 20 minutes after the last direct recall.36 Wechsler Digit Span 
(DS) forward and backward tests were used to determine attention and working memory.37 
For the DS forward test participants had to immediately repeat strings of  numbers that 
range from two to eight numbers, whereas for the DS backward test, the strings had to 
be repeated in reserve order. Trail Making Test (TMT) part A and B measure information 
processing speed and concept shifting interference, respectively.38 For part A, numbers 
in ascending order had to be connected by a line as fast as possible, whereas for part B 
alternating numbers and letters had to be connected (1-A-2-B etcetera). Stroop Color-Word 
Test determines selective attention and susceptibility to behavioral interference.39 Stroop I 
and II consisted of  a sheet of  color names in black, and blocks of  colors resp. that had to be 
read by the participant. Stroop III consisted of  a sheet of  color names printed in a different 
color; the participant had to name the color of  the ink. The Verbal Fluency test was used 
to measure executive functioning; participants had to name as many words starting with the 
letter ‘P’, and words in the category ‘animals’.40 This test battery was always performed in the 
afternoon in the same quiet room following a standard protocol. Coffee and tea were not 
allowed before and during the test session. 
Reaction time was measured by the computerized finger-cuing task,41, 42 after an overnight 
fast following a strict protocol. This test was a four-choice reaction task, with index and 
middle fingers of  both hands operating four response keys. Goal was to react as quickly and 
accurately as possible to a single plus-sign on the screen, matching one of  the four fingers. 
The screen always showed a reference row consisting of  four plus signs indicating the four 
possible stimulus locations. A trial was started by showing a cue signal, which could be four 
plus signs in all four positions (neutral uncued condition) or only two plus signs, i.e.: the 
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hand-cued condition in which the cue specifies two fingers on the same hand; the finger-
cued condition in which the cue specifies the same finger on two hands; or the neither-cued 
condition in which the cue specifies different fingers on two hands. Those cues reduce 
the number of  possible stimulus locations from four to two and would be of  benefit for 
the reaction time. After a preparation interval of  2000 ms, the target signal (one plus sign) 
appeared in one of  the cued positions. Participants had to react as quickly as possible to the 
target signal by pressing the corresponding response key. Outliers were defined as reaction 
time less than 150 ms or in excess of  2000 ms and were excluded from data analysis (mean 
percentage of  outliers was 1.4% based on 160 trials per test session). Reaction time was 
based only on correct trials.
Blood sampling 
Fasted blood samples were collected at baseline to determine glucose homeostasis and 
renal function. Plasma glucose concentrations were analyzed with a COBAS FARA analyzer 
(Uni Kit III; Roche, Basel, Switzerland). Plasma insulin was analyzed by radioimmunoassay 
(Insulin RIA Kit; LINCO Research Inc, St Charles, MO). Serum creatinine was measured by 
using Roche Modular System P (Roche Diagnostics GmbH, Mannheim, Germany).
Dietary intake 
Participants recorded their food intake for three days at baseline, after 12 weeks, and after 
24 weeks to assess potential changes in daily food intake during the intervention period. 
Trained dieticians gave oral and written instructions about recording the type of  foods and 
estimating portion sizes in household measures. Furthermore, they checked the food records 
for completeness, obtained additional information about unclear items or amounts and used 
household measures to improve the estimation of  portion size. Dietary intake data were 
coded (type of  food, time of  intake, and amount) and energy and macronutrient intakes 
were calculated using a nutrient calculation program (Komeet, BaS nutrition software, 2004, 
Arnhem, the Netherlands) and the Dutch food composition database.43
Other measurements
Height was measured at baseline with a wall-mounted stadiometer to the nearest 0.1 cm. 
Weight was measured at baseline, after 12 weeks and after 24 weeks in a fasted state to the 
nearest 0.1 kg with a calibrated digital scale (ED-6-T; Berkel, Rotterdam, The Netherlands). 
Information about the highest education level, smoking habits, alcohol intake, depression 
(Center for Epidemiologic Studies Depression Scale), and medical history was obtained by 
questionnaires. Blood pressure was measured in the morning after 10 minutes of  rest with an 
Omron HEM-907 (Lake Forest, IL, USA) device. At baseline, 12 weeks and 24 weeks, four 
measurements were done, with an interval of  two minutes, of  which the first measurement 
was discarded. The mean value of  the three subsequent measurements for systolic and 
diastolic blood pressure was taken.
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Statistics
Data analyses were performed by the intention-to-treat principle. Data are expressed as 
means ± SD, or as median [interquartile range (IRQ)] for non-normal distributed data. 
Baseline characteristics were compared between treatment groups using independent samples 
T-test or Chi-square test. 
WLT decayed recall was calculated as the number of  words recalled after approximately 15 
minutes following the fifth session of  the WLT minus the number of  words recalled during 
the fifth session of  the WLT. To control for the effect of  motor speed on performance we 
calculated interference measures for TMT (TMT B/TMT A) and Stroop III (Time needed 
for Stroop III – (mean time needed for Stroop I and II)). To take into account errors made 
during the Stroop Test, accuracy and speed-accuracy trade-offs (Stroop-SAT) were calculated. 
Accuracy = ((maximum right answers – amount of  errors) / maximum right answers). 
Speed-accuracy trade-off  = accuracy / time needed to complete the task.44 The three cued 
conditions of  the reaction time test (hand-cued, finger-cued and neither-cued) were averaged 
to one value (reaction time test cued). 
To compare the results of  the individual cognitive tests and to limit the number of  
dependent variables, crude test scores were clustered into compound scores for four 
neuropsychological domains: Episodic memory; Attention and working memory; 
Information processing speed; and Executive functioning. Data of  baseline were used as 
norm data to create individual Z-scores for baseline and 24-week data (Z-score = (score test 
– mean baseline)/SD baseline). The following domains in formula form were formed: 
Episodic Memory = (ZWLT total immediate recall + ZWLT decayed recall + ZWLT recognition)/3
Attention and working Memory = (ZDigit Span forward + ZDigit Span backward)/2
Information processing speed = (ZStroop-SAT mean I and II + -ZTrail making test part A + -ZReaction time test 
uncued + -ZReaction time test cued)/4
Executive Functioning = (ZStroop-SAT interference + ZVerbal Fluency Animtal + ZVerbal Fluency Letter P + -ZTrail 
making ratio)/4
Differences between treatments overtime were analyzed using analyses of  covariance 
(ANCOVA), in which baseline data acted as the covariate factor, the outcome measures as 
the dependent factor and treatment as the fixed between-subject factor. To assess the effect 
of  protein supplementation on reaction time, which was measured at three time points, 
Linear Mixed Models were used with the unstructured covariance type. Time, treatment and 
their interaction were defined as fixed factors, whereas subject was defined as random factor. 
An α-level of  0.05 was used to determine statistical significance. All statistical analyses were 
performed using SPSS Statistics v19 (SPSS Inc. Chicago, IL). 
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Results
Participants
At baseline, 65 participants were enrolled. Eight subjects, four in each treatment group, 
discontinued the study because of  the following reasons: side-effects of  the drink (diarrhea, 
nausea; n = 3), dislike of  the drink (n = 1), medical reasons (n = 2), depression (n = 1), and 
burden too high (n = 1). After 12 weeks, reaction time data were missing from all drop-
outs, whereas after 24 weeks reaction time data were obtained from 60 participants. For the 
other cognitive tests data from 59 participants were collected. Compliance to the treatment, 
counted as returned full drinks and ticked calendars, was very high (92%, with only five 
subjects <80%). 
Baseline characteristics did not differ between treatment groups (Table 1). Mean age was 
78 ± 8 years in the protein group and 81 ± 7 in the placebo group. Percentage of  lower 
educated was slightly higher in the protein group (9%) than in the placebo group (0%, p = 
0.21), as was the percentage of  smokers (15 vs. 3%, p = 0.20). MMSE-score was high in both 
groups (median of  29 in the protein group and 28 in the placebo group [IQR: 26-30 in both 
groups]), indicating no impaired cognitive performance of  most participants. Ten subjects 
had a score <25 indicating mild cognitive impairment (6 in protein and 4 in placebo group).45 
Habitual protein intake did not differ between groups and did not significantly change over 
time (only baseline data shown). 
Cognitive performance
Mean cognitive baseline scores did not differ between the two treatment groups (Table 
2). Table 3 shows the changes in cognitive test scores after 24 weeks. A significant larger 
improvement in reaction time was found in the protein group than in the placebo group 
(without taking the measurements at week 12 into account). Reaction time in the uncued 
condition improved with 68 ± 157 ms in the protein group and 18 ± 142 ms in the placebo 
group (p = 0.03), and in the cued condition, a similar improvement was found (p = 0.05). 
Overall error rate was very low (2.5% for the protein group and 2.3% for the placebo 
group), with small, non-significant reductions in error rate for both groups at the end of  the 
treatment compared to baseline. 
No significant differences were found on the other cognitive tests. Subjects in the protein 
group recalled one more word at the WLT-direct recall (Δend-baseline 2.9 ± 7.6) than 
subjects in the placebo group (Δend-baseline 2.1 ± 5.5), whereas they recognized one word 
less on WLT-recognition (Δend-baseline = -0.7 ± 1.9) than the placebo group (Δend-baseline 
0.3 ± 2.8), but these differences were not significant. Participants in the protein group 
became slightly slower at the TMT part A; time to complete the task increased 3.7 ± 20.1 s 
over time in the protein group and decreased 3.5 ± 14.6 s in the placebo group (p = 0.11). 
Domain scores did not differ between treatment groups after 24 weeks (Table 3). After 
24 weeks, scores in the domains episodic memory and information processing speed were 
slightly better in the placebo group, though these effects were not significant. Executive 
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functioning improved by 0.19 ± 0.43 in the protein group and 0.09 ± 0.42 in the placebo group 
(p = 0.41). 
Table 4 shows the scores of  all three time points that reaction time task was measured. 
After 12 and 24 weeks, both intervention groups improved their reaction time, but treatment 
effects were larger after 24 weeks than after 12 weeks. Significance however, was not reached 
in neither the uncued condition (treatment*time p = 0.25, treatment p = 0.14) nor in the 
cued conditions (treatment*time p = 0.34, treatment p = 0.17 for the mean cued condition). 
In both groups, reaction time was fastest in the hand-cued condition and slowest in the 
neither-cued condition. In all cuing conditions, a similar trend in treatment*time effect was 
observed. 
Table 1 Characteristics of  65 Dutch pre-frail and frail elderly people
Protein Placebo
Age (yrs)a 78 ± 8 81 ± 7
Sex, men, n (%) 14 (41) 15 (48)
Education Low/ Middle/ High (%) 9 / 59 / 32 0 / 55 / 45
BMI (kg/m2) 27.0 ± 4.6 26.2 ± 3.2
Smokers, n (%) 5 (15) 1 (3)
 Number of  cigarettes/cigars per day 12 10
Alcohol consumers (%) 68 71
 Alcohol consumption (g/day)b 12 ± 14 9 ± 11
MMSEc 29 [26-30] 28 [26-30]
 Range 21-30 22-30
CES-D 6.6 ± 5.7 7.0 ± 4.1
Pre-frail / frail, n (%) 27 (79) / 7 (21) 20 (65) / 11 (35)
Baseline glucose (mmol/L) 5.2 ± 0.4 5.3 ± 0.4
Baseline insulin (mU/L) 18.0 ± 7.4 18.2 ± 7.1
eGFR (mL/min/1.73 m2 ) 84.4 ± 20.2 77.6 ± 12.5
Blood pressure, diastolic (mmHg) 77 ± 10 75 ± 9
Blood pressure, systolic (mmHg) 152 ± 25 150 ± 23
Energy intake, kJ 8335 ± 2457 8114 ± 1748
Protein intake, g/day (En%) 78 ± 26 (16 ± 3) 74 ± 14 (16 ± 3)
Fat intake, g/day (En%) 83 ± 30 (36 ± 5) 73 ± 23 (33 ± 7)
Carbohydrate intake, g/day (En%) 211 ± 63 (44 ± 8) 228 ± 65 (48 ± 8)
Protein intake g/kg body weight/day 1.1 ± 0.3 1.0 ± 0.2
Notes: BMI, Body Mass Index; MMSE, Mini-Mental State Examination; CES-D, Center for Epidemiologic Studies 
Depression Scale; eGFR, estimated Glomerular Filtration Rate. a Mean ± SD (all such values); b Mean use in consumers 
only; c Median [IQR].
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Table 2 Baseline scores of  cognitive tests (mean ± SD) in a Dutch pre-frail and frail elderly population (n = 65) 
Protein Placebo
Episodic memory
Word learning test – Immediate recall, max. 75 words 34.6 ± 11.8 33.5 ± 10.5
Word learning test – Decayed recall (delayed-WLT trial 5) -2.8 ± 1.5 -2.6 ± 2.0
Word learning test – Recognition, max. 30 words 28.2 ± 1.9 27.1 ± 2.7
Attention and working memory
Digit Span forward, max. 16 points 7.9 ± 1.4 8.3 ± 2.1
Digit Span backward, max. 14 points 5.2 ± 1.3 6.0 ± 2.3
Information processing speed
Trail Making Part A (s)a 61.6 ± 27.2 62.6 ± 23.0
Stroop 1b, c 1.91 ± 0.36 1.80 ± 0.33
Stroop 2b, c 1.54 ± 0.35 1.44 ± 0.28
Reaction time, uncued (ms)a 764 ± 301 830 ± 243
Reaction time, cued (ms)a 753 ± 330 821 ± 263
Executive functioning
Stroop Interference (Part 3 – (Part 1 + Part 2/2))b,c -0.90 ± 0.24 -0.79 ± 0.20
Word Fluency – Animalsb 21.4 ± 6.4 20.6 ± 5.8
Word Fluency – Letter Pb 15.2 ± 5.8 14.1 ± 3.8
Trail Making Test (Part B/Part A)a 1.77 ± 0.61 1.83 ± 0.62
Domain scores
Episodic memory 0.08 ± 0.56 -0.08 ± 0.75
Attention and working memory -0.15 ± 0.63 0.17 ± 1.12
Information processing speedb -0.08 ± 0.94 -0.27 ± 0.72
Executive functioningb 0.05 ± 0.67 -0.02 ± 0.60
Notes: a Higher scores indicate more time was needed to complete the task, so it indicates a poorer performance; b 
Placebo group n = 30; c Time corrected for errors (time needed / accuracy). 
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Table 3 Changes in cognitive test scores and domain scores (mean ± SD) of  58 Dutch pre-frail and frail elderly (only 
participants with baseline and 24 weeks data)a, b
Baseline 24 wks Change p
Episodic memory
Word learning test - Immediate recall, max. 75 words 0.58
Protein 35.9 ± 11.1 38.8 ± 12.0 2.9 ± 7.6
Placebo 34.4 ± 9.8 36.5 ± 10.4 2.1 ± 5.5
Word learning test – Decayed recall (delayed-WLT trial 5) 0.47
Protein -2.7 ± 1.6 -2.6 ± 2.1 0.1 ± 2.4  
Placebo -2.7 ± 2.1 -2.2 ± 2.0 0.5 ± 2.6
Word learning test – Recognition, max. 30 words 0.43
Protein 28.4 ± 1.9 27.7 ± 2.2 -0.7 ± 1.9
Placebo 27.4 ± 2.4 27.7 ± 2.6 0.3 ± 2.8
Attention and working memory
Digit Span forward, 16 points 0.46
Protein 8.0 ± 1.4 8.1 ± 1.7 0.1 ± 1.4
Placebo 8.3 ± 2.2 8.0 ± 2.1 -0.3 ± 1.7
Digit Span backward, 14 points 0.92
Protein 5.3 ± 1.3 5.4 ± 1.5 0.0 ± 1.2
Placebo 6.2 ± 2.3 6.0 ± 2.4 -0.1 ± 1.7
Information processing speed
Trail Making Part A (s)c,d 0.11
Protein 57.2 ± 21.8 61.7 ± 36.6 3.7 ± 20.1
Placebo 63.5 ± 24.0 60.0 ± 24.6 -3.5 ± 14.6
Stroop 1e 0.89
Protein 1.96 ± 0.33 1.96 ± 0.29 -0.01 ± 0.20
Placebo 1.80 ± 0.33 1.83 ± 0.38 0.03 ± 0.20
Stroop 2e 0.71
Protein 1.60 ± 0.31  1.61 ± 0.28 0.00 ± 0.11
Placebo 1.44 ± 0.27  1.45 ± 0.30 0.01 ± 0.16
Reaction time, uncued (ms)c,f  0.03
Protein 739 ± 246 671 ± 183 -68 ± 157
Placebo 826 ± 233 808 ± 238 -18 ± 142
Reaction time test, cued (ms)c,f  0.05
Protein 724 ± 265 635 ± 208 -89 ± 149
Placebo 818 ± 257 775 ± 266 -44 ± 130
Executive functioning
Trail Making Ratio (Part B/Part A)c 0.95
Protein 1.75 ± 0.63 1.77 ± 0.57 0.01 ± 0.60
Placebo 1.83 ± 0.62 1.77 ± 0.66 -0.05 ± 0.78
Stroop Interference (Part 3 – (Part 1 + Part 2/2))e 0.43
Protein -0.92 ± 0.24 -0.84 ± 0.21 0.08 ±0.18
Placebo -0.79 ± 0.21 -0.80 ± 0.21 -0.01 ± 0.17
Table continues on next page
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Table 3 Changes in cognitive test scores and domain scores (mean ± SD) of  58 Dutch pre-frail and frail elderly 
(only participants with baseline and 24 weeks data)a, b (continued)
Baseline 24 wks Change p
Word Fluency – Animals 0.19
Protein 21.8 ± 6.2 24.2 ± 6.5 2.4 ± 4.1
Placebo 20.7 ± 5.7 22.0 ± 6.2 1.3 ± 3.6
Word Fluency – Letter P 0.83
Protein 15.7 ± 5.6 15.7 ± 6.7 0.0 ± 4.9
Placebo 14.3 ± 3.8 14.8 ± 5.5 0.5 ± 4.0
Domain scores
Episodic memory 0.40
Protein 0.15 ± 0.56 0.16 ± 0.81 0.01 ± 0.57
Placebo -0.03 ± 0.67 0.17 ± 0.86 0.20 ± 0.78
Attention and working memory 0.54 
Protein -0.08 ± 0.62 -0.04 ± 0.78 0.04 ± 0.56
Placebo 0.23 ± 1.14 0.11 ± 1.11 -0.12 ± 0.68
Information processing speed 0.39
Protein 0.19 ± 0.58 0.25 ± 0.75 0.05 ± 0.30
Placebo -0.24 ± 0.74 -0.14 ± 0.81 0.10 ± 0.34
Executive functioning 0.41
Protein 0.01 ± 0.62 0.20 ± 0.68 0.19 ± 0.45
Placebo 0.02 ± 0.59 0.11 ± 0.61 0.09 ± 0.42
Notes: Differences between the two groups were measured using ANCOVA (with test scores at 24 weeks as dependent 
variable and baseline cognitive test scores as covariate). a n = 30 for the protein group; b n = 28 for the placebo group; 
c Higher scores indicate more time was needed to complete the task, so it indicates a poorer performance; d n = 31 for 
protein group; e Corrected for errors (time needed / accuracy); f  n = 32 for protein group.
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Table 4 Reaction time measured at baseline, after 12 weeks and at the end, in a pre-frail and frail elderly population 
(mean ± SD)
Baselinea 12 wksb 24 wksc treatment * 
time effect 
(p)
treatment 
effect 
(p)
time effect 
(p)
Reaction time, uncued (ms) 0.25 0.14 0.01
Protein 764 ± 301 663 ± 151 671 ± 183
Placebo 830 ± 243 778 ± 196 808 ± 238
Reaction time, hand-cued (ms) 0.29 0.21 0.01
Protein 716 ± 318 597 ± 170 612 ± 210
Placebo 767 ± 263 726 ± 208 740 ± 260
Reaction time, finger-cued (ms) 0.22 0.13 <0.01
Protein 772 ± 333 640 ± 179 643 ± 208
Placebo 840 ± 261 773 ± 215 799 ± 291
Reaction time, neither-cued (ms) 0.50 0.16 <0.01
Protein 771 ± 342 648 ± 184 650 ± 213
Placebo 857 ± 275 781 ± 221 785 ± 251
Reaction time, mean cued (ms) 0.34 0.17 <0.01
Protein 753 ± 330 628 ± 176 635 ± 208
Placebo 821 ± 263 760 ± 212 775 ± 266
Notes: Higher scores indicate more time was needed to complete the task, so it indicates a poorer performance. Differ-
ences among the two groups were measured using Linear Mixed Models. a n = 34 for the protein group, n = 31 for the 
placebo group; b  n = 28 for the protein group, n = 29 for the placebo group; c n = 32 for the protein group, n = 28 for 
the placebo group
Discussion
We investigated the impact of  24 weeks protein supplementation on cognitive performance 
in pre-frail and frail elderly people. Dietary protein did not improve the cognitive domains 
of  episodic memory, attention and working memory, information processing speed, and 
executive functioning. Performance on the reaction time task however, improved significantly 
more in the protein group than in the placebo group. In fact, after 24 weeks of  treatment, 
the improvement in reaction time was more than twice as large in the protein compared with 
the placebo group. This finding suggests that the protein supplementation improved reaction 
time performance above and beyond the improvement, which may have occurred due to 
learning (i.e., repeated task performance) in the placebo group. Furthermore, the percentages 
of  errors were stable over time, which indicates that reaction time improved without losing 
accuracy. Looking at the number of  tests analyzed, however, it is possible that it was a chance 
finding. 
To the best of  our knowledge, this was the first intervention study investigating the impact 
of  long-term protein supplementation on cognitive performance in frail elderly people. To 
investigate this, we included a variety of  sensitive neuropsychological tests, covering the 
domains most affected by aging. By clustering the data of  individual cognitive tests by means 
of  standardization into Z-scores, we created a more robust cognitive score. Moreover, we 
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limited the number of  dependent variables thereby decreasing the possibility of  chance 
findings. Cognitive performance was measured in a valid and standardized way by following 
a strict protocol and by not allowing coffee and tea during the tests. However, because of  
increasing inter-individual differences with aging,46 the relatively small study population made 
it difficult to uncover more subtle changes on cognitive performance. Also the duration of  
the study might have been too short to pick up an intervention effect on cognitive domains. 
Because cognitive decline is a rather slow process, it is recommended to conduct trials with a 
duration of  at least 18 months to study the effects on cognitive performance.47 However, by 
including a population at high risk for cognitive decline, such as our frail elderly population, 
a trial could be more efficient in finding an effect and therefore, a shorter time period would 
be sufficient.
Daily protein intake did not change over time in the two treatment groups, which suggested 
that participants who received the protein supplement did not compensate for the extra 
protein by eating less daily protein products. Together with the high compliance (92%), 
this showed that the supplement indeed was an extra protein source. The placebo drink 
was a non-caloric drink and did not contain any ingredients that may affect cognitive 
performance. Levels of  eGFR were not lower after 24 weeks of  supplementation in both 
intervention groups, indicating no harmful effects of  extra protein intake occurred on kidney 
functioning.31
The results of  our study were in accordance with the results of  Jacobsen and colleagues 
who investigated the effects of  a high-protein diet on several health outcomes, including 
cognitive performance, in young men.7 After three weeks following a high-protein diet, 
reaction time improved significantly; on other cognitive functions however (attention, 
verbal fluency, memory, language, and visuospatial function), no effect was found. Reaction 
time, as measured in the present study with the finger-cuing task, is part of  the domain 
information processing speed, together with the Stroop test (part I and II) and TMT part 
A. These latter tests did not improve after protein supplementation. This may be due to the 
fact that the finger-cuing task is a computer task, which may minimize external influences 
such as influence of  research assistants. Also, computer tasks have much more trials and 
therefore the result will be more robust than the result of  a test with a single trial. The 
finger-cuing task reaction time task could therefore be a more sensitive test than the Stroop 
test and TMT. Nevertheless, it should be taken into account that our positive findings on 
reaction time may be due to chance. Because of  the large number tested, the likelihood of  
type I error increases. The construction of  compound scores would overcome this risk, and 
the compound scores are therefore preferred over the single test scores. Performance on 
the reaction time test improved significantly over time and although the test was carefully 
explained and practiced beforehand, it would have been better to include a complete training 
session for all neuropsychological tests to forestall effects of  training. It is possible that the 
large time effect may have diluted possible treatment effects.
Previous studies showed associations between cognitive performance, gait speed and balance 
in elderly people.44, 48 Functions important for gait speed and balance, such as planning, 
monitoring and executing complex actions, are also needed for cognitive functions. In our 
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study population, a beneficial effect of  dietary protein supplementation was already shown 
on physical functioning.31 The improvement in reaction time we found in the current study 
might be linked to this improvement in physical functioning. 
Protein supplementation may have an effect on blood concentrations of  single amino 
acids,18, 49 which causes variations in the uptake of  amino acids into the brain and therewith 
influences the production of  neurotransmitters.50 Optimum levels of  neurotransmitters for 
cognitive performance vary for different cognitive domains.51 We used provided dairy protein 
as opposed to any mixture of  specific amino acids, and as such, we cannot draw conclusions 
about the effect of  specific amino acids. Other possible mechanisms for the effect of  protein 
supplementation on cognitive performance might relate to vascular health. Cardiovascular 
diseases are a risk factor for cognitive decline; a better vascular health can be beneficial for 
cerebral perfusion.52 A small beneficial effect of  protein on blood pressure was suggested 
in a systematic review by Altorf-Van der Kuil et al.53 This could be due to triggering a 
vasodilatory response, or via insulin sensitivity.54 In additional data analyses though, we did 
not find an effect of  protein on blood pressure.31 
To conclude, in our study population of  pre-frail and frail elderly people, protein 
supplementation did not improve performance on the cognitive domains episodic memory, 
attention and working memory, information processing speed, and executive functioning. 
However, our results indicate that extra protein intake might improve reaction time.
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Abstract
Objective: Physical activity has been proposed as one of  the most effective strategies to 
prevent cognitive decline. Protein supplementation may exert an additive effect. The effect 
of  resistance-type exercise training with or without protein supplementation on cognitive 
functioning in frail and pre-frail elderly people was assessed in a secondary analysis. 
Methods: Two 24-week, double-blind, randomized, placebo-controlled intervention studies 
were carried out in parallel. Subjects performed a resistance-type exercise program of  
two sessions per week (n = 62) or no exercise program (n = 65). In both studies subjects 
were randomly allocated to either a protein (2 x 15 g daily) or a placebo drink. Cognitive 
functioning was assessed with a neuropsychological test battery focusing on the cognitive 
domains episodic memory, attention and working memory, information processing speed, 
and executive functioning. 
Results and conclusions: In frail and pre-frail elderly resistance-type exercise training in 
combination with protein supplementation improved information processing speed (changes 
in domain score 0.08 ± 0.51 versus -0.23 ± 0.19 in the non-exercise group, p = 0.04). 
Exercise training without protein supplementation was beneficial for attention and working 
memory (changes in domain scores 0.35 ± 0.70 versus -0.12 ± 0.69 in the non-exercise 
group, p = 0.02). There were no significant differences among the intervention groups on 
the other cognitive tests or domain scores.
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Introduction
Current estimates indicate that 35.6 million people worldwide are living with dementia and 
because of  the aging population this number is predicted to double by 2030 and more than 
triple by 2050.1 Interventions targeted at risk factors for cognitive decline and Alzheimer’s 
Disease (AD) may offer opportunities for development of  an optimal preventive strategy. 
Dementia is preceded by a decline in cognitive functioning; however, this decline in cognitive 
functioning is not uniform across all older individuals or across all cognitive domains. 
One of  the factors that have been associated with cognitive decline is physical activity. 
Several meta-analyses and systematic reviews have summarized the evidence for the impact 
of  physical activity on cognitive function in older individuals that is provided by either 
observational studies,2, 3 randomized controlled trials (RCTs),4-10 or both.11, 12 Generally, 
it has been suggested that physical activity improves cognitive function and prevents 
cognitive decline, but results of  observational as well as experimental studies are limited and 
inconsistent to draw firm conclusions. 
The heterogeneous results may be explained by varying study populations and differences 
in study duration, but also by the different intensities and types of  exercise employed. 
Beneficial effects, though not all significant, of  various kinds of  exercise programs were 
observed; aerobic, strength, balance, flexibility, or a combination of  these. It is unclear which 
type of  exercise program is most effective, for what aspect of  cognition and for which 
specific population. The importance of  resistance training is stressed in the meta-analysis by 
Colcombe et al., who showed that aerobic-based training exercises together with resistance 
training exercises had a greater beneficial effect on cognition than programs of  aerobic-based 
exercise training alone 13 and is also postulated by a recent literature review of  Bherer et al.12 
Also, the few RCTs that used resistance training alone were largely positive. Study durations 
ranged from 8-52 weeks and effects were mainly observed on the cognitive domains memory 
and executive functioning.7-9, 14, 15 A very recent study that was performed in frail older adults 
showed that three months of  a combination of  aerobic and strength exercise significantly 
improved several domains of  cognitive performance.16 Studies on different types of  exercise 
in relation to brain function, structure and connectivity assessed using magnet resonance 
imaging (MRI) have also started to emerge and results are promising as has been summarized 
by Voelcker-Rehage and Niemann.17
In addition to exercise, dietary protein might improve cognitive functioning. Van de Rest 
et al. performed a literature review on the role of  protein intake in relation to cognitive 
functioning and concluded that this has barely been studied.18 Five observational and three 
case-control studies were found, showing mixed results. However, all three RCTs that were 
performed showed some beneficial effects. A population of  physically frail older individuals 
would be a suitable target population for a combined exercise and protein supplementation 
intervention, as physical frailty has been identified as a risk factor for cognitive decline 
and AD,19 frail elderly people generally have a limited habitual physical activity level and 
moreover, they have a suboptimal protein intake.20 
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We hypothesized that resistance-type exercise training would beneficially affect cognitive 
functioning, in particular in subjects supplemented with dietary protein, which would 
augment the exercise effect. Therefore, we examined the effect of  24 weeks resistance-type 
exercise training with or without protein supplementation on cognitive function in frail and 
pre-frail elderly people. 
Methods
Participants
Individuals ≥65 years of  age were recruited between December 2009 and October 2010, by 
using an existing database of  volunteers, through distribution of  information flyers, and by 
local information meetings. Potentially eligible participants were screened for pre-frailty and 
frailty using the five criteria from Fried et al.: [1] unintentional weight loss, [2] weakness, [3] 
self-reported exhaustion, [4] slow walking speed, and [5] low physical activity.21 Pre-frailty was 
classified when one or two criteria were present and frailty when three or more criteria were 
present. Individuals who were diagnosed with cancer, chronic obstructive pulmonary disease, 
muscle disease, type 2 diabetes (plasma glucose concentration ≥7.0 mmol/L) 22 or renal 
insufficiency (estimated Glomerular Filtration Rate <60 mL/min/1.73 m2) 23 were excluded. 
For participants in the resistance-type exercise training program, a resting electrocardiogram 
was performed to exclude silent ischemia. The Wageningen University Medical Ethical 
Committee approved the study and all subjects gave their written informed consent.
Study design 
For the present study we used data of  two randomized, placebo-controlled trials that were 
carried out in parallel. Both trials covered a 24-week intervention period and investigated the 
effect of  protein versus placebo supplementation; in the absence or presence of  additional 
resistance-type exercise training.24, 25 Primary outcome in both studies was muscle mass, but 
one of  the secondary outcome measures was cognitive functioning.
Sample size was calculated based on an expected difference in lean body mass of  1.1 kg 
between groups 26, 27 with a SD of  1.4 kg, a minimum of  24 subjects per treatment group 
would be required to detect a difference (power = 80%, α = 0.05). With an expected dropout 
rate of  25% 28, 29 a sample size of  30 subjects per treatment group was considered adequate.
After inclusion, 62 of  the 127 subjects participated in a 24-week resistance-type exercise 
training program and 65 did not perform any exercise program. All subjects were randomly 
allocated to either protein or placebo supplementation for 24 weeks. Allocation was carried 
out independently for both trials by an independent person using a computer-generated 
random numbers in stratified permuted blocks of  size 4 and was stratified by gender. All 
outcome measures were collected at baseline and after 12 (except most cognitive function 
tests) and 24 weeks of  intervention.
101
5Exercise, protein supplementation and cognition
Resistance-type exercise program
The resistance-type exercise training was performed twice per week under personal 
supervision for a 24-week period. The sessions were performed in the morning and 
afternoon with at least 72 hours between sessions. The training consisted of  a 5-minute 
warm-up on a cycle ergometer, followed by 4 sets on the leg-press and leg-extension 
machines and 3 sets on chest press, lat pulldown, pec-dec, and vertical row machines 
(Technogym, Rotterdam, the Netherlands). The workload started at 50% of  1-Repetition 
Maximum (1-RM) (10–15 repetitions per set) to 75% of  1-RM (8–10 repetitions) to stimulate 
muscle hypertrophy. Resting periods of  1 minute were allowed between sets and 2 minutes 
between exercises. To evaluate changes in muscle strength, 1-RM was repeated after 4, 8, 12, 
16, and 20 weeks of  training. Workload intensity was adjusted based on the 1-RM outcomes.
Protein supplementation
Twice daily, the subjects received either a 250-mL protein-supplemented beverage containing 
15 g protein (MPC80; milk protein concentrate), 7.1 g lactose, 0.5 g fat, and 0.4 g calcium, 
or a matching placebo supplement containing no protein, 7.1 g lactose, and 0.4 g calcium 
(FrieslandCampina Consumer Products Europe, Wageningen, the Netherlands). All 
beverages were vanilla flavoured to mask the contents of  the drinks and packages were non-
transparent. The participants consumed one beverage after breakfast and one beverage after 
lunch. Adherence to the protein and placebo drinks was judged by returned ticked calendars 
and non-consumed beverages. Staff  members and subjects were blinded toward treatment 
allocation until completion of  data analysis.
Cognitive performance
At baseline, the Mini-Mental State Examination (MMSE) was performed to determine 
general cognitive status.30 At baseline, after 12 weeks (only reaction time) and after 24 
weeks of  intervention, a standard battery of  neuropsychological tests was performed 
by well-trained research assistants to assess the cognitive domains episodic memory, 
working memory and attention, information processing speed, and executive functioning. 
The Word Learning Test (WLT) measures immediate and delayed memory and retrieval 
of  newly acquired verbal material.31 The forward test of  the Wechsler Digit Span Task 
measures attention and the backward test measures working memory.32 The Trail Making 
Test (TMT) version A measures sensorimotoric speed and version B measures concept 
shifting interference (executive function).33 The Stroop Color-Word Test measures selective 
attention and susceptibility to behavioral interference.34 The Verbal Fluency test measures 
semantic memory and language.35 The finger precuing task is a four-choice reaction time 
task 36 requiring participants to respond to spatial-location stimuli on a computer screen 
with discrete button-press responses by index and middle fingers of  both hands. The screen 
always showed a reference row consisting of  four plus signs indicating the four possible 
stimulus locations. A trial was started by showing a cue signal, which could be four plus signs 
in all four positions (neutral uncued condition) or only two plus signs, i.e.: the hand-cued 
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condition in which the cue specifies two fingers on the same hand; the finger-cued condition 
in which the cue specifies the same finger on two hands; or the neither-cued condition 
in which the cue specifies different fingers on two hands. Those cues reduce the number 
of  possible stimulus locations from four to two. After a preparation interval of  2000 ms, 
the target signal (one plus sign) appeared in one of  the cued positions. Participants had to 
react as quickly as possible to the target signal by pressing the corresponding response key. 
Outliers were defined as reaction time less than 150 ms or in excess of  2000 ms and were 
excluded from data analysis (mean percentage of  outliers was 1.5% based on 160 trials per 
test session). Reaction time was based only on correct trials.
Blood sampling 
Fasted blood samples were collected at baseline, after 12 weeks, and directly after the 
intervention to determine glucose homeostasis and renal function (only baseline data 
shown). Plasma glucose concentrations were analyzed with a COBAS FARA analyzer (Uni 
Kit III; Roche, Basel, Switzerland). Insulin was analyzed by radioimmunoassay (Insulin RIA 
Kit; LINCO Research Inc, St Charles, MO). Serum creatinine was measured by using Roche 
Modular System P (Roche Diagnostics GmbH, Mannheim, Germany). 
Dietary intake 
Participants recorded their food intake for three days at baseline, after 12 weeks, and after 
24 weeks to assess potential changes in daily food intake during the intervention period 
(only baseline data shown). Trained dieticians gave oral and written instructions about 
recording the type of  foods and estimating of  portion sizes in household measures, and they 
checked the food records for completeness, obtained additional information about unclear 
items or amounts and used household measures to improve the estimation of  portion size. 
Dietary intake data were coded (type of  food, time of  intake, and amount) and energy and 
macronutrient intakes were calculated using a nutrient computation program (Komeet) and 
the Dutch food composition database.37 
Other measurements
Physical performance was assessed by the short physical performance battery (SPPB), 
which consists of  three components: balance, gait speed, and chair rise ability.38 Scores of  
0 to 4 were based on categories of  performance in the balance tests, on the time necessary 
to complete the walk, and on the time needed to perform the chair-rise test. A summary 
performance score of  0 to 12 was calculated by summing the scores of  the tests. Habitual 
physical activity data were quantified using a tri-axial accelerometer (ActiGraph GTX3, 2009, 
Pensacola, FL, USA) worn on the hip for 1 week. Change of  acceleration per second and 
epochs of  60 s were used. After 7 days, data were uploaded and analyzed using the MAH/
UFFE analyzer, version 1.9.0.3 (MRC Epidemiology Unit, Cambridge, UK). Data files that 
did not meet 10 hours of  monitoring per day on at least 5 days as well as files that included 
periods of  >100 min without activity were excluded from the analysis. Mental health was 
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assessed using the Center for Epidemiologic Studies Depression Scale (CES-D), a 20-item, 
self-report scale developed to measure depressive symptoms experienced in the past week.39 
Overall health status and quality of  life of  the subjects was assessed using the 12-Item Short 
Form Health Survey (SF-12) 40 and the EuroQol-5D (EQ-5D).41 The SF-12 is a short form 
of  the widely used SF-36 that generates a physical (PCS12) and a mental (MCS12) composite 
score. The EQ-D5 defines health in five dimensions and a visual analogue scale indicates 
health status from 0-100. Height was measured at baseline with a wall-mounted stadiometer 
to the nearest 0.1 cm. Body weight was measured in the fasted state to the nearest 0.1 kg with 
a calibrated digital scale (ED-6-T; Berkel, Rotterdam, The Netherlands). Blood pressure was 
measured in the morning after a 10-minute rest with an Omron HEM-907 (Lake Forest, IL, 
USA) device. At each visit four measurements were done, with an interval of  two minutes, 
of  which the first measurement was discarded. The mean value of  the three subsequent 
measurements for systolic and diastolic blood pressure was taken.
Statistics
Differences in baseline characteristics among the four intervention groups were compared 
using Analysis of  Variance (ANOVA) for continuous variables or chi-square for categorical 
variables. Z-scores were created for cognitive tests at baseline and 24-week using the baseline 
data as norm data to calculate the grand mean and SD per test. Individual neuropsychological 
tests were clustered into compound scores for four neuropsychological domains: 
Episodic memory = (ZWLT total1-5 immediate recall + ZWLT decay + ZWLT recognition)/3
Attention and working memory = (ZDigit Span forward + ZDigit Span backward)/2
Information processing speed = (-ZTrail making test part A + ZStroop mean I and II + -ZReaction time uncued + 
-ZReaction time cued)/4
Executive functioning = (ZVerbal Fluency Animal + ZVerbal Fluency Letter P + ZStroop interference + - ZTrail making 
interference)/4
To take into account errors made during the Stroop test, accuracy (maximum right answers – 
amount of  errors / maximum right answers) and speed-accuracy trade-off  (accuracy / time 
needed to complete the task) were calculated.42 To control for the effect of  motor speed on 
performance we calculated interference measures for TMT (TMT B/TMT A) and Stroop 
part 3 (Stroop part 3-(part 1+part 2)/2).43 For the finger precuing task trials with errors or 
outliers (reaction time <150 ms or >2000 ms) were excluded from data analyses. The three 
cued conditions of  the reaction time test (hand-cued, finger-cued, and neither-cued) were 
averaged to obtain one variable cued reaction time. Analyses were performed for the effect 
of  resistance-type exercise versus non-exercise within both protein supplemented groups and 
separately for the effect of  resistance-type exercise versus non-exercise within both placebo 
supplemented groups. Differences between interventions overtime were analyzed using 
analyses of  covariance (ANCOVA), in which the baseline data were included as the covariate, 
the outcome measures as the dependent factor and exercise intervention as the fixed factor. 
Linear Mixed Models with unstructured covariance structure was used to assess the effect of  
the intervention on reaction time, which was measured at three time points. Time, treatment 
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and their interaction were defined as fixed factors, whereas subject was defined as random 
factor. Data were analyzed by intention-to-treat and an α-level of  0.05 was used to determine 
statistical significance. All statistical analyses were performed using SPSS Statistics v19.
Results
Participants
Details of  the participant flow of  recruitment and screening have been published before.24, 
25 In total 127 frail and pre-frail elderly men and women fulfilled to the inclusion criteria and 
were willing to participate: 62 in the study with and 65 in the study without resistance-type 
exercise training. Nineteen participants withdrew during the intervention: eleven from the 
exercise intervention (five from the protein and six from the placebo group) and eight from 
the non-exercise intervention (four from the protein and four from the placebo group). Of  
these drop-outs eight were willing to have final measurements, so they could be included 
in the intention-to-treat analysis. The average adherence to the protein and placebo drinks 
based on ticked calendars and non-consumed returned beverages was 98% in the exercise 
study and 93% in the non-exercise study.
Mean age of  the participants at baseline was 79 ± 8 years, 39% were men and these 
distributions were not significantly different among the intervention groups. There were also 
no significant differences in any of  the other baseline characteristics among the intervention 
groups (Table 1). In total, 15 subjects had a MMSE score <25, suggesting a cognitive 
impairment.44 However, the overall median MMSE score of  28 showed that most subjects 
were cognitively healthy.
Cognitive functioning
Baseline mean cognitive function scores for each of  the individual tests and for the four 
cognitive domains composite scores did not differ among the groups (Table 2). Table 
3 shows the changes in cognitive tests and domains after 24 weeks of  intervention. 
When comparing the exercise and non-exercise group who received additional protein 
supplementation for 24 weeks, the non-exercise group improved compared to the exercise 
group on Verbal Fluency Animals (2.4 ± 4.1 more animals compared to -0.6 ± 4.1 animals 
respectively, p < 0.01). On the domain of  information processing speed the exercise group 
(change in domain score 0.08 ± 0.51) improved significantly compared to the non-exercise 
group (change in domain score -0.23 ± 0.19) (p = 0.04).
After 24 weeks of  placebo supplementation, the exercise group significantly improved on 
the Digit Span forward test (0.7 ± 1.7 versus -0.3 ± 1.7 for the exercise and non-exercise 
group respectively, p = 0.04) (Table 3). Accordingly, this significant improvement was also 
observed in the corresponding cognitive domain of  attention and working memory (change 
in domain score 0.35 ± 0.70 in the exercise group versus -0.12 ± 0.69 in the non-exercise 
group, p = 0.02). On the other cognitive tests or domain scores no significant differences 
were found among the intervention groups. 
105
5Exercise, protein supplementation and cognition
Table 1 Baseline characteristics of  127 Dutch frail and pre-frail elderly people by intervention group
Protein (n = 65) Placebo (n = 62)
Characteristic Exercise 
(n = 31)
Non-exercise 
(n = 34)
Exercise 
(n = 31)
Non-exercise 
(n = 31)
Age (yrs)a 77.7 ± 8.8 77.9 ± 8.1 79.2 ± 6.3 81.2 ± 7.4
Sex, men, n (%) 11 (36%) 14 (41%) 10 (32%) 15 (48%)
Education Low/ Middle/ 
High (%)
10 / 55 / 36 9 / 59 / 32 3 /71 /26 0 / 55 / 45
BMI (kg/m2) 28.7 ± 4.5 27.0 ± 4.6 28.2 ± 4.6 26.2 ± 3.2
Smokers 2 (7) 5 (15) 1 (3) 1 (3)
Number of  cigarettes/cigars 
per day
8 12 5 10
Alcohol consumers (%) 74 68 77 71
Alcohol consumption (g/
day)b
11 (6-22) 15 (5-30) 9 (3-17) 11 (3-22)
MMSE score (0-30)c 28 [27-29] 29 [26-30] 28 [27-29] 28 [26-30]
Range 23-30 21-30 23-30 22-30
CES-D score (0-60) 8.2 ± 6.9 6.6 ± 5.7 6.1 ± 6.0 7.0 ± 4.1
PCS12 (0-100 points) 42.6 ± 6.4 43.9 ± 10.0 42.7 ± 9.8 42.7 ± 9.8
MCS12 (0-100 points) 56.0 ± 8.2 54.0 ± 7.9 56.6 ± 7.2 54.9 ± 8.0
EQ-5D (0-1 points) 0.7 ± 0.2 0.7 ± 0.2 0.8 ± 0.1 0.7 ± 0.2
Frailty score (1-5)d 1.5 ± 0.7 1.7 (1-2) 1.6 ± 0.8 2.0 (1-3)
Frail/pre-frail, n 4/27 7/27 7/24 11/20
Physical activity score 
(counts/minute)e
159 ± 111 153 ± 101 122 ± 69 115 ± 88
Baseline glucose (mmol/L) 5.4 ± 0.5 5.2 ± 0.4 5.2 ± 0.5 5.3 ± 0.4
Baseline insulin (mU/L) 19.6 ± 6.9 18.0 ± 7.4 18.1 ± 6.7 18.2 ± 7.1
eGFR (mL/min/1.73 m2 ) 80.6 ± 14.1 84.4 ± 20.2 79.3 ± 13.9 77.6 ± 12.5
Blood pressure, systolic 
(mmHg)
142 ± 19.2 152 ± 25 143 ± 20.3 150 ± 23
Blood pressure, diastolic 
(mmHg)
74 ± 8.3 77 ± 10 73 ± 9.8 75 ± 9
SPPB (0-12) 8.0 ± 2.4 8.9 ± 2.8 7.9 ± 2.4 7.8 ± 3.6
Energy intake, kcal 1980 [1687-2226] 1981 [1513-2295] 1698 [1543-2128] 1932 [1593-2261]
Protein intake, g/day (En%) 72 [61-85] (16) 72 [57-92] (16) 75 [62-85] (17) 72 [64-78] (16)
Fat intake, g/day (En%) 76 [49-95] (33) 83 [55-107] (36) 71 [58-92] (35) 73 [57-94] (33)
Carbohydrate intake, g/day 
(En%)
234 [190-270] (47) 198 [166-256] (44) 184 [162-254] (45) 216 [173-273] (48)
Notes: BMI, Body Mass Index; MMSE, Mini-Mental State Examination; CES-D, Center for Epidemiologic Studies 
Depression Scale; PCS12, Physical Composite Score; MCS12, Mental Composite Score; EQ-5D, EuroQol-5D; eEGR, 
estimated Glomerular Filtration Rate; SPPB, Short Physical Performance Battery. a Mean ± SD (all such values); b Mean 
use in consumers only; c Median [interquartile range] (all such values); d Higher scores indicate being more frail accord-
ing to Fried et al. 21; e Significant difference between the protein and the placebo group (p < 0.05).
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Both uncued as well as mean cued reaction time (and also all three individual cued 
conditions) significantly improved over time in all intervention groups (p < 0.05) (Table 
4). However, neither exercise plus protein supplementation nor exercise without protein 
supplementation showed a significant benefit compared to non-exercise. Overall error rate 
was very low (1.7%), with small, non-significant reductions in error rate for all groups at the 
end of  the treatment compared to baseline.
Table 2 Baseline cognitive test scores (mean ± SD) of  Dutch frail and pre-frail elderly people, by intervention group
Protein (n = 65) Placebo (n = 62)
Cognitive tests, maximum score Exercise 
(n = 31)
Non-exercise 
(n = 34)
Exercise 
(n = 31)
Non-Exercise 
(n = 31)
Episodic memory
Word learning test - Immediate 
recall 1-5, 75 words
31.8 ± 10.9 34.6 ± 11.8 33.6 ± 10.0 33.5 ± 10.5
Word learning test - Delayed 
recall, 15 words
6.1 ± 2.7 6.2 ± 3.1 6.5 ± 3.1 5.9 ± 2.9
Word learning test - Decay 
(delayed recall – WLT5)
-2.0 ± 1.8 -2.8 ± 1.5 -2.3 ± 1.8 -2.6 ± 2.0
Word learning test - 
Recognition, 30 words
27.5 ± 2.5 28.2 ± 1.9 28.1 ± 1.8 27.1 ± 2.7
Attention and working memory
Digit Span forward, 16 points 8.0 ± 1.8 7.9 ± 1.4 7.9 ± 1.7 8.3 ±2.1
Digit Span backward, 14 points 5.2 ± 1.9 5.2 ± 1.3 5.5 ± 1.8 6.0 ± 2.3
Information processing speed
Stroop 1a 1.85 ± 0.33b 1.91 ± 0.36 1.91 ± 0.37c 1.80 ± 0.33
Stroop 2a 1.47 ± 0.28b 1.5 ± 0.4 1.51 ± 0.32c 1.44 ± 0.28
Trail Making Part A (s)d 63.7 ± 29.0 61.6 ± 27.2 54.4 ± 24.3c 62.6 ± 23.0
Reaction time uncued (ms)d 833 ± 290b 764 ± 301 787 ± 221c 830 ± 243
Reaction time, mean cued 
conditions (ms)d
832 ± 309 753 ± 330 779 ± 240 821 ± 263
Executive functioning
Stroop Interference (Part 3 – 
(Part 1 + Part 2/2))a
-0.89 ± 0.29b -0.90 ± 0.24 -0.89 ± 0.25c -0.79 ± 0.21
Trail Making Test (Part B/
Part A)d
1.93 ± 0.63 1.77 ± 0.61 1.68 ± 0.49c 1.83 ± 0.62
Word Fluency - Animals 20.6 ± 6.3 21.4 ± 6.4 20.0 ± 6.8 20.6 ± 5.8
Word Fluency - Letter P 13.0 ± 6.2 15.2 ± 5.8 14.7 ± 5.5 14.1 ± 3.8
Domain specific z-scores
Episodic memory -0.01 ± 0.63 0.04 ± 0.60 0.09 ± 0.62 -0.13 ± 0.77
Attention and working memory -0.07 ± 0.90 -0.11 ± 0.64 -0.04 ± 0.87 0.22 ± 1.13
Information processing speed -0.06 ± 0.74c 0.10 ± 1.00 0.11 ± 0.81c -0.09 ± 0.75
Executive functioning -0.14 ± 0.64c 0.06 ± 0.60 0.05 ± 0.58c 0.08 ± 0.55
Notes: a Corrected for errors (time needed / accuracy); b n = 30; c n = 29; d Higher scores indicate more time was needed 
to complete the task, so poorer performance.
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Table 3 Changes on cognitive test scores (mean ± SD) of  Dutch frail and pre-frail elderly people, by intervention 
group (only participants with baseline and end data) 
Cognitive tests/
domains
Exercise (n = 28) Non-exercise (n = 30)
Protein Baseline 24 weeks Change Baseline 24 weeks Change p
Episodic memory
Word learning test - 
Immediate recall, 75 
words
31.9 ± 10.9 35.1 ± 10.9 3.3 ± 7.4 35.9 ± 11.1 38.8 ± 12.0 2.9 ± 7.6 0.83
Word learning test 
- Delayed recall, 15 
words
6.2 ± 2.6 6.8 ± 3.2 0.6 ± 1.9 6.6 ± 2.9 6.8 ± 3.6 0.2 ± 2.3 0.53
Word learning test - 
Decay
-2.0 ± 1.8 -2.1 ± 1.5 -0.2 ± 2.6 -2.7 ± 1.6 -2.6 ± 2.1 0.1 ± 2.4 0.37
Word learning test - 
Recognition, 30 words
27.4 ± 2.5 27.4 ± 2.8 0.0 ± 2.3 28.4 ± 1.9 27.7 ± 2.2 -0.7 ± 1.9 0.54
Attention and working memory
Digit Span forward, 16 
points
7.7 ± 1.6 7.9 ± 1.9 0.1 ± 1.4 8.0 ± 1.4 8.1 ± 1.7 0.1 ± 1.4 0.92
Digit Span backward, 
14 points
5.2 ± 1.9 5.8 ± 1.9 0.6 ± 1.5 5.3 ± 1.3 5.4 ± 1.5 0.0 ± 1.2 0.16
Information processing speeda
Trail Making Part A (s)b 59.4 ± 21.1 58.2 ± 25.8 -1.1 ± 24.2 57.2 ± 21.8 60.8 ± 36.9 3.7 ± 20.1 0.85
Stroop 1 (s)c 1.9 ± 0.3 1.9 ± 0.3 0.0 ± 0.2 2.0 ± 0.3 2.0 ± 0.3 -0.0 ± 0.2 0.95
Stroop 2 (s)c 1.5 ± 0.3 1.5 ± 0.3 0.0 ± 0.2 1.6 ± 0.3 1.6 ± 0.3 0.1 ± 0.1 0.60
Reaction time, uncued 
(ms)b
834 ± 295 744 ± 181 -90 ± 162 686 ± 136 644 ± 154 -42 ± 122 0.20
Mean reaction time 
cued (ms)b
830 ± 312 726 ± 226 -104 ± 149 667 ± 147 604 ± 172 -63 ± 107 0.19
Executive functioninga
Stroop Interferencec -0.9 ± 0.3 -0.9 ± 0.2 0.0 ± 0.2 -0.9 ± 0.2 -0.8 ± 0.2 0.1 ± 0.2 0.42
Word Fluency - 
Animals
21.2 ± 6.1 20.6 ± 5.8 -0.6 ± 4.1 21.8 ± 6.2 24.2 ± 6.5 2.4 ± 4.1 <0.01
Word Fluency - Letter 
P
13.0 ± 6.5 13.6 ± 6.1 0.6 ± 4.3 15.7 ± 5.6 15.7 ± 6.7 0.0 ± 4.9 0.99
Trail Making Test (Part 
B/Part A)b
1.86 ± 0.54 1.86 ± 0.57 0.01 ± 0.76 1.75 ± 0.63 1.77 ± 0.57 0.01 ± 0.60 0.75
Domain specific z-scores
Episodic memory -0.02 ± 0.64 0.05 ± 0.77 0.07 ± 0.62 0.11 ± 0.57 0.13 ± 0.83 0.01 ± 0.57 0.79
Attention and working 
memory
-0.16 ± 0.85 0.03 ± 0.97 0.19 ± 0.63 -0.03 ± 0.63 0.01 ± 0.79 0.04 ± 0.57 0.38
Information processing 
speeda
-0.05 ± 0.71 0.03 ± 0.41 0.08 ± 0.51 0.34 ± 0.60 0.10 ± 0.54 -0.23 ± 0.19 0.04
Executive functioninga -0.09 ± 0.64 -0.05 ± 0.52 0.04 ± 0.44 0.07 ± 0.60 0.25 ± 0.64 0.17 ± 0.43 0.09
Table continues on the next page 
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Exercise (n = 27) Non-exercise (n = 28)
Placebo Baseline 24 weeks Change Baseline 24 weeks Change p
Episodic memory
Word learning test - 
Immediate recall, 75 
words
33.3 ± 10.5 37.0 ± 10.3 3.7 ± 6.2 34.4 ± 9.8 36.5 ± 10.4 2.1 ± 5.5 0.36
Word learning test 
- Delayed recall, 15 
words
6.5 ± 3.3 6.9 ± 3.4 0.4 ± 2.2 6.1 ± 2.8 6.8 ± 3.5 0.7 ± 2.4 0.72
Word learning test - 
Decay
-2.1 ± 1.7 -2.4 ± 1.8 -0.3 ± 2.3 -2.7 ± 1.8 -2.2 ± 2.0 0.5 ± 2.6 0.58
Word learning test - 
Recognition, 30 words
28.2 ± 1.8 27.9 ± 2.1 -0.3 ± 1.6 27.4 ± 2.4 27.7 ± 2.6 0.3 ± 2.8 0.78
Attention and working memory
Digit Span forward, 16 
points
8.0 ± 1.7 8.8 ± 2.7 0.7 ± 1.7 8.3 ± 2.2 8.0 ± 2.1 -0.3 ± 1.7 0.04
Digit Span backward, 
14 points
5.6 ± 1.8 6.2 ± 2.1 0.5 ± 1.6 6.2 ± 2.3 6.0 ± 2.4 -0.1 ± 1.7 0.22
Information processing speedd,e
Trail Making Part A (s)b 55.9 ± 25.9 51.2 ± 17.6 -4.7 ± 15.5 63.9 ± 24.3 60.1 ± 25.1 -3.8 ± 14.8 0.50
Stroop 1 (s)c 1.9 ± 0.4 2.0 ± 0.4 0.0 ± 0.2 1.8 ± 0.3 1.8 ± 0.4 0.0 ± 0.2 0.85
Stroop 2 (s)c 1.5 ± 0.3 1.6 ± 0.4 0.1 ± 0.2 1.4 ± 0.3 1.5 ± 0.3 0.0 ± 0.2 0.47
Reaction time, uncued 
(ms)b
792 ± 239 722 ± 189 -69 ± 138 832 ± 236 812 ± 242 -21 ± 144 0.10
Mean reaction time 
cued (ms)b
794 ± 261 696 ± 206 -98 ± 148 813 ± 260 772 ± 271 -41 ± 135 0.10
Executive functioningd,f
Stroop Interferencec -0.9 ± 0.3 -0.9 ± 0.3 0.0 ± 0.2 -0.8 ± 0.2 -0.8 ± 0.2 -0.0 ± 0.2 0.84
Word Fluency - 
Animals
20.6 ± 7.3 20.2 ± 7.7 -0.4 ± 4.4 20.9 ± 5.6 22.0 ± 6.3 1.1 ± 3.7 0.21
Word Fluency - Letter 
P
15.7 ± 5.5 15.9 ± 6.1 0.2 ± 4.8 14.6 ± 3.8 14.9 ± 5.7 0.3 ± 4.1 0.99
Trail Making Test (Part 
B/Part A)b
1.62 ± 0.47 1.59 ± 0.43 -0.04 ± 0.59 1.83 ± 0.65 1.79 ± 0.69 -0.04 ± 0.81 0.37
Domain specific z-scores
Episodic memory 0.11 ± 0.65 0.13 ± 0.71 0.02 ± 0.57 -0.08 ± 0.68 0.12 ± 0.87 0.20 ± 0.79 0.51
Attention and working 
memory
0.05 ± 0.85 0.40 ± 1.27 0.35 ± 0.70 0.28 ± 1.16 0.16 ± 1.13 -0.12 ± 0.69 0.02
Information processing 
speedd, e
0.11 ± 0.87 0.18 ± 0.47 0.07 ± 0.48 -0.14 ± 0.78 -0.01 ± 0.46 0.13 ± 0.50 0.32
Executive functioningd,f 0.09 ± 0.62 0.12 ± 0.55 0.02 ± 0.42 0.10 ± 0.58 0.17 ± 0.61 0.07 ± 0.42 0.78
Notes: Differences between the two groups were measured using ANCOVA (baseline cognitive function as covariate). 
a n = 26 for the exercise-protein group; b Higher scores indicate more time was needed to complete the task, so poorer 
performance; c Corrected for errors (time needed / accuracy); d n = 24; e n = 27; f  n = 26.
Table 3 Changes on cognitive test scores of  Dutch frail and pre-frail elderly people, by intervention group (only 
participants with baseline and end data) (mean ± SD) (continued)
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Table 4 Reaction time (in ms) of  Dutch frail and pre-frail elderly measured at baseline, and after 12 and 24 weeks, by 
intervention group (mean ± SD)
Baseline 12 weeks 24 weeks Treatment*time 
(p)
Treatment 
effect 
(p)
Time ef-
fect 
(p)
Protein
RT uncued 0.69 0.17 <0.01
Exercise 833 ± 290 832 ± 268 769 ± 220
Non-exercise 764 ± 301 663 ± 151 671 ± 183
RT hand-cued 0.92 0.86 <0.01
Exercise 798 ± 321 756 ± 267 725 ± 249
Non-exercise 716 ± 318 597 ± 170 613 ± 210
RT finger-cued 0.22 0.13 <0.01
Exercise 847 ± 304 844 ± 303 765 ± 262
Non-exercise 772 ± 333 640 ± 179 643 ± 208
RT neither-cued 0.90 0.47 <0.01
Exercise 850 ± 310 820 ± 266 762 ± 259
Non-exercise 771 ± 342 648 ± 184 650 ± 213
RT mean cued 0.79 1.00 <0.01
Exercise 832 ± 309 807 ± 276 751 ± 255
Non-exercise 753 ± 330 628 ± 176 635 ± 208
Placebo
RT uncued 0.43 0.27 0.01
Exercise 787 ± 221 741 ± 182 722 ± 189
Non-exercise 830 ± 243 778 ± 196 808 ± 238
RT hand-cued 0.37 0.41 0.02
Exercise 748 ± 234 689 ± 201 670 ± 196
Non-exercise 767 ± 263 726 ± 208 740 ± 260
RT finger-cued 0.25 0.32 <0.01
Exercise 790 ± 239 752 ± 211 706 ± 217
Non-exercise 840 ± 261 773 ± 215 799 ± 291
RT neither-cued 0.52 1.00 <0.01
Exercise 800 ± 256 752 ± 218 711 ± 210
Non-exercise 857 ± 275 781 ± 221 785 ± 251
RT mean cued 0.37 1.00 <0.01
Exercise 779 ± 240 731 ± 208 696 ± 206
Non-exercise 821 ± 263 760 ± 212 775 ± 266
Notes: Differences between the two groups were measured using Linear Mixed Models. Higher scores indicate more 
time was needed to complete the task, so poorer performance.
Protein with exercise: Baseline n = 30, 12 weeks n = 30, 24 weeks n = 27
Protein non-exercise: Baseline n = 28, 12 weeks n = 32, 24 weeks n = 32
Placebo with exercise: Baseline n = 29, 12 weeks n = 27, 24 weeks n = 24
Placebo non-exercise: Baseline n = 31, 12 weeks n = 29, 24 weeks n = 28  
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Discussion
In this study performed in frail and pre-frail elderly people, 24 weeks of  resistance-
type exercise training in combination with protein supplementation improved the 
cognitive domain information processing speed and the same training without protein 
supplementation was beneficial for attention and working memory.
To the best of  our knowledge, this is the first study that investigated the effect of  resistance-
type exercise in combination with protein supplementation on cognitive functioning. 
As cognitive function was not the primary outcome of  the study, the total number of  
participants included was not based on cognition function as outcome measure, but on 
the primary outcome muscle mass. However, compared to the other interventions studies 
that have been performed on resistance-type exercise and cognitive function, this was still 
one of  the largest studies 14-16, 45-51 and the only one that combined exercise with protein 
supplementation. Furthermore, cognitive function was measured in a standardized way with 
an extensive neurological test battery, which enabled us to thoroughly investigate the effects 
of  the intervention on multiple cognitive domains that are sensitive to age-related cognitive 
decline. 
As frailty has been associated with cognitive impairment 19 we expected this study population 
to be relatively cognitively impaired and therefore subjective to change. However, except 15 
individuals who scored <25 points on the MMSE, the group in general was still cognitively 
healthy. Still we observed beneficial changes in cognitive functioning on the cognitive 
domain information processing speed after the exercise plus protein intervention and on 
attention and working memory after the exercise intervention without additional protein 
supplementation. In more cognitively impaired elderly people, exercise might benefit other 
individual neuropsychological tests or cognitive domains as well.  
The current study of  24 weeks might also have been too short to pick up an effect of  the 
interventions on the other cognitive domains, because the process of  cognitive decline is 
a rather slow process. According to the IANA taskforce, trials studying effect on cognitive 
functioning should have a study duration of  at least 18 months.52 Though, compared to the 
other resistance-type exercise intervention studies that did find effects on cognitive function, 
our intervention was of  average length. Only two studies were longer with respectively 9 
and 12 months of  intervention 14, 45 and because our study population of  frail and pre-frail 
older individuals was expected to be more sensitive, effects could have occurred faster. 
Additionally, seen the extensive exercise program that was used in our study and the fact that 
this was performed by frail and pre-frail individuals, 24 weeks was a substantial period for 
this target group and a longer study duration could have resulted in a relatively large number 
of  drop-outs and age-related co-morbidities interfering with the effects of  the intervention.
The majority of  the other intervention studies that focused on the effects of  resistance 
training on cognitive function also observed an effect, mostly on the cognitive domains of  
memory and executive functioning.7-9, 14-16 We did observe an effect of  the resistance training 
on attention and working memory, but not on episodic memory. Additionally, we observed 
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an effect of  resistance-type exercise plus protein supplementation on information processing 
speed. It may be that for improvement in speed related tasks, where the neuromuscular 
system is involved, additional protein is needed to reinforce the effect of  exercise. Also, in 
our cognitive domain of  information processing speed, the finger precuing task was a major 
component. This is a complex reaction time task, which involves more central processing 
and may be more likely to show improvements than simple reaction time tasks. More trials of  
sufficient duration and size, performed in susceptible target groups, and with extensive and 
sensitive neuropsychological test batteries like ours, are needed to disentangle these effects. 
Although the suggestion that physical exercise training is beneficial for cognitive functioning 
is becoming more and more established, the underlying biological mechanisms are not yet 
elucidated. In the review of  Bherer et al. (2013) the current ideas have been summarized and 
include direct effects at the supramolecular and molecular level.12 In animal studies, physical 
activity has been shown to induce angiogenesis, neurogenesis, neural cell proliferation or 
synaptogenesis. The evidence for molecular mechanisms also comes from animal studies 
and include changes in molecular growth factors such as brain-derived neurotrophic factor 
(BDNF) and insulin-like growth factor (IGF-1).12 The findings for an exercise-related 
increase in BDNF have also been shown for the first time in humans and were associated 
with an increased hippocampal volume and improved memory.53 Recently, also differences 
in underlying molecular mechanisms for different types of  exercise were postulated; 
aerobic training increased BDNF in the hippocampus and resistance training increased 
IGF-1 levels.54 Something to take into consideration in future studies is that there are also 
some factors that might moderate the effects of  physical activity on brain health, such as 
apolipoprotein E (APOE), BDNF, catechol-O-methyltransferase (COMT) and the dietary 
omega-3 fatty acids.55, 56 Furthermore, studies on physical activity and brain function, 
structure and connectivity assessed using MRI are still in their early stages, but with these 
studies could also provide more insight in underlying mechanisms.17
In addition to the resistance-type exercise program participants were also supplemented 
with either protein or placebo. One of  the possible links between protein and cognitive 
functioning may be the fact that dietary protein contains some indispensable amino 
acids, tryptophan and tyrosine in particular, which act as precursors for several brain 
neurotransmitters.57 However, the number of  studies on supplementation with protein or 
some individual amino acids is very small and more research is needed to elucidate the effects 
on cognitive functioning. 
Our main interest was in the effects of  resistance-type exercise training, with or without 
protein supplementation, on cognitive functioning. This is the first time that the effects 
of  a resistance-type exercise intervention could be examined in a frail elderly population. 
However, to examine this interesting effect, analyses had to be performed across the two 
trials, which may be a methodological limitation. Although not designed as such, the two 
trials together also approach a 2x2 factorial design. To examine possible interaction effects 
between exercise and protein, we explored the results of  adding an interaction term to 
our models, despite the fact that the trials were each powered for main effects and not 
for interaction effects. There was no significant interaction between exercise and protein 
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supplementation on any of  the cognitive domains, but on the individual cognitive tests a 
significant interaction was observed for the uncued and cued reaction time tests (p = 0.05 
for both tests). However, taking into account the limited power, these p-values have to be 
interpreted with caution. Moreover, this interaction was not observed in the corresponding 
cognitive domain of  information processing speed. Still, a possible interaction between 
exercise and protein supplementation has to be taken into account in future studies using 
similar interventions in parallel.
In summary, in this population of  frail and pre-frail elderly people 24 weeks of  resistance-
type exercise training in combination with protein supplementation was beneficial for the 
cognitive domain information processing speed and the same training without protein 
supplementation was beneficial for attention and working memory. We were able to 
investigate the effect of  exercise with or without protein supplementation, as an example for 
a study on interaction or synergy between diet and physical activity, an area which is relatively 
unexplored so far.  
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Abstract
Objective: We investigated the effects of  two-year folic acid and vitamin B12 
supplementation on cognitive performance in elderly people with elevated homocysteine 
(Hcy) levels.
Methods: This multicenter, double-blind, randomized, placebo-controlled trial included 
2,919 elderly participants (≥65 years) with Hcy levels between 12 and 50 µmol/L. 
Participants received daily either a tablet with 400 µg folic acid and 500 µg vitamin B12 
(B-vitamin group), or a placebo tablet. Both tablets contained 15 µg vitamin D3. Data were 
available for global cognitive functioning assessed by MMSE (n = 2,556), episodic memory (n 
= 2,467), attention and working memory (n = 759), information processing speed (n = 731), 
and executive function (n = 721). 
Results: Mean age was 74.1 ± 6.5 years. Hcy concentrations decreased 5.0 (95% CI -5.3--
4.7) µmol/L in the B-vitamin group and 1.3 (95% CI -1.6--0.9) µmol/L in the placebo group. 
Cognitive domain scores did not differ over time between the two groups, as determined by 
ANCOVA. MMSE score decreased with 0.1 (95% CI -0.2--0.0) in the B-vitamin group and 
0.3 (95% CI -0.4--0.2) in the placebo group (p = 0.05), as determined by an independent 
t-test. 
Conclusions: Two-year folic acid and vitamin B12 supplementation did not beneficially affect 
performance on four cognitive domains in elderly people with elevated Hcy levels. It may 
slightly slow the rate of  decline of  global cognition, but the reported small difference may be 
due to chance. 
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Introduction
With the aging of  populations, the prevalence of  dementia is growing dramatically.1 A 
possible modifiable risk factor of  dementia is an elevated plasma homocysteine level 
(Hcy). Hcy may be toxic for neurons and vascular endothelial cells,2 and cross-sectional 
and prospective studies have shown associations between elevated Hcy levels and cognitive 
decline and dementia.2, 3 
Hcy levels can be lowered by supplementation with folic acid and vitamin B12.4 Serum 
folate and vitamin B12 are involved in the Hcy pathway, acting on the conversion of  Hcy 
into methionine. Deficiencies of  these vitamins may result in elevated Hcy levels, impaired 
DNA synthesis and methylation, and accumulation of  abnormal fatty acids in membranes 
of  neural tissue.2, 5 This may negatively influence cognitive performance. Although 
observational studies have shown associations between poor vitamin B12 and folate status 
and cognitive performance,2 evidence from randomized controlled trials (RCTs) is limited 
and less convincing.3 A meta-analysis of  thirteen trials in healthy older adults did not 
observe beneficial effects of  supplementation with vitamin B12, folic acid, vitamin B6, or 
a combination of  these vitamins.3 However, the studies were heterogeneous in their used 
dosage and study population, which makes comparisons difficult. Furthermore, only four 
trials had a study period of  one year or longer. Therefore, we investigated the effects of  two-
year folic acid and vitamin B12 supplementation on cognitive performance in elderly people 
with elevated Hcy levels through a double-blind, randomized, placebo-controlled trial. 
Methods
Study design and Participants 
The study was conducted among Dutch elderly men and women who participated in the 
B-PROOF (B-Vitamins for the Prevention of  Osteoporotic Fractures) study.6 Primary goal 
of  the B-PROOF study was to assess the efficacy of  oral supplementation with 400 µg folic 
acid and 500 µg vitamin B12 in the prevention of  fractures, with cognitive performance as 
secondary outcome. The study was conducted in three research centers in the Netherlands: 
VU University Medical Center (VUmc, Amsterdam), Erasmus MC (Rotterdam) and 
Wageningen University (WU, Wageningen). 
Primary outcome of  the current study was the difference between treatment groups in 
performance on episodic memory after two years of  supplementation (Class I evidence). 
We hypothesized that supplementation with folic acid and vitamin B12 would delay decline in 
episodic memory by, among others, lowering plasma Hcy levels. Secondary outcomes were 
the differences in performance at follow-up on attention and working memory, information 
processing speed, executive function, and single test scores (Class I evidence). 
Participant selection and attrition have been extensively described elsewhere.6 In short, 
most participants were recruited via the registries of  municipalities in the surroundings of  
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the research centers. The study was carried out between October 2008 and March 2013. 
Inclusion criteria were being 65 years and older, having an elevated plasma Hcy level (12-
50 µmol/L), being competent to make own decisions, and having a compliant tablet intake 
(≥85%) in the run-in period. Exclusion criteria were: cancer diagnosis within the last five 
years except for basal cell carcinoma and squamous cell carcinoma, bedridden, serum 
creatinine level >150 µmol/L, current or recent (<4 months) use of  intramuscular injections 
of  vitamin B12 or folic acid supplementations (>300 µmol), and participation in other 
intervention studies. 
Standard Protocol Approvals, Registrations, and Patient Consents
The WU Medical Ethical Committee approved the study and the Medical Ethics Committees 
of  Erasmus MC and VUmc gave approval for local feasibility. All participants gave their 
written informed consent. This trial is registered at clinicaltrials.gov as NCT00696514 and at 
Netherlands Trial Register as NTR1333.
Randomization and masking
Participants were randomly allocated (1:1 ratio) to receive either a daily tablet with 400 µg 
folic acid and 500 µg vitamin B12, or a placebo tablet for two years. Both tablets contained 
15 µg (600 IU) of  vitamin D3 to ensure normal vitamin D status. Randomization was done 
by an independent person by means of  computer-generated randomization numbers in 
stratified permuted blocks of  size 4, stratified by study center, sex, age (65-80 years, ≥80 
years), and Hcy levels (12-18 µmol/L, ≥18 µmol/L). All participants and employees of  the 
study were blinded until data analyses were finished. Every six months participants received 
new tablets and participants were requested to return any remaining tablets in order to 
measure compliance. 
Descriptive characteristics
Standing height was measured with a stadiometer to the nearest 0.1 cm. Weight was 
measured to the nearest 0.5 kg with a calibrated scale (Seca, Deventer, the Netherlands). 
Information about education level, marital status, living situation, smoking habits, alcohol 
intake, and medical history was obtained by questionnaires. Depressive symptoms were 
measured with the short Geriatric Depression Scale (GDS-15), in which a score ≥5 indicates 
being at risk for depression.7 Physical activity was measured with the LASA Physical Activity 
Questionnaire; frequency and duration of  activities during the past two weeks were assessed 
to calculate physical activity in kcal/day.8 
Cognitive tests
Cognitive performance was assessed at baseline and at the end of  the intervention period 
by well-trained research assistants following a standard protocol. We used the Mini-Mental 
State Examination (MMSE) 9 and an extensive, sensitive, and validated neuropsychological 
test battery to assess the cognitive domains episodic memory, attention and working 
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memory, information processing speed, and executive function. The battery consisted of  
the Rey Auditory Verbal Learning Test (RAVLT),10 Digit Span forward and backward,11 Trail 
Making Test (TMT) part A and B,12 Stroop Color-Word Test,13 Symbol Digit Modalities Test 
(SDMT),14 and the Letter Fluency (three letters) (see Appendix 1 for a detailed description).15 
The MMSE and the RAVLT were performed in all three research centers, the other tests 
were only assessed in the WU participants. For the RAVLT, TMT, and Verbal Fluency test, 
validated parallel versions were used for baseline and the two-year measurement to minimize 
learning effects. 
RAVLT decayed recall was calculated as the number of  words recalled after approximately 
15 minutes following the fifth session of  the RAVLT, minus the number of  words recalled at 
the fifth session of  the RAVLT. To control for the effect of  motor speed on performance we 
calculated interference measures for TMT (TMT B/TMT A) and Stroop part 3 (Time needed 
for Stroop part 3 – (mean time needed for Stroop part 1 and 2)). The scores on the three 
letters of  Verbal Fluency test were summed.
To compare the results of  the individual cognitive tests and to limit the number of  
dependent variables, crude test scores were clustered into compound scores for the four 
neuropsychological domains. Data of  baseline measurements were used as norm data to 
create individual Z-scores for baseline and two-year follow-up data (Z-score = (score test – 
mean baseline)/SD baseline). 
Blood markers 
Before and immediately after the intervention period blood samples through venapunction 
were collected in a fasted state or after a restricted breakfast to obtain whole blood, 
plasma, serum and buffy coats.6 Plasma Hcy, serum creatinine, vitamin B12, folate, 
holotranscobalamin (holoTC), and methylmelonic acid (MMA) were determined. DNA was 
isolated to determine the genotype for Methylenetetrahydrofolate reductase (MTHFR 677T) 
and Apolipoprotein E (ApoE, rs429358) genotype. Detailed methodology can be found in 
the Appendix 1.
Statistics
Analyses were performed before unblinding of  the treatment code. Intention-to-treat 
analyses, with all participants who completed reliable baseline and follow-up measurements 
included, and per-protocol analyses, with those participants who were compliant to the study 
protocol (≥80% of  total tablet intake), were performed. Data are reported as n (%), means 
± SD, or as median [interquartile range (IQR)] for non-normally distributed data. Baseline 
characteristics were compared between treatment groups using Chi-square, independent-
samples t or Mann-Whitney non-parametric tests. Also differences in age, sex, Hcy, and 
MMSE between dropouts and participants who completed the study were tested. 
Differences between treatment groups over time were analyzed using analyses of  covariance 
(ANCOVA), in which the outcome measures at two-year acted as the dependent factor, 
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baseline data as a covariate factor, and treatment as the fixed between-subject factor. In 
the fully adjusted model, age, sex, and study center were added as covariates. Because test 
scores on the MMSE violated normality assumptions of  ANCOVA, change over time was 
calculated and analyzed for treatment effects with an independent-samples t-test.
For all four cognitive domains, predefined interaction terms of  treatment with sex, baseline 
age (<80, ≥80 years), plasma Hcy (<18, ≥18 µmol/L), and ApoE genotype (ApoE-ε4 or not) 
were tested. A p<0.10 for interaction was considered as a justification for stratified subgroup 
analyses. Exploratory post-hoc analyses were done for MTHFR genotype, baseline levels of  
vitamin B12, folate, MMA, and holoTC, and for follow-up Hcy concentration (<12.0, ≥12.0 
µmol/L).  
A two-sided p-value of  < 0.05 was considered statistically significant. All statistical analyses 
were performed using SPSS Statistics v20 (SPSS Inc. Chicago, IL, USA). 
Results
Participants
Figure 1 shows the CONSORT participant flow through the study for the total study 
population. In the placebo group, 200 participants (14%) discontinued use of  tablets, 
whereas this number was 222 in the B-vitamin group (15%, n.s.). Dropouts were older (77.1 
years, p < 0.01), had a higher median Hcy level (15.2 µmol/L, p < 0.01), had a lower MMSE 
score (median 27, p < 0.01), and were more likely to be women (16% versus 13% men, p = 
0.01) compared to persons who completed the study. Average compliance to treatment was 
90%, and 84% of  all participants had an overall compliance ≥80%. Compliance was equal 
for both treatment groups. 
Mean age of  the total population was 74.1 ± 6.5 years, 50% were men, and MMSE score was 
28 (IQR 27-29, range 14-30) (Table 1). Baseline characteristics were equal for both treatment 
groups, except for serum holoTC (p = 0.03, data not shown). In the WU subpopulation with 
extensive cognitive tests (n = 856), baseline characteristics were all similar for both treatment 
groups. In this subgroup, mean age was 72.6 ± 5.8 years and 58% were men (Table 1). 
Plasma Hcy levels decreased more in the B-vitamin group compared to placebo (p<0.01) 
(total population). In the B-vitamin group, levels decreased from a median of  13.9 [IQR 
12.9-16.2] to 9.3 [IQR 8.2-11.2] µmol/L (mean change of  -5.0, 95% CI -5.3--4.7), versus 14.4 
[IQR 12.9-16.4] to 13.3 [IQR 11.5-16.0] µmol/L (mean change of  -1.3, 95% CI -1.6--0.9) in 
the placebo group. 
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Figure 1 Screening, randomization and follow-up in the B-PROOF study concerning the cognitive assessment.
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Table 1 Baseline characteristics of  the cognitive subsample per treatment group (n = 856) and the total B-PROOF 
population (n = 2,919)
Cognitive subsample Total population
Placebo (n = 431) B-vitamin (n = 425) n = 2,919
Descriptive measures
Age (yrs)a 72.6 ± 5.8 72.6 ± 5.7 74.1 ± 6.5
Sex, menb 255 (59%) 244 (57%) 1459 (50%)
Education
Low 184 (43%) 184 (43%) 1545 (53%)
Middle 99 (23%) 91 (21%) 615 (21%)
High 148 (34%) 150 (35%) 757 (26%)
Marital status
Living together or married 295 (68%) 296 (70%) 1845 (63%)
Widow 81 (19%) 75 (18%) 712 (24%)
Unmarried or divorced 55 (13%) 54 (13%) 361 (12%)
Smoker behavior
Current smoker 49 (11%) 38 (9%) 281 (10%)
Former smoker 249 (58%) 253 (60%) 1649 (57%)
Never smoked 133 (31%) 134 (32%) 989 (34%)
Alcohol consumers 381 (88%) 385 (91%) 2511 (86%)
BMI (kg/m2) 27.2 ± 3.8 27.2 ± 4.0 27.1 ± 4.0
MMSE scorec 29 [8-30] 29 [27-30] 28 [27-29]
Score <25 21 (5%) 24 (6%) 177 (6%)
GDS score 1 [0-2] 1 [0-2] 1 [0-2]
Score≥5 21 (5%) 26 (6%) 200 (7%)
Total physical activity (kcal/day) 661 ± 483 669 ± 471 650 ± 479
Biochemical measures
Plasma Hcy (µmol/L) 14.4 [12.9-16.4] 14.0 [12.9-16.2] 14.4 [13.0–16.6]
Serum vitamin B12 (pmol/L) 263 [200-345] 257 [200-326] 266 [208-343]
Serum folate (nmol/L) 18.9 [14.2-22.7] 19.2 [14.0-22.6] 18.7 [14.7-24.2]
Serum holoTC (pmol/L) 60 [42-80] 59 [46-78] 64 [46-85]
Serum MMA (µmol/L) 0.23 [0.19–0.31] 0.23 [0.19-0.30] 0.23 [0.18-0.30]
Genetic polymorphism
MTHFR genotyped
677 TT 47 (12%) 57 (15%) 334 (13%)
677 CT/CC 344 (88%) 318 (85%) 2236 (87%)
ApoE-ε4e
TT 301 (73%) 276 (68%) 2023 (73%)
TC  105 (25%) 117 (29%) 692 (25%)
CC  7 (2%) 10 (2%) 60 (2%)
Notes: BMI, Body Mass Index; MMSE, Mini-Mental State Examination; GDS, Geriatric Depression Scale; Hcy, Ho-
mocysteine; holoTC, holotranscobalamin; MMA, Methylmelonic acid; MTHFR, Methylenetrahydrofolate reductase; 
ApoE-ε4, apolipoprotein E-ε4. a Mean ± SD; b n (%); c median [IQR]; d data available for n = 766 in the cognitive 
subsample and n = 2,570 in the total population; e Data available for n = 816 in the cognitive subsample and n = 2,721 
in the total population.
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Cognitive performance
Mean baseline cognitive test scores did not differ between treatment groups 
(Supplementary Table 1). In the intention-to-treat analyses (Table 2), both treatment 
groups improved performance on episodic memory (total population) and executive 
functioning (subpopulation) after two years, but no effect of  B-vitamin treatment was 
observed. More specifically, episodic memory improved with 0.08 (95% CI 0.05-0.12) in 
the placebo group and with 0.11 (95% CI 0.07-0.14) in the B-vitamin group (p = 0.42). 
Performance by the subpopulation on attention and working memory, and information 
processing speed declined over time, but there was no treatment effect. 
Table 3 shows the performance on single cognitive tests at baseline and after two years. 
Performance on the MMSE, measured in the total population, decreased slightly less in the 
B-vitamin group compared to the placebo group (p-value for difference between groups 
= 0.05). None of  the other single cognitive tests at two years were significantly different 
between the treatment groups. Verbal fluency tended to improve more in the B-vitamin 
group (change 2.6, 95% CI 1.8-3.4) compared to the placebo group (change 1.6, 95% CI 0.9-
2.3), but this was not significant (p = 0.10). The per-protocol analyses revealed slightly larger 
differences between groups, but no significant effects were observed (n = 2,284 for episodic 
memory and n ≈ 688 for the other domains) (data not shown). 
Subgroup analyses
The predefined variables that were tested for interaction effects with treatment only revealed 
a significant interaction effect for age on information processing speed. Stratified analyses 
in participants <80 years (n = 686) and ≥80 years (n = 45), however, did not show any 
treatment effect (see Supplementary Table 2 and Table 3). Results of  explorative post-
hoc subgroup analyses did not reveal beneficial effects of  B-vitamin treatment, except that 
participants with a low holoTC concentration in the B-vitamin group improved more (0.13, 
95% CI 0.08-0.18) on their episodic memory performance than the placebo group (0.08, 
95% CI 0.03-0.13, p = 0.04) (Supplementary Table 3).
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Discussion
This large randomized, placebo-controlled trial did not reveal beneficial effects of  two 
years supplementation with folic acid and vitamin B12 on the cognitive domains of  
episodic memory, attention and working memory, information processing speed, and 
executive function in elderly people with elevated Hcy levels. However, decline of  global 
cognitive performance was slightly lower in the B-vitamin group, but the effect would have 
disappeared when correcting for multiple testing. 
Although cross-sectional studies have often demonstrated positive associations between 
folate or vitamin B12 status and cognitive performance, results from RCTs do not 
convincingly support this.2 We add evidence to this with our study, which is one of  the 
largest intervention study in elderly people up till now that investigated the effects of  long-
term B-vitamin supplementation on global cognitive function, episodic memory, attention 
and working memory, information processing speed, and executive functioning. Only 
a few studies have shown beneficial effects of  combined supplementation of  folic acid 
and vitamin B12 on cognitive performance; in elderly people with elevated psychological 
distress on overall cognitive functioning, immediate and delayed recall,16 and in elderly 
people with mild cognitive impairment (MCI).17 Like our study, most other studies that 
were performed in non-demented elderly with a study duration of  at least one year did not 
show significant effects of  B-vitamin supplementation.18-20 One study even showed that 
two-year supplementation with 500 µg vitamin B12 and 1000 µg folic acid resulted in worse 
information processing speed and overall cognitive function compared to the placebo 
group.21 
Table 2 Changes in cognitive domain scores of  elderly people (only participants with baseline and two-year data)
Unadjusted mean ± SD Mean change 
(95% CI)
Model 1 Model 2
Baseline 2 yr p p
Episodic memory (n = 2,467)a
 Placebo 0.04 ± 0.69 0.13 ± 0.75 0.08 (0.05-0.12) 0.27 0.42
 B-vitamins 0.05 ± 0.69 0.16 ± 0.75 0.11 (0.07-0.14)
Attention and working memory (n = 759)
 Placebo 0.02 ± 0.86 -0.04 ± 0.88 -0.06 (-0.12-0.01) 0.38 0.37
 B-vitamins -0.01 ± 0.84 -0.10 ± 0.82 -0.09 (-0.16--0.02)
Information processing speed (n = 731)
 Placebo 0.08 ± 0.75 0.06 ± 0.79 -0.02 (-0.06-0.01) 0.65 0.51
 B-vitamins 0.04 ± 0.75 0.01 ± 0.77 -0.03 (-0.07-0.00)
Executive functioning (n = 720)
 Placebo 0.04 ± 0.54 0.10 ± 0.68 0.06 (-0.00-0.12) 0.20 0.26
 B-vitamins -0.01 ± 0.52 0.13 ± 0.66 0.13 (0.07-0.19)
Notes: Differences between the two groups over time were measured using ANCOVA. Model 1: Adjusted for baseline 
domain scores; Model 2: Adjusted for baseline domain scores, age, sex (a and study center)
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Table 3 Changes in cognitive test scores of  Dutch elderly people (only participants with baseline and two-year data) 
(unadjusted means ± SD)
Baseline 2 yr Change (95% CI) p
Global cognition (n = 2,556)
MMSE, max 30 pointsa
Placebo 28.2 ± 1.8 27.9 ± 2.0 -0.3 (-0.4--0.2) 0.05
B-vitamins 28.1 ± 1.8 28.0 ± 1.9 -0.1 (-0.2--0.0)
Episodic memory (n = 2,485)
RAVLT – Immediate recall, max. 75 words 
Placebo 37.2 ± 10.0 38.5 ± 10.4 1.3 (0.9-1.8) 0.47
B-vitamins 37.4 ± 9.8 38.9 ± 10.1 1.5 (1.0-1.9)
RAVLT – Decayed recall (delayed-WLT trial 5) 
Placebo -2.2 ± 1.9 -1.9 ± 1.9 0.3 (0.2-0.5) 0.44
B-vitamins -2.2 ± 1.9 -1.8 ± 2.0 0.4 (0.2-0.5)
RAVLT – Recognition, max. 30 words
Placebo 28.0 ± 2.2 27.9 ± 2.5 -0.1 (-0.3--0.0) 0.38
B-vitamins 28.0 ± 2.2 27.9 ± 2.5 -0.1 (-0.2-0.1)
Attention and working memory (n = 760)
Digit Span forward, max. 16 points
Placebo 8.1 ± 1.8 8.0 ± 1.8 -0.1 (-0.3-0.0) 0.31
B-vitamins 8.2 ± 1.7 8.0 ± 1.7 -0.2 (-0.4--0.1)
Digit Span backward, max. 14 points
Placebo 6.0 ± 1.8 5.9 ± 1.8 -0.1 (-0.2-0.1) 0.64
B-vitamins 5.9 ± 1.8 5.8 ± 1.7 -0.1 (-0.2-0.1)
Information processing speed (n = 755)
Trail Making Part A, secb
Placebo 43.7 ± 16.2 44.1 ± 17.1 0.4 (-1.0-1.8) 0.54
B-vitamins 44.3 ± 16.4 45.1 ± 16.3 0.8 (-0.6-2.1)
Stroop 1 and 2 mean, secb
Placebo 58.5 ± 11.7 59.3 ± 11.6 0.8 (0.1-1.6) 0.48
B-vitamins 58.6 ± 11.2 59.0 ± 11.2 0.4 (-0.4-1.3)
Symbol Digit Modalities Test, correct number
Placebo 47.0 ± 9.5 46.4 ± 9.9 -0.6 (-1.2--0.1) 0.97
B-vitamins 46.4 ± 8.8 45.9 ± 9.6 -0.5 (-1.1-0.1)
Executive functioning (n = 754)
Trail Making Test (Part B/Part A)b
Placebo 2.4 ± 0.8 2.4 ± 0.8 -0.0 (-0.1-0.1) 0.41
B-vitamins 2.4 ± 0.8 2.3 ± 0.7 -0.0 (-0.1-0.0)
Stroop Interference (Part 3 – (Part 1 + Part 2/2))b
Placebo 57.9 ± 30.2 59.6 ± 34.1 1.6 (-0.6-3.7) 0.31
B-vitamins 57.4 ± 31.2 57.4 ± 31.7 0.0 (-2.5-2.5)
Verbal Fluency, total number
Placebo 37.2 ± 11.9 38.8 ± 12.2 1.6 (0.9-2.3) 0.10
B-vitamins 36.2 ± 10.5 38.8 ± 11.4 2.6 (1.8-3.4)
Notes: MMSE, Mini-Mental State Examination; RAVLT, Rey Auditory Verbal Learning Test. Difference between groups 
over time were measured using ANCOVA, adjusted for baseline values. a Difference in change between groups was 
measured with independent-samples t-test; b Higher score indicates that more time was needed to complete the task, 
reflecting a poorer performance. 
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We showed a small beneficial effect of  B-vitamin supplementation on global cognitive 
performance, as measured with the MMSE. In a different study with MCI patients, and only 
in participants with elevated Hcy levels, a beneficial effect of  moderate doses of  vitamin 
B12 and folic acid supplementation on the MMSE was observed (placebo group decreased 
with 1.2 point, B-vitamin group with 0.3 point).17 Although the MMSE is a widely used 
and validated cognitive screening tool, it has limitations because of  ceiling effects and its 
sensitivity to pick up subtle changes has been questioned,22 especially in well-educated 
populations like ours. Our significant finding was therefore somewhat unexpected and the 
results may be due to the large study population. The difference between treatment groups 
in our study was only 0.2 on a maximum score of  30 and this difference is far from clinical 
relevance. Furthermore, based on the number of  statistical tests we performed, it should also 
be taken into account that our finding might be a chance finding. Adjustments for multiple 
testing would have resulted in non-significant results.
Because effects of  supplementation may be more pronounced in people with higher baseline 
Hcy levels 17, 23 and low dietary folate and vitamin B12 intake,18 we analyzed predefined 
interaction terms. These analyses did not reveal significant results for sex, age, plasma 
Hcy, and ApoE-ε4 genotype. Post-hoc analyses, however, showed that participants with 
low HoloTC levels, the active form of  vitamin B12, had more benefits of  the B-vitamin 
supplementation on the domain of  information processing speed. 
In addition to our large sample size as strength of  our study, is the use of  validated 
neuropsychological tests, which enabled us to study the effects of  B-vitamins on a broad 
spectrum of  cognitive functions that decline with aging.24 By combining tests measuring 
the same cognitive concept, we were able to create sensitive and reliable domain compound 
scores and to decrease the risk of  chance findings or ceiling performances. Furthermore, 
compliance to the treatment was high, as was also reflected by the decreased plasma 
Hcy levels in the B-vitamin group compared to a much smaller decrease in the placebo 
group. Additionally, the duration of  two years is adequate in order to induce a change in 
cognitive performance; according to the IANA taskforce a minimum of  18 months would 
be required.25 Nevertheless, even though our study population was hypothesized to be at 
a higher risk for cognitive decline due to the elevated Hcy levels and therefore would be 
expected to be even more sensitive for changes, it is possible that the decreased plasma Hcy 
levels may not have revealed their possible beneficial effects yet at time of  the measurements. 
A limitation of  the study design was the lack of  intermediate measurements, which 
made intention-to-treat analyses in participants who did not come to their two-year visit 
not possible. Another relevant point is that both treatment groups received vitamin D3. 
High serum 25-OH-vitamin D concentrations have been associated with better cognitive 
performance.26 RCTs investigating the effects of  vitamin D supplementation in elderly 
people, however, are scarce. Although vitamin D supplementation is recommended for 
elderly people in the Netherlands, still 44% of  our total population was vitamin D deficient 
at baseline (< 50 nmol/L).27 Possibly, supplementation of  vitamin D may have diluted 
potential effects of  vitamin B12 and folic acid on cognitive performance, although these 
nutrients may have different mechanisms that account for a possible effect.
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Recently, concerns have been put forward on folic acid supplementation and increased risk 
of  cancer. Post-hoc analyses of  adverse events in the B-PROOF population showed that 
participants in the B-vitamin group reported cancer more often than those in the placebo 
group.28 Nevertheless, a recent meta-analysis did not observe a significant negative effect 
based on thirteen studies.29 Our dose of  folic acid was well below the upper tolerable limit 
that is used in the Netherlands (1 mg/day).30 Although our finding could be attributed to 
chance, we should interpret it with care and it makes daily supplementation with folic acid in 
the given dose questionable. 
Based on the current results and results from previous RCTs, we conclude that 
supplementation with folic acid and vitamin B12 in healthy elderly people did not beneficially 
affect cognitive performance on four cognitive domains in elderly people with elevated 
Hcy levels. We cannot extrapolate this to persons who already have cognitive impairments. 
Furthermore, cross-sectional and prospective magnetic resonance imaging (MRI) studies 
31, 32 as well as one RCT in MCI patients,33 observed beneficial effects of  these vitamins on 
brain atrophy. To unravel the effects on B-vitamins, a closer look into early brain pathologies 
would be useful to uncover subtle effects that are difficult to pick up with paper-pencil tests. 
Within the B-PROOF study we have anticipated on these innovative developments and 
results with respect to MRI are awaited. 
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Supplementary material
Appendix 1
Cognitive performance tests
The Rey Auditory Verbal Learning Test (RAVLT) was used to measure direct recall, delayed 
recall and recognition for word lists, as indices of  immediate and delayed episodic memory. 
The Digit Span forward and backward from the Wechsler Adult Intelligence Test (WAIS-
III) measures attention and working memory, respectively. Trail Making Test (TMT) part A 
measures information processing speed and part B assesses concept shifting interference. 
Stroop Color-Word Test determines selective attention and susceptibility to behavioral 
interference. The Symbol Digit Modalities Test (SDMT) measures information processing 
speed. Letter Fluency (three letters) measures language. The following domains in formula 
form were formed: 
Episodic memory = (ZRAVLT total immediate recall + ZRAVLT decayed recall + ZRAVLT recognition)/3 
Attention and working memory = (ZDigit Span forward + ZDigit Span backward)/2 
Information processing speed = (-ZStroop mean I and II + -ZTrail making test part A + ZSymbol Digit Modalities 
Test)/3 
Executive functioning = (-ZStroop interference + -ZTrail making ratio + ZVerbal Fluency)/3.
Blood parameters
Plasma Hcy was measured using the Architect i2000 RS analyzer (VUmc), HPLC method 
(WU), and LCMS/ MS (EMC). Cross-calibration showed that outcomes of  the three centers 
did not differ significantly. Serum creatinine was measured using the enzymatic colorimetric 
Roche CREA plus assay (CV=2%). Serum vitamin B12 and serum folate were analyzed 
using immunoelectrochemiluminescence assay (Elecsys, 2010, Roche GmbH, Mannheim, 
Germany) (CV vitamin B12 5.1% at 125 pmol/L and 2.9% at 753 pmol/L; CV folate: 5.9% at 
5.7 nmol/L and 2.8% at 23.4 nmol/L). Serum holotranscobalamin (holoTC) was determined 
by the Abbott AxSYM analyser (Abbott Diagnostics, Hoofddorp, The Netherlands) (CV 
<8% at 20, 40 and 80 pmol/L). Serum methylmelonic acid (MMA) was determined using 
LC-MS/MS (CV = 6.7%, 5.0% and 5.0% at 0.15, 0.36 and 0.65 µmol/L, respectively). 
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Supplementary Table 1 Cognitive performance on baseline per treatment group in a Dutch elderly population 
(mean ± SD)
Placebo group B-vitamin group
Episodic memory n = 1410a n = 1407a
RAVLT – Immediate recall, max. 75 words 36.5 ± 10.1 36.7 ± 10.0
RAVLT – Delayed recall, max. 15 words 7.0 ± 3.0 7.1 ± 3.1
RAVLT – Decayed recall (delayed-RAVLT- trial 5) -2.2 ± 1.9 -2.2 ± 1.9
RAVLT – Recognition, max. 30 words 27.8 ± 2.3 27.8 ± 2.4
Attention and working memory n = 426a n = 418a
Digit Span forward, max. 16 points 8.1 ± 1.8 8.2 ± 1.7
Digit Span backward, max. 14 points 6.0 ± 1.8 5.8 ± 1.8
Information processing speed n = 422a n = 415a
Trail Making Test Part A (s)b 44.1 ± 16.4 45.1 ± 17.0
Stroop 1 (s)b 51.8 ± 11.3 51.7 ± 10.7
Stroop 1, # corrections 0.1 ± 0.4 0.1 ± 0.3
Stroop 2 (s)b 65.6 ± 14.2 66.5 ± 15.1
Stroop 2, # corrections 0.4 ± 0.8 0.4 ± 0.8
Symbol Digit Modalities Test, correct number 46.7 ± 9.6 45.7 ± 9.3
Symbol Digit Modalities Test, incorrect number 1.3 ± 1.5 1.4 ± 1.7
Executive functioning n = 421a n = 414a
Trail Making Test Part B (s)b 103.6 ± 48.0 104.7 ± 47.6
Trail Making Test ratio (Part B/Part A)b 2.4 ± 0.8 2.4 ± 0.8
Stroop 3 (s)b 117.3 ± 36.6 117.4 ± 35.9
Stroop 3, number of  corrections 1.1 ± 1.8 1.0 ± 1.8
Stroop Interference (Part 3 – (Part 1 + Part 2/2))b 58.6 ± 30.6 58.3 ± 31.6
Verbal Fluency, total words 37.2 ± 11.7 35.9 ± 10.6
Notes: Abbreviations: RAVLT, Rey Auditory Verbal Learning Test. a Number of  participants may deviate a little between 
tests for all these values. b Higher scores indicate poorer performance.
Supplementary Table 2 Interaction p-values between treatment and predefined and post-hoc terms (intention-
to-treat) 
Episodic 
memory
Working 
memory
Information 
processing 
speed
Executive 
function
Predefined terms
Age, <80 years≥ 0.27 0.11 0.07 0.46
Gender, men/women 0.59 0.17 0.67 0.25
Homocysteine, <14.4 µmol/L≥ 0.44 0.75 0.31 0.99
APOE-e4, TT / CT&CC 0.58 0.53 0.31 0.52
Post-hoc terms
MTHFR genotype, CC&CT / TT 0.74 0.09 0.17 0.47
Serum vitamin B12, <266.4 pmol/L ≥ 0.42 0.68 0.11 0.59
Serum folic acid, <18.73 nmol/L ≥ 0.40 0.75 0.05 0.61
Serum holotranscobalamin, <64 µmol/L ≥ 0.09 0.84 0.08 0.86
Serum methylmalonic acid, <0.23 pmol/L ≥ 0.90 0.06 0.57 0.68
Notes: ApoE-ε4, apolipoprotein E-ε4; MTHFR, Methylenetrahydrofolate reductase
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Supplementary Table 3 Stratified analyses for those interaction terms that were significant (p<0.10) in the 
intention-to-treat analyses 
Adjusted means ± SE 
at 2-year
Change over 2 years 
(95%CI)
p
Episodic memory
HoloTC, <64 pmol/L (n = 1,212)
Placebo 0.09 ± 0.02 0.08 (0.03-0.13) 0.04
B-vitamins 0.16 ± 0.02 0.13 (0.08-0.18)
HoloTC, ≥64 pmol/L (n = 1,255)
Placebo 0.17 ± 0.02 0.09 (0.04-0.14) 0.70
B-vitamins 0.16 ± 0.02 0.08 (0.03-0.14)
Working memory
MTHFR genotype, CC/CT (n = 601)
Placebo -0.04 ± 0.04 -0.05 (-0.12-0.02) 0.22
B-vitamins -0.10 ± 0.04 -0.10 (-0.18--0.02)
MTHFR genotype, TT (n = 88)
Placebo -0.08 ± 0.08 -0.14 (-0.35--0.00) 0.13
B-vitamins 0.10 ± 0.08 0.03(-0.13-0.18)
MMA, <0.23 µmol/L (n = 367)
Placebo -0.11 ± 0.04 -0.10 (-0.19--0.01) 0.45
B-vitamins -0.06 ± 0.04 -0.06 (-0.15-0.04)
MMA, ≥0.23 µmol/L (n = 392)
Placebo 0.01 ± 0.04 -0.01(-0.10-0.07) 0.06
B-vitamins -0.11 ± 0.05 -0.12 (-0.22--0.01)
Information processing speed
Age, <80 yrs (n = 686)
Placebo 0.09 ± 0.02 -0.01 (-0.05-0.02) 0.30
B-vitamins 0.06 ± 0.02 -0.03(-0.07-0.00)
Age, ≥80 yrs (n = 45)
Placebo -0.74 ± 0.08 -0.20(-0.38--0.02) 0.23
B-vitamins -0.58 ± 0.10 -0.03(-0.29-0.22)
Folic acid, <18.73 nmol/L (n = 419)
Placebo -0.01 ± 0.02 -0.01(-0.06-0.03) 0.11
B-vitamins -0.07 ± 0.02 -0.06 (-0.11--0.02)
Folic acid 18.73≥ nmol/L (n = 312)
Placebo 0.10 ± 0.03 -0.04 (-0.10-0.01) 0.26
B-vitamins 0.15 ± 0.03 0.01 (-0.05-0.06)
HoloTC, <64 pmol/L (n = 409)
Placebo -0.03 ± 0.03 -0.05 (-0.10-0.00) 0.43
B-vitamins -0.01 ± 0.03 -0.02 (-0.07-0.04)
HoloTC, ≥64 pmol/L (n = 322)
Placebo 0.13 ± 0.03 0.01 (-0.05-0.06) 0.08
B-vitamins 0.04 ± 0.03 -0.05 (-0.10-0.00)
Notes: Differences between the two groups over time were measured using ANCOVA, adjusted for baseline perfor-
mance. HoloTC, holotranscobalamin; MTHFR, Methylenetrahydrofolate reductase; MMA, methylmalonic acid.
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Abstract
Objective: We investigated the cross-sectional associations between circulating 
homocysteine (Hcy), folate and biomarkers of  vitamin B12 status with brain volumes, and 
we compared brain volumes of  participants who received daily folic acid and vitamin B12 
supplementation for two years with participants who did not.
Methods: Participants of  the B-PROOF study (n = 2,919) were assigned to 400 µg folic 
acid and 500 µg vitamin B12, or a placebo. After two years of  intervention, T1-weighted MRI 
scans were made in a random subsample (n = 218) to obtain volumes of  grey and white 
matter, and a sum score of  total brain volume (TBV). Follow-up plasma Hcy, serum folate, 
vitamin B12, holotranscobalamin, and methylmalonic acid concentrations were measured. 
ANCOVA was used to determine group differences. Multiple linear regression analyses were 
used to assess the associations between these blood biomarkers and brain volumes. 
Results: Mean age differed significantly between the group with B-vitamin supplementation 
(mean ± SD 72.7 ± 5.3 years) and without supplementation (mean ± SD 74.5 ± 6.3 years, 
p = 0.02). In the fully adjusted ANCOVA model, the group that received B-vitamins had a 
lower TBV (mean ± SE 1064 ± 3 mL) than the non-supplemented group (mean ± SE 1072 
± 3 mL, p = 0.03). Cross-sectionally, inverse associations between plasma Hcy with TBV 
(β ± SE of  -0.89 ± 0.48, p = 0.06) and between serum folate and TBV (β ± SE of  -0.20 ± 
0.09, p = 0.03) were observed. No significant associations were observed for serum vitamin 
B12 and holotranscobalamin.
Conclusions: Results were contradictory, with both higher Hcy and folate levels associated 
with lower TBV. Furthermore, participants who had received B-vitamin supplementation had 
a slightly lower TBV, which might be explained by the age difference between groups.
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Introduction
Elevated homocysteine (Hcy) levels have been associated with faster cognitive decline, 
cognitive impairment, and dementia 1 by being neurotoxic or via other, probably vascular, 
pathways.2 Remethylation of  Hcy into methionine is dependent of  vitamin B12 and folate. 
Observational studies have shown associations between vitamin B12 and folate with 
cognitive performance, but the majority of  intervention studies does not show an effect of  
supplementation with vitamin B12 and folic acid, despite a lowering effect on Hcy.3 
Another method to investigate the role of  Hcy, vitamin B12 and folate in brain health, is by 
studying brain volumes. Cross-sectional studies have shown associations of  Hcy levels with 
ventricle-brain ratios 2 and white-matter lesions as an index of  the integrity of  white matter.11 
Additionally, inverse associations were observed between vitamin B12 status and white-matter 
lesions.11, 12 Positive associations were observed between vitamin B12 status and total brain 
volume, cross-sectionally 2, 4 and prospectively.5 Higher folate levels have been associated with 
less white matter lesions, but not with more hippocampal or amygdalar volume.6 
We investigated the associations of  levels of  plasma Hcy, serum folate and three markers 
related to vitamin B12 status (serum B12, MMA, and holoTC) with volumes of  grey and white 
matter, and total brain volume as a derivative, measured by magnetic resonance imaging 
(MRI) scans in the B-PROOF study. We also studied the difference between participants who 
received a daily supplement with folic acid and vitamin B12 for two years and those who did 
not receive this. 
Methods
Study design and Participants
This study was part of  the B-PROOF (B-vitamins for the PRevention Of  Osteoporotic 
Fractures) study that was conducted between October 2008 and April 2013 in three research 
centers in the Netherlands; VU medical center, Erasmus Medical Center, and Wageningen 
University. Primary objective of  this randomized, double-blind, placebo-controlled 
intervention study was to assess the efficacy of  two years oral supplementation with 400 
µg folic acid and 500 µg vitamin B12 in the prevention of  osteoporotic fractures. Both the 
placebo tablet and the B-vitamin tablet contained 15 µg (600 IU) vitamin D. Participants 
were people aged ≥65 years with mildly elevated plasma Hcy levels (12-50 µmol/L). 
Participant selection has been extensively described elsewhere.7 MRI scans were made in a 
random subsample of  the population of  Wageningen University. Participants who came for 
their two-year follow-up measurement between July 2012 and April 2013 and who had not 
dropped out during the intervention period were invited to participate in the MRI study (see 
Figure 1 for the participant flow). MRI scans were made within one month after completion 
of  the intervention period, before unblinding the treatment allocation. Participants were 
carefully screened on contra-indications for MRI scans. The Wageningen University Medical 
Ethical Committee approved the study and all participants gave their written informed 
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consent. This trial is registered at clinicaltrials.gov as NCT00696514 and at Netherlands Trial 
Register as NTR1333.
Figure 1 Flowchart of  participants that were enrolled in the MRI study, a sub-study of  the B-PROOF trial
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Descriptive measures
Global cognitive performance was measured with the Mini-Mental State Examination 
(MMSE).8 Depressive symptoms were assessed with the 15-item Geriatric Depression Scale 
(GDS-15),9 in which a score ≥5 is indicated as being likely to be depressed. Standing height 
was measured with a stadiometer to the nearest 0.1 cm and weight was measured to the 
nearest 0.5 kg with a calibrated scale (Seca, Deventer, the Netherlands). Body mass index 
(BMI) was calculated by dividing the weight by the squared height (kg/m2). Information 
about highest educational level, smoking habits, alcohol intake (Garrett index),10 marital 
status, and living situation was obtained by structured questionnaires. Physical activity 
was measured with the LASA Physical Activity Questionnaire (LAPAQ).11 Self-reported 
frequency and duration of  activities during the past two weeks were checked by a research 
assistant and were used to calculate physical activity in kcal/day. 
MRI scans
Cranial volumetric MRI scans were made after 2 years of  intervention at the Hospital 
Gelderse Vallei (Ede, the Netherlands) on a 3-Tesla Siemens Magnetom Verio (Siemens, 
Erlangen, Germany), with a 32-channel head coil. Here, we analyzed the T1-weighted scan 
(MPRAGE, repetition time = 2300 ms, echo time = 3.0 ms, inversion time = 900 ms, 9º flip 
angle, field of  view = 256x256mm, 192 sagittal slices, voxel size = 1 x 1 x 1mm, acceleration 
factor (GRAPPA) = 2).   
The voxel-based morphometry (VBM8) toolbox within the SPM8 software (Wellcome 
Department of  Imaging Neuroscience, London, UK, http://www.fil.ion.ucl.ac.uk/spm/
software/spm8/) and FSL-VBM v6.0 (FMRIB Software Library, Oxford, UK, http://fsl.
fmrib.ox.ac.uk/fsl/fslwiki/FSLVBM) 12 were used for segmentation. T1-weighted images 
were first reoriented to match the standard template images in FSL-VBM. VBM8 spatially 
normalizes participants’ brain images to a standard space, and then automated segments 
into grey matter, white matter, and cerebrospinal fluid, using a unified tissue segmentation 
approach.13 These three measures were summed to calculate intracranial volume. Grey and 
white matter volumes were summed to calculate total brain volume. 
Blood measurements
Blood samples were obtained in the morning, when participants were fasted or had 
consumed a restricted breakfast. For the current study, follow-up levels of  serum folate and 
vitamin B12 biomarkers were used. Plasma Hcy was measured using the HPLC method (intra 
assay CV = 3.1%, inter assay CV = 5.9%). Serum vitamin B12 and serum folate were analyzed 
by using electrochemiluminescence immunoassay (Elecsys, 2010, Roche GmbH, Mannheim, 
Germany) (CV vitamin B12 5.1% at 125 pmol/l and 2.9% at 753 pmol/l; CV folate: 5.9% at 
5.7 nmol/l and 2.8% at 23.4 nmol/l). Serum holoTC was determined by the AxSYM analyser 
(Abbott Diagnostics, Hoofddorp, The Netherlands) (intra assay CV<8%) and serum MMA 
was measured by LC-MS/MS (intra assay CV = 8.1% at 0.18 μmol/L, inter assay CV = 
1.6% at 0.24 μmol/L). DNA was isolated from buffy coats to determine the genotype for 
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methylenetetrahydrofolate reductase (MTHFR 677TT) using the Illumina Omni-express 
array and to determine Apolipoprotein E (ApoE) genotype by using Taqman. All analyses 
were done in the biochemical laboratory of  Erasmus MC, except Hcy, which was measured 
at Wageningen University.
Statistics
Population characteristics are reported as n (%), means ± SD, or as median [interquartile 
range (IQR)] for non-normally distributed data. Comparisons between treatment groups 
were made using Chi-square test, independent-samples t-test or Mann-Whitney non-
parametric test. Differences between treatment groups were analyzed using analyses of  
covariance (ANCOVA), in which the brain volumes acted as dependent factor, treatment as 
fixed between-subject factor, and intracranial volume, age and sex as covariates (model 1). 
Model 2 included the covariates from model 1 plus BMI, smoking, alcohol, education, and 
physical activity.
Linear regression analyses were used to examine the associations between serum folate, 
different markers of  vitamin B12 status (serum B12, holoTC, MMA), and plasma Hcy, with 
volumes of  grey and white matter and total brain volume. The crude model was adjusted for 
intracranial volume, in model 1 additional adjustments were made for age and sex, and model 
2 included the covariates of  model 1 plus BMI, smoking, alcohol, education, and physical 
activity. Because we expected different regression slopes for the two treatment groups, we 
tested for interaction and stratified the regression analyses for treatment. 
Results are presented as adjusted means ± SE for the ANCOVA analyses, and as 
β-coefficients±SE for the regression analyses. Alpha was set at 0.05 and two-tailed analyses 
were performed. All statistical analyses were performed using SPSS Statistics v22 (SPSS Inc. 
Chicago, IL, USA). 
Results
Participants
The general characteristics of  the total subgroup at time of  the MRI measurement are 
presented in Table 1. The group that received two years of  B-vitamin supplementation 
(n = 106) and the group that did not receive B-vitamins (n = 112) contained both 57% 
men. Participants in the B-vitamin group were significantly younger and had a slightly 
higher MMSE score (age: 72.7 ± 5.3; median MMSE 29, IQR 27-30, range 19-30) than 
the non-supplemented group (age: 74.5 ± 6.3, p = 0.02; median MMSE 28, IQR 27-29, 
range 24-30, p = 0.09). Follow-up concentrations of  folate, vitamin B12 and holoTC were 
higher in the group that received B-vitamin supplementation than in the group that did not, 
whereas MMA and Hcy were lower (all p-values < 0.001), as a consequence of  the two-year 
supplementation.
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Table 1 Population characteristics at time of  MRI measurements in participants who received two years of  B-
vitamin supplementation and participants who did not receive this supplementation.
Variable Total population 
(n = 218)
With B-vitamin 
supplementation 
(n = 106)
Without B-vitamin 
supplementation 
(n = 112)
p
Age (yrs)a 73.6 ± 5.9 72.7 ± 5.3 74.5 ± 6.3 0.02
Sex, menb 124 (57%) 60 (57%) 64 (57%) 0.94
Body mass index (kg/m2) 27.7 ± 4.2 27.3 ± 4.4 28.1 ± 4.1 0.21
Education 0.12
Low 90 (41%) 49 (46%) 41 (37%)
Medium 52 (24%) 19 (18%) 33 (30%)
High 76 (35%) 38 (36%) 39 (34%)
Smoking 0.67
Never 64 (29%) 27 (26%) 37 (33%)
Former 139 (64%) 70 (66%) 69 (62%)
Current 15 (7%) 9 (9%) 6 (5%)
Alcohol 0.72
Light 152 (70%) 73 (69%)/ 79 (71%)
Moderate 60 (28%) 31 (29%)/ 29 (26%)
Excessive 6 (3%) 2 (2%) 4 (3%)
MMSE, max 30 pointsc 28 [27-29] 29 [27-30] 28 [27-29] 0.09
Low MMSE <25 6 (3%) 4 (4%) 2 (2%) 0.37
GDS, max 15 points 1 [0-2] 1 [0-2] 1[0-2] 0.89
Physical activity (kcal/day) 664 ± 416 642 ± 288 683 ± 440 0.47
ApoE-ε4, carrier 60 (28%) 32 (30%) 28 (25%) 0.45
MTHFR,  677TT 28 (13%) 17 (15%) 11 (10%) 0.40
Grey matter (mL) 574 ± 56 577 ± 57 572 ± 55 0.51
Grey matter / ICV 0.42 ± 0.02 0.42 ± 0.02 0.42 ± 0.02 0.98
White matter (mL) 493 ± 61 495 ± 63 492 ± 60 0.73
White matter / ICV 0.36 ± 0.02 0.36 ± 0.02 0.36 ± 0.02 0.74
Cerebrospinal fluid (mL) 304 ± 52 306 ± 51 302 ± 53 0.62
Cerebrospinal fluid / ICV 0.22 ± 0.03 0.22 ± 0.03 0.22 ± 0.03 0.81
Serum folate (nmol/L) 36.7 [23.4-54.2] 53.1 [42.5-68.3] 24.1 [19.5-31.8] <0.001
Serum vitamine B12 
(pmol/L) 
404 [262-558] 558 [459-715] 274 [222-373] <0.001
Vitamin B12<258 pmol/L 49 (23%) 1 (1%) 48 (43%) <0.001
Serum HoloTC (pmol/L) 81 [56-111] 111 [89-147]d 63 [44-80] <0.001
HoloTC <30 pmol/L 12 (6%) 1 (1%) 11 (10%) 0.01
Serum MMA (µmol/L) 0.20 [0.16-0.25] 0.17 [0.15-0.21] 0.24 [0.19-0.30] <0.001
MMA >0.30 µmol/L 35 (16%) 5 (5%) 30 (27%) <0.001
Plasma Hcy (µmol/L) 11.4 (8.9-14.4) 9.1 (7.8-10.6)e 13.9 (12.0-16.3)f <0.001
Notes: MMSE, Mini-Mental State Examination; GDS, Geriatric Depression Scale; ApoE-ε4, Apolipoprotein E-ε4 ; 
MTHFR, methylenetetrahydrofolate reductase; ICV, intracranial volume; HoloTC, holotranscobalamin; MMA, Meth-
ylmalonic acid; Hcy, homocysteine. a Mean ± SD (all such values); b n (%) (all such values); c median [IQR] (all such 
values); d n = 96; e n = 103; f  n = 109. 
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Differences between supplementation groups
Table 2 presents the differences in brain volumes between the group that received B-vitamin 
supplementation and the group that did not. Unadjusted analyses did not show a difference 
between groups. The fully adjusted model, however, revealed a lower total brain volume in 
the B-vitamin group (1063.6 ± 2.7 mL) compared to the non-supplemented group (1072.3 
± 2.6 mL, p = 0.03). This was also reflected by a non-significant (p = 0.07) lower volume of  
white matter in the B-vitamin group (490.2 ± 2.6 mL) compared to the non-supplemented 
group (496.7 ± 2.5 mL). Grey matter volume did not differ between groups. 
Table 2 Differences in brain volumes (mL) between participants who received two-year B-vitamin supplementation 
(n = 106) and participants who did not receive this supplementation (n = 112)
Grey matter volume White matter volume Total brain volume
Adjusted 
means ± SE
p Adjusted 
means ± SE
p Adjusted 
means ± SE
p
Crude model 0.78 0.67 0.93
Without B-vitamin 
supplementation
573.6 ± 2.9 493.8 ± 2.6 1067.4 ± 3.5
With B-vitamin 
supplementation
574.7 ± 3.0 492.2 ± 2.7 1066.9 ± 3.6
Model 1 0.40 0.13 0.03
Without B-vitamin 
supplementation 
575.7 ± 2.6 495.6 ± 2.4 1071.3 ± 2.6
With B-vitamin 
supplementation
572.5 ± 2.7 490.3 ± 2.5 1062.8 ± 2.7
Model 2 0.57 0.07 0.03
Without B-vitamin 
supplementationa
575.6 ± 2.8 496.7 ± 2.5 1072.3 ± 2.6
With B-vitamin 
supplementationa
573.4 ± 2.8 490.2 ± 2.6 1063.6 ± 2.7
Notes: Differences between groups were tested with ANCOVA, adjusted for intracranial volume (crude model), age, sex 
(model 1), BMI, alcohol, smoking, education, and physical activity (model 2). a n = 111 for the group without B-vitamin 
supplementation; b n = 103 for the group with B-vitamin supplementation.
B-vitamin status and brain MRI volumes
Fully adjusted linear regression models of  follow-up biomarkers and brain volumes in the 
total population (Table 3) showed an inverse association for serum folate with total brain 
volume (β ± SE = -0.20 ± 0.09, p = 0.03), and a borderline significant association with white 
matter volume (β ± SE = -0.17 ± 0.09, p = 0.06). Furthermore, plasma Hcy was borderline 
significantly inversely associated with total brain volume (β ± SE = -0.89 ± 0.48, p = 0.06). 
No significant associations were observed for serum B12, holoTC, or MMA with any of  the 
brain volumes in the fully adjusted models.
Associations differed between the group that received B-vitamin supplementation and 
the group that did not (Table 4), more specifically, interaction terms with treatment were 
significant or tended towards significance for MMA and grey matter (p = 0.04), MMA and 
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total brain volume (p = 0.10), and Hcy and total brain volume (p = 0.10). In both groups, 
serum MMA was inversely associated with total brain volume, but only in the B-vitamin 
group it remained significant after adjustment for covariates (B-vitamin group: β ± SE -126.8 
± 53.1, p = 0.02; group without B-vitamins: β ± SE -27.2 ± 15.4, p = 0.08). Only in the 
B-vitamin group, MMA was also associated with grey matter volume (β ± SE -136.2 ± 53.1, 
p = 0.01). Inverse associations were observed for Hcy and total brain volume in both groups, 
with stronger associations in the supplemented group (β ± SE -4.24 ± 1.31, p < 0.01) than 
in the non-supplemented group (β ± SE -1.78 ± 0.65, p = 0.01). In the B-vitamin group, a 
trend was observed for Hcy and grey matter volume (β ± SE -2.53 ± 1.40, p = 0.07), but not 
for white matter volume. In the non-supplemented group, a trend was observed for Hcy and 
white matter volume (β ± SE -1.00 ± 0.59, p = 0.09), but not for grey matter volume.
Table 3 Associations between follow-up blood values and brain MRI measures (n = 218) 
Models Grey matter volume White matter volume Total brain volume
β-coefficients 
± SE
p β-coefficients 
± SE
p β-coefficients 
± SE
p
Serum folate (nmol/L)
Crude 0.04 ± 0.10 0.71 -0.09 ± 0.09 0.31 -0.06 ± 0.12 0.64
Model 1 -0.05 ± 0.09 0.61 -0.14 ± 0.08 0.09 -0.19 ± 0.09 0.04
Model 2a -0.03 ± 0.09 0.71 -0.17 ± 0.09 0.06 -0.20 ± 0.09 0.03
Serum vitamin B12 (pmol/L)
Crude 0.00 ± 0.01 0.76 0.01 ± 0.01 0.28 0.01 ± 0.01 0.29
Model 1 -0.01 ± 0.01 0.41 0.00 ± 0.01 0.80 -0.01 ± 0.01 0.56
Model 2a -0.01 ± 0.01 0.42 -0.00 ± 0.01 0.95 -0.01 ± 0.01 0.39
Serum holotranscobalamin (pmol/L)
Crudeb  0.07 ± 0.05 0.17 0.07 ± 0.04 0.10 0.14 ± 0.06 0.02
Model 1b -0.00 ± 0.04 0.97 0.02 ± 0.04 0.66 0.02 ± 0.05 0.71
Model 2c  0.01 ± 0.04 0.90 0.01 ± 0.04 0.81 0.02 ± 0.05 0.73
Serum methylmalonic acid (µmol/L)
Crude -27.2 ± 14.5 0.06 -18.0 ± 13.3 0.18 -45.2 ± 17.4 0.01
Model 1 -13.2 ± 13.2 0.32 -7.7 ± 12.4 0.54 -20.9 ± 13.5 0.12
Model 2a -14.5 ± 13.2 0.27 -7.2 ± 12.7 0.58 -21.7 ± 13.4 0.11
Plasma homocysteine (µmol/L)
Cruded -1.36 ± 0.48 <0.01 -1.19 ± 0.44 <0.01 -2.55 ± 0.57 <0.001
Model 1 -0.33 ± 0.47 0.49 -0.36 ± 0.44 0.42 -0.69 ± 0.48 0.15
Model 2e -0.53 ± 0.48 0.26 -0.36 ± 0.45 0.43 -0.89 ± 0.48 0.06
Notes: Crude: Adjusted for intracranial volume; Model 1: Adjusted for intracranial volume, age, sex; Model 2: Adjusted 
for model 1 and BMI, alcohol, smoking, education, physical activity. a n = 214; b n = 208; c n = 205;  d n = 212; e n = 208.
Table 4 Stratified analyses follow-up blood values and MRI brain volumes for the group with (n = 106) and without a history of B-vitamin 
supplementation (n = 112) 
Models Grey matter volume White matter volume Total brain volume
β ± SE p β ± SE p β ± SE p
Without B-vitamin supplementation (n = 112)
Serum folate (nmol/L)
Crude 0.16 ± 0.26 0.53 -0.20 ± 0.23 0.37 -0.04 ± 0.31 0.90
Model 1 0.29 ± 0.23 0.22 -0.08 ± 0.21 0.71 0.20 ± 0.24 0.39
Model 2a 0.19 ± 0.23 0.43 -0.06 ± 0.22 0.79 0.13 ± 0.24 0.60
Serum vitamin B12 (pmol/L)
Crude 0.04 ± 0.03 0.13 0.04 ± 0.02 0.11 0.08 ± 0.03 0.02
Model 1 0.02 ± 0.02 0.47 0.02 ± 0.02 0.26 0.04 ± 0.02 0.08
Model 2a 0.01 ± 0.02 0.75 0.02 ± 0.02 0.31 0.03 ± 0.02 0.22
Serum holotranscobalamin (pmol/L)
Crude 0.08 ± 0.12 0.52 0.19 ± 0.10 0.07 0.26 ± 0.14 0.07
Model 1 0.00 ± 0.11 0.98 0.15 ± 0.10 0.11 0.16 ± 0.11 0.15
Model 2a -0.04 ± 0.11 0.74 0.16 ± 0.10 0.12 0.12 ± 0.11 0.28
Serum methylmalonic acid (µmol/L)
Crude -16.9 ± 16.8 0.32 -23.4 ± 14.5 0.11 -40.3 ± 19.9 0.05
Model 1 -8.9 ± 15.0 0.55 -19.9 ± 13.5 0.14 -28.9 ± 15.0 0.06
Model 2a -10.5 ± 15.1 0.49 -16.7 ± 13.9 0.23 -27.2 ± 15.4 0.08
Plasma homocysteine (µmol/L)
Crude -1.70 ± 0.69 0.02 -1.77 ± 0.58 <0.01 -3.47 ± 0.77 <0.001
Model 1b -0.67 ± 0.66 0.31 -1.08 ± 0.58 0.07 -1.75 ± 0.64 0.01
Model 2c -0.78 ± 0.66 0.24 -1.00 ± 0.59 0.09 -1.78 ± 0.65 0.01
With B-vitamin supplementation (n = 106)
Serum folate (nmol/L)
Crude -0.01 ± 0.16 0.93 -0.10 ± 0.16 0.54 -0.11 ± 0.20 0.58
Model 1 -0.07 ± 0.16 0.66 -0.14 ± 0.15 0.37 -0.20 ± 0.16 0.19
Model 2d -0.03 ± 0.17 0.88 -0.24 ± 0.16 0.15 -0.26 ± 0.16 0.11
Serum vitamin B12 (pmol/L)
Crude -0.01 ± 0.02 0.51 0.02 ± 0.01 0.21 0.01 ± 0.02 0.66
Model 1 -0.01 ± 0.01 0.48 0.02 ± 0.01 0.15 0.01 ± 0.01 0.50
Model 2d -0.01 ± 0.01 0.37 0.02 ± 0.01 0.22 0.00 ± 0.01 0.76
Serum holotranscobalamin (pmol/L)
Crudee 0.10 ± 0.07 0.16 0.11 ± 0.07 0.12 0.21 ± 0.09 0.02
Model 1e 0.05 ± 0.07 0.49 0.06 ± 0.07 0.39 0.10 ± 0.07 0.13
Model 2f  0.06 ± 0.07 0.38 0.05 ± 0.07 0.49 0.11 ± 0.07 0.12
Serum methylmalonic acid (µmol/L)
Crude -179.5 ± 53.0 <0.01 -18.8 ± 54.1 0.73 -198.3 ± 66.0 <0.01
Model 1 -136.6 ± 50.7 0.01 29.9 ± 50.5 0.55 -106.7 ± 51.5 0.04
Model 2d -136.2 ± 53.1 0.01 9.4 ± 54.1 0.86 -126.8 ± 53.1 0.02
Plasma homocysteine (µmol/L)
Crude d -3.44 ± 1.30 0.01 -3.56 ± 1.26 <0.01 -7.00 ± 1.51 <0.001
Model 1d -1.88 ± 1.30 0.15 -2.10 ± 1.25 0.10 -3.98 ± 1.26 <0.01
Model 2g -2.53 ± 1.40 0.07 -1.71 ± 1.35 0.21 -4.24 ± 1.31 <0.01
Notes: Crude: Adjusted for intracranial volume; Model 1: Adjusted for intracranial volume, age, sex; Model 2: Adjusted for model 1 and BMI, alcohol, 
smoking, education, physical activity. a n = 111; b n = 109; c n = 108; d n = 103; e n = 96; f n = 93; g n = 93.
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Discussion
Our cross-sectional analyses showed that higher levels of  folate were associated with 
lower brain volume. After dividing the study population into those who received two-year 
supplementation with vitamin B12 and folic acid and those who did not, the association 
was not present anymore in the latter group, whereas a trend was still observed in the 
B-vitamin group. In contrast, higher levels of  Hcy and MMA were associated with lower 
total brain volumes, and with stronger associations in the B-vitamin group than in the non-
supplemented group. No associations were observed for serum vitamin B12 or holoTC with 
brain volumetric measures. Furthermore, directly comparing the supplementation groups 
with respect to brain volumes does not point towards a beneficial effect of  B-vitamin 
treatment; after adjustment for important covariates the group that received the B-vitamin 
supplementation had a lower brain volume compared to the placebo group.
The data add to two other findings on cognitive function within the B-PROOF study. Cross-
sectionally, we observed baseline associations between MMA, Hcy and folate, indicating 
a better vitamin B12 and folate status, with episodic memory and information processing 
speed.14 Two-year supplementation with folic acid and vitamin B12, however, did not show 
beneficial effects on specific cognitive function domains.15 Most other randomized controlled 
trials (RCTs) investigating the effects of  B-vitamin supplementation with at least one year 
follow-up also failed to show a beneficial effect on cognitive performance.16, 17 Potentially, 
study populations were not sensitive enough to induce an effect, study durations were too 
short to significantly slow down the development of  cognitive decline, or the effects were 
too subtle to be detected by the neuropsychological testing. Neuropsychological tests may 
be susceptible to practice effects or short-term fluctuations in test performance,18 while 
structural MRI may be less susceptible to these fluctuations. Brain volume can therefore act 
as a predictor for brain health,18-20 as rate of  brain volume loss is correlated with performance 
on cognitive tasks and it may predict the conversion of  mild cognitive impairment (MCI) 
into dementia.20-22
We observed a negative association between folate and brain volume in the total population. 
After stratification, the association was not present in the group that did not receive 
B-vitamin supplementation, whereas a trend was still seen in the supplemented group. 
The non-supplemented group might reflect a sample with blood levels closer to normal 
instead of  being intervened by folic acid supplementation, and thus it might be that 
these associations come closer to normal values. Folic acid, the synthetic form used in 
supplements, has a higher bioavailability than folate naturally present in food. Because the 
conversion of  folic acid to metabolized folate is low as a result of  low activity of  the enzyme 
dihydrofolate reductase, high intake of  synthetic folic acid may cause an accumulation of  
unmetabolized folic acid. Studies have suggested that high folate levels, in combination with 
and without vitamin B12 deficiency are detrimental for cognitive health.23-26 Especially older 
adults who took folic acid supplements containing >400 µg folic acid supplements, had a 
higher risk for cognitive decline.26 Hence, it is possible that folate levels follow an inverted 
U-shape regarding optimal cognitive performance and brain health; cross-sectional and 
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intervention studies, however, are inconclusive in their findings.6, 27, 24 We cannot speculate 
on the possible negative effects on brain volume in our study population because we do 
not have data on unmetabolized folic acid. To unravel the role of  folate and folic acid, in 
combination with and without low vitamin B12 levels, in brain health requires more research.
Our cross-sectional findings regarding Hcy and vitamin B12 status and brain volumes are 
similar to other studies. Studies that investigated Hcy concentrations and brain atrophy 
showed clear associations, with higher levels associated with more total atrophy 2, 28, 29 and 
lower hippocampal volume.30 In line with our findings, associations of  MMA and Hcy 
with total brain volume measured 4.6 years later are shown, but not with serum vitamin 
B12.4 A prospective study (n = 107, mean age 73 years), however, showed that lower serum 
concentrations of  vitamin B12 and holoTC, but not folate, Hcy or MMA, were associated 
with smaller brain volumes after 5 years of  follow-up.5 The only RCT currently published 
was performed in 168 patients with MCI, showing that B-vitamin (B12 , B6 and folic acid) 
supplementation slowed down total brain atrophy and grey matter atrophy, but only in those 
with the highest Hcy levels.31 We observed a borderline significant association between 
Hcy and grey matter in our healthier study population, but only in the group that received 
B-vitamin supplementation. Interestingly, the observed associations were thus stronger in 
those with lower Hcy levels as a consequence of  the B-vitamin treatment. It might be that 
the stronger associations between vitamin B12 status, as reflected by Hcy and MMA, and 
brain volumes in the B-vitamin group are the results of  the intervention, but since baseline 
MRI data are lacking, no conclusions can be drawn about the causality of  the relation 
between the intervention and the MRI measures.
In contrast to our hypothesis, we observed that participants who received B-vitamin 
supplementation had lower brain volumes than the non-supplemented group. Participants 
who received B-vitamins were significantly younger than participants who did not receive the 
supplements. As age is a major predictor for brain atrophy,32 it is possible that our findings 
may be the result of  this two-year age difference between the two groups. This hypothesis is 
supported by the fact that the unadjusted model did not show differences on brain volumes 
between treatment groups, whereas a difference was expected due to the age difference. 
When adjustments for age were made, this resulted in a significant difference in brain volume 
between the two groups. 
To put our findings into perspective, some methodological issues need to be discussed. 
Limitations include the lack of  baseline data on brain volumes, which makes it impossible 
to draw conclusions on the effects of  two years B-vitamin supplementation on grey and 
white matter volume. Furthermore, one of  the inclusion criteria of  the B-PROOF study 
was an elevated Hcy level, which makes the generalizability to the total elderly population 
difficult. Last, we performed multiple statistical tests, which increased the risk on chance 
findings. Strengths of  our study are the use of  a 3T scanner to make high-precision images, 
our relatively large study population for conducting MRI scans, the possibility to adjust for 
multiple confounders, and the available data of  folate, Hcy and three markers of  vitamin 
B12 status. Due to the two-year supplementation with vitamin B12 and folic acid, we created 
measureable variation between participants regarding their folate and vitamin B12 status. 
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The observed cross-sectional associations of  higher Hcy concentrations and lower brain 
volume may be explained by several mechanisms. Hcy may be neurotoxic, which can induce 
brain atrophy and hamper neurogenesis.2, 28 Furthermore, elevated Hcy levels may lead to an 
increase of  phosphorylated tau, which is associated with atrophy in specific brain regions.33, 
34 Higher Hcy levels have also been associated with more white matter hyperintensities 35 and 
decreased myelination and consequently on the integrity of  white matter.36, 37 
The results of  the current study suggest that lower levels of  Hcy and the vitamin B12-
metabolite MMA may be important in order to attenuate brain atrophy in elderly people. 
Brain volume reduction in healthy older people (>60 years) is around 0.5 to 1.1 % per year,5 
which is equivalent to about 5 to 10 mL. In the B-PROOF study, Hcy levels decreased with 5 
µmol/L after two years of  B-vitamin supplementation.38 This decrease can be considered as 
one to three years less brain atrophy based on the observational results in the current study, 
which might be considered substantial. However, the negative associations of  folate and the 
lack of  a baseline measurement withhold us from giving recommendations on whether folic 
acid and vitamin B12 supplementation will be beneficial above and beyond normal dietary 
intake. Nevertheless, in relation to brain health a lower Hcy level seems to be beneficial for 
healthy elderly people. 
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Main findings
The effects of  different nutrients, i.e. glucose and sucrose, protein, resistance-type exercise 
with and without protein, and vitamin B12 and folic acid on cognitive performance in 
different older study populations were investigated in this thesis. Table 1 presents the 
main findings. In general, the described interventions caused small effects on cognitive 
performance and different cognitive domains were affected. Yet, processing speed seems to 
be the most susceptible cognitive domain to the nutritional interventions presented in this 
thesis. 
There are multiple plausible mechanisms on how these nutrients could influence cognitive 
performance. Observational studies have often suggested a certain role of  nutrition 
in the process of  cognitive decline. Despite an appreciation of  the possible biological 
mechanisms and associations from epidemiological studies, adequate evidence from 
randomized controlled trials (RCTs) is lacking.1 This is not only due to the smaller number 
of  RCTs compared to observational studies, but also because many RCTs did not confirm 
the expected effects of  a dietary intervention on cognitive performance. Our limited 
effects do not provide sufficient evidence in the field of  nutritional neurosciences, but 
does this imply that the role of  nutrition in cognitive decline is limited? Or are other, for 
instance methodological issues, the underlying explanation for the limited effects? In this 
final chapter, methodological issues relating to the studies are described in the context 
of  nutritional neurosciences. This is followed by a discussion on the implications of  the 
investigated nutrients, proposed future research and summary remarks.  
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Table 1 Summary of  main findings
Nutrient Design Findings Chapter
Beneficial effects/
associations
No/negative effects/
associations
Sweet Thoughts
Glucose (acute 
effects)
Literature review Glucose may improve 
episodic memory in elderly 
people
Limited number of  studies 
regarding other cognitive 
domains; results were 
inconclusive
2
Cross-over 
intervention trial in 
43 adults ≥70 y with 
light self-reported 
memory complaints
No effects on episodic memory, 
working memory, attention and 
information processing speed, 
or executive functions
3
Sucrose (acute 
effects)
Literature review Very limited number of  studies 
done; little evidence of  a 
beneficial effect
2
Cross-over 
intervention trial in 
43 adults ≥70 y with 
light self-reported 
memory complaints
Beneficial effect on 
information processing 
speed
No effect on episodic memory, 
working memory, or executive 
functioning
3
ProMuscle
Protein 
supplementation 
24-week 
intervention trial in 
65 pre-frail and frail 
adults ≥65 y 
Improved reaction time No effects on episodic memory, 
attention and working memory, 
information processing speed, 
executive functioning
4
Exercise training 
without protein 
supplementation
24-week 
intervention trial in 
62 pre-frail and frail 
adults ≥65 y
Improved attention and 
working memory
No effects on episodic memory, 
information processing speed, 
executive functioning
Unfavourable effect on Letter 
Fluency test
5
Exercise training 
with protein 
supplementation 
24-week 
intervention trial in 
65 pre-frail and frail 
adults ≥65 y
Improved information 
processing speed
No effects on episodic memory, 
attention and working memory, 
executive functioning
5
B-PROOF
Supplementation 
with folic acid 
and vitamin B12
2-year intervention 
in 2,919 adults ≥65 
y with elevated 
homocysteine levels
Small beneficial effect 
on global cognitive 
performance
No effects on episodic memory, 
attention and working memory, 
information processing speed, 
executive functioning (n = 856)
6
Serum levels 
vitamin B12-
related markers
Cross-sectional 
study in 218 adults 
≥65 y
Higher methylmalonic 
acid levels were inversely 
associated with total brain 
volume and grey matter 
in the group with a 2-yr 
history of  B-vitamin 
supplementation
No associations of  serum B12 
or holotranscobalamin with 
brain volumes
7
Serum levels 
folate
Folate levels were inversely 
associated with white matter 
volume and total brain volume 
7
Plasma levels 
homocysteine 
Homocysteine levels were 
inversely associations with 
total brain volume
7
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Methodological considerations
The great complexity of  nutritional neurosciences is challenging. Specifically for the topics in 
the previous chapters, several strengths and limitations have already been discussed. Despite 
the fact that the presented studies were diverse in their exposure, design, duration and 
population, which makes comparisons slightly difficult, some generic methodological issues 
and considerations about study design, target population, study duration, outcome measures, 
and the investigated nutrients will be discussed. 
Study design
The core of  this thesis (Chapter 3, 4, 5 and 6) consists of  placebo-controlled intervention 
trials, and except for one study (Chapter 5, effect of  resistance-type exercise) all were 
randomized and double-blind. RCTs can confirm causal relationships and therefore stand 
high in the evidence pyramid. Limitations of  RCTs include the generalizability of  the 
observed effects and the feasibility of  the translation of  a controlled environment into daily 
life.2 
When investigating the slow process of  cognitive decline and dementia, another drawback 
of  RCTs becomes apparent. As cognitive functions gradually decline over multiple years, it 
is difficult to halt this process in the often short time span of  an RCT. Additionally, dietary 
intake during the entire life or during specific sensitive periods in life may be more important 
than dietary or supplement intake during an intervention period. In order to identify possible 
risk factors for cognitive decline, long-term cohort studies can be used to define dietary 
intake during life and to associate this with the gradual decline in cognitive performance. 
Certainly, observational studies have their limitations as well. It is, for instance, challenging 
to adjust for all possible confounders, which results in residual confounding. Furthermore, 
the assessment of  dietary intake is prone to errors and misclassifications, among others, due 
to self-reported measures and the lack of  accurate biomarkers.3 And finally, reverse causality 
prevents the drawing of  conclusions on the causal relationship of  nutrients on cognitive 
health, although with prospective studies this limitation can be more or less overcome. 
Prospective studies with multiple measurements over time can be initiated in middle age, 
as brain abnormalities and cognitive decline may already be present by then.4 People who 
are at higher risk of  developing dementia, for instance people with the apolipoprotein E-ε4 
(ApoE-ε4) allele, or having a family history of  dementia are preferably included. It still 
remains that observational evidence needs to be confirmed with data from intervention 
trials.5 Consensus statements on nutritional neurosciences still advocate long-term 
intervention trials as the gold standard.6 Based on results of  prospective studies, intervention 
trials can be designed, with regard to target populations and duration. 
Target populations 
Intervention studies provide the highest level of  evidence, but at the same time they are 
costly, and it is therefore important to consider and select the right circumstances in which to 
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perform a trial. We undertook our trials in elderly people older than 65 or 70 years without 
known diagnosis of  mild cognitive impairment (MCI) or dementia. Several changes in the 
brain occur when growing older and this makes the group of  elderly people an interesting 
group to study. Based on the inclusion criteria, the study populations that were used for 
our studies were at risk of  cognitive decline 7-9 and therefore, they were assumed to be more 
susceptible to the possible effects of  nutritional interventions. Although we aimed to include 
vulnerable individuals, our populations were well educated, generally healthy, had high scores 
on the Mini-Mental State Examination (MMSE), and consequently may have had good brain 
reserves. The inclusion of  healthy individuals is a common feature of  response bias, as it is 
likely that people who are willing to participate are, in general, healthier, higher educated, 
more conscious about a healthy lifestyle, and more willing to change their habits than those 
who do not volunteer for scientific studies. This may explain the small observed changes 
in their cognitive performance during the intervention periods, as was clearly observed in 
the B-PROOF study after two-year follow-up. Consequently, it may be the reason why we 
observed few effects in our nutritional intervention studies. Therefore, our findings cannot 
be generalized to the entire elderly population.
Nutrient deficiencies
Older adults are more susceptible to nutrient deficiencies than younger populations, because 
of  impaired absorption or inadequate diet.10 More than 20% of  older adults have vitamin 
B12 deficiency, and around 10% of  community-dwelling and frail older individuals have an 
insufficient protein intake.11 Supplementation may therefore be useful or even necessary to 
treat nutritional deficiencies, although, whether there is an additional effect on health, e.g. 
cognitive performance, beyond normal homeostasis levels is still uncertain.12 Nutritional 
status is often not taken into account in trials, while well-nourished older individuals may not 
benefit from nutritional supplements.13 It is suggested that research in deficient participants 
will yield larger effects, but it has to be considered that when choosing this target population 
not treating the control group may have ethical concerns. With the inclusion criteria of  
elevated homocysteine levels, it was suspected that the B-PROOF population was at risk 
of  vitamin B12 and/or folate deficiency, and subsequently responsive to the effects of  
supplementation. Depending on which marker and cut-off  values are used, vitamin B12 
deficiency ranged from 8-30% in this population, indicating that the majority had adequate 
vitamin B12 levels. 
MCI patients
Populations who already have some cognitive problems, such as patients with depressive 
symptoms,14 mild cognitive impairment (MCI),15 or dementia,16 may be more susceptible 
to nutritional interventions than cognitively healthy older adults. They are suggested to 
be suitable to study the effects of  nutrition in the process of  cognitive decline, as these 
populations will decline more over time than healthy older individuals. 
Studies in patients with MCI or dementia do, however, not have consistent findings.1, 10 
Concerns have been raised whether brain damage that may be present in patients with MCI 
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or dementia, and even already in healthy older adults, is reversible. When a clinical diagnosis 
of  dementia is made, underlying brain damage leading to the disease has been present for 
many years 6, 12 and at the moment of  diagnoses, it might be too late to undo the existing 
damage or to prevent further decline.17 Therefore, suggestions have been put forward to 
conduct research in younger populations, for instance in midlife adults, aiming to build more 
cognitive reserve and minimize neuronal damage. A debate is ongoing concerning the age 
at which cognitive decline presents, with a meta-analysis showing decline starting at the age 
of  60 years. However, another large study that was not included in the meta-analysis showed 
the presence of  decline already at the age of  45 years.4 Younger populations less often have 
a comprised nutrition status, making them less susceptible to nutritional interventions. In 
addition, intervention trials in midlife adults require very long study duration before an 
effect, if  any, can be detected using neuropsychological test batteries. As brain pathologies 
may be present at a younger age than cognitive decline,18 early biomarkers, including imaging 
studies or markers in cerebrospinal fluid (CSF), should be considered. Till biomarkers 
are further validated, MCI patients and elderly populations who are at high risk for either 
malnutrition, cognitive decline, or both are the preferred target populations for nutritional 
interventions. Cognitive decline can still be reversible in these populations, as is reflected 
by the fact that almost half  of  the MCI patients return to ‘‘normal’’ in the first year after 
diagnosis.19 Patients with severe-stage dementia on may, on the other hand, have too much 
brain damage to counteract this with nutrition or medication.  
Study duration 
To induce changes in cognitive functions and to be able to detect them, an intervention study 
should be at least 18 months long according to consensus guidelines of  the IANA.20 The 
follow-up period should be based on the mechanisms of  action 6 and can be slightly shorter 
when very vulnerable participants are included, such as patients with MCI or frail older 
adults.20 With its 24 months, the B-PROOF study should have been long enough to induce 
an effect of  B-vitamin supplementation. Nevertheless, it is possible that the main expected 
mechanism, namely reducing homocysteine levels, had not revealed its effects yet, and as 
such, no beneficial effects were observed. Homocysteine levels increase with age 21 and, in 
addition, the negative effects of  homocysteine on cognitive performance may accumulate.22 
If  homocysteine already has damaged the brain, it is difficult to undo the damage. The 
ProMuscle study was shorter, being only 24 weeks long, but we observed beneficial effects 
of  the exercise programme with and without protein supplementation. An intervention 
with physical exercise might induce faster or larger effects than nutritional compounds, and 
can therefore be detected after a shorter study duration.23, 24 In addition, with the exercise 
programme we used in the ProMuscle study, it may be questionable whether participants 
would still have complied to the treatment if  the study had a longer follow-up. 
The recommended guidelines are an indication for all nutritional intervention studies on 
cognitive functioning in cognitively healthy people, but whether it is really possible to induce 
and detect an effect of  any nutritional intervention within 18 months, remains uncertain. 
Currently, some longer-term studies have been performed, including the EPDI studies, 
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with a follow-up time of  6 years in older adults without a diagnosis of  MCI or dementia.25 
Longer-term intervention studies are, however, difficult to perform in view of  manpower, 
participants, compliance, and they often do not fit into subsidy programs regarding costs and 
time. By including populations who are at higher risk of  cognitive decline than normal, as 
suggested in the previous section, studies of  a slightly shorter duration might be feasible.
Measuring brain health
Neuropsychological tests
Cognitive performance can be measured in various ways. Global measures for cognitive 
performance, such as the MMSE and the Clinical Dementia Rating scale have often been 
used in observational studies. These measures are easy to use, cheap, and are mainly 
developed as screening tools to detect MCI or dementia. They are, however, prone to ceiling 
effects, and they are not very sensitive tools to discriminate performance in healthy elderly 
persons or to detect an effect of  a nutritional intervention.26 Therefore, the MMSE as an 
outcome measure has been considered questionable, although we used it as a rough measure 
for global cognitive change over a two-year period and were able to observe a small effect 
of  B-vitamin supplementation. A better method to measure cognitive performance is by 
applying neuropsychological test batteries, as were used in the studies described in this thesis 
(see Table 1 in Chapter 1).26 The tests we used have been validated and have more often 
been used in comparable studies in older populations. They were supposed to be difficult 
enough to avoid ceiling effects, but also not too demanding to avoid stress or to affect 
motivation. They covered a wide range of  cognitive functions that are vulnerable to age-
related decline. Single test scores were combined into cognitive domain composition scores 
in order to create robust measures. The clustering was based on the cognitive concepts that 
were measured, similar to other studies.27, 28 A limitation of  this method, however, is that 
the clustering is not always straightforward, as some of  the cognitive tests assess more than 
one function. In addition, certain functions are needed to perform other functions, e.g. to 
remember a list of  words you have to pay attention to this list. As a result, it is possible that 
a compound score did not change after an intervention, while one of  the tests was affected 
by the treatment, but another test was not due to a difference in sensitivity or difficulty. We 
therefore always investigated the single cognitive scores as well. 
An abundance of  different neuropsychological tests is available, which makes the choice of  
the most accurate tests difficult. A known or hypothesized relationship between a nutrient 
and a cognitive function should be the lead in selecting cognitive tasks, rather than the 
availability or easiness of  the tests.26 The use of  different tests and the subsequent difficulties 
comparing them is a problem and suggestions have therefore been put forward for a 
standard neuropsychological test battery that can be used in nutritional neurosciences.26 This 
will enable firm conclusions to be drawn on postulated nutritional benefits.
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Imaging techniques
The impairment in cognitive performance has been suggested to be one of  the last features 
of  brain dementia pathologies.26, 29 According to a hypothetical model of  biomarkers of  
Alzheimer’s disease (AD), preclinical AD starts with an elevation of  β-amyloid accumulation. 
This is followed by synaptic dysfunction, tau-mediated neuronal damage, changes in brain 
structures, and only then by problems with cognitive functions.29 Imaging techniques 
that measure these changes could therefore be of  great use to investigate early effects of  
nutrition. However, to date they have not often been applied in nutritional studies.1 
One of  the imaging techniques includes structural MRI scans to measure brain volumes. 
Total grey and white matter volume, and volume of  cerebrospinal fluid (CSF) are relatively 
rough measures for the rate of  atrophy.1 Together with hippocampal atrophy, total brain 
atrophy can be a predictor for cognitive decline.30, 31 At the population level, brain volumes 
correlate with neuropsychological performance and daily functioning,32, 33 although these 
relations are not always present at an individual level. Within the B-PROOF study, we 
obtained different types of  images to study brain volume (Chapter 7), and to be able to 
investigate more specific brain regions volumes, white matter integrity, and associate these 
measures with cognitive performance measures and B-vitamin status. 
Other structural imaging techniques include the presence of  white matte integrity by 
measuring white matter hyperintensities, diffusion tensor imaging (DTI), and Positron 
emission tomography (PET). Functional imaging techniques include functional MRI (fMRI), 
fluorine-18 fluorodeoxyglucose PET (FDG-PET), proton magnetic resonance spectroscopy 
(MRS), phosphorous MRS, near-infrared spectroscopy (NIRS), electroencephalonography 
(EEG), magnetoencephalography (MEG). Molecular biomarkers in CSF are also available, 
such as Aβ42, Tau, and p-tau,1 but the measurements are rather invasive. Research on 
biomarkers in blood, which has a lower burden for the participants than a lumbar puncture 
and is more accessible, is developing.34, 35 
Not everyone with pathologies will end up with dementia due to greater brain reserve and 
better compensation strategies. Brain imaging and CSF biomarkers may predict cognitive 
decline at group level,18, 36 and the use of  these methods can give more understanding 
about possible mechanisms. However, the predictive values of  the mentioned biomarkers 
for cognitive decline or dementia have not yet been established for individual diagnosis.37 
It is furthermore debatable what it means when a nutritional intervention affects these 
brain biomarkers, but when cognitive performance measurements or daily activities are not 
changed.2 What benefit does it give to people when they do not notice it in daily life, even 
though on the longer-term it may be beneficial? The use of  combinations of  biomarkers, 
imaging techniques and cognitive performance measures in research should be encouraged to 
increase the understanding and predictive value of  biomarkers.5 
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Nutritional factors
Single nutrients, multi-nutrients, dietary patterns, or multi-domain studies
The rationale for the investigated nutrients in this thesis has extensively been discussed in 
the previous chapters. The interventions covered different dietary approaches, including 
single macronutrients (glucose and protein), combinations of  nutrients (sucrose, folic acid 
and vitamin B12), and a multi-domain intervention (exercise and protein). A topic of  interest 
in nutritional (neuro)science is that people consume whole diets rather than single nutrients. 
By investigating single nutrients, interactions with other nutrients are not being taken into 
account and it may be questionable to what extent intervening with one or two nutrients may 
influence brain health when the normal diet has not been adjusted. As such, a single tablet 
with a certain nutrient without a controlled diet might be ineffective.12 An advantage of  the 
single-nutrient approach is that when observing an effect, it is clear this effect was caused 
by the particular nutrient and it consequently gives a clue to potential mechanisms. Possible 
interactions of  nutrients and other lifestyle factors may have additional effects compared to 
single nutrients. Therefore, micronutrient combinations, dietary patterns, and multi-domain 
studies are receiving more attention nowadays. 
Multi-nutrients combinations
The combination of  vitamin B12 and folic acid, and sometimes with added vitamin B6, has 
often been used in other trials. It is suggested that these B-vitamins work on at least one 
common mechanism, via lowering homocysteine, to affect brain health. Studies on other 
combinations of  multi-nutrient supplements are heterogeneous and show mixed effects. A 
meta-analysis in older adults without dementia suggested a possible effect of  multivitamin 
supplements on free recall performance, but not on other cognitive domains.38 A study in 
older men that was not yet included in the meta-analysis but with a follow-up of  12 years 
did not observe any beneficial effect at all.39 The multi-nutrient drink Souvenaid® contains 
a combination of  nutrients that is hypothesized to target one mechanism, namely synaptic 
loss. Beneficial effects were observed on memory performance in MCI patients and mild 
AD patients,40, 41 but not in mild-to-moderate AD patients.42 The combination of  nutrients 
may yield larger effects, but alternatively, it is important to take into account that different 
nutrients may have opposing directions because of  different mechanisms, which can cause 
conflicting results. Targeting one specific mechanism with a multi-nutrient approach is an 
opportunity for future research. 
Dietary patterns
A step further in investigating combinations of  nutrients is studying whole dietary patterns. 
It has been shown that people with AD adhere less to the Mediterranean diet,43 and 
prospective studies have shown that this type of  diet may be protective for dementia.43, 44 
A meta-analysis of  longitudinal studies with follow-up times ranging from 2.2 to 8 years 
showed a 33% lower risk of  cognitive impairment (MCI or AD) in the tertile who complied 
most to a Mediterranean diet than those in the lowest tertile, and also the conversion of  
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MCI to AD was lower in the highest Mediterranean diet tertile.44 Other healthy diet indexes, 
such as the DASH (Dietary Approaches to Stop Hypertension) 45 also showed associations 
with cognitive performance. A difficulty with these diet scores is that cut-offs are not based 
on absolute values, but on relative levels for the study populations. This makes comparisons 
between studies difficult and generic recommendations to the public somewhat challenging. 
To our knowledge, only one RCT (the PreDimed-Navarra study) has been done thus far 
with Mediterranean components, i.e. olive oil or nuts, and showed a beneficial effect of  olive 
oil on cognitive performance after 6.5 years in older adults initially without cardiovascular 
disease but with a high risk on cardiovascular diseases.46 More trials are needed to investigate 
the efficacy of  Mediterranean diet on cognitive performance.
Multi-domain studies
To gain a better understanding of  the role of  lifestyle factors in relation to the multifactorial 
process of  cognitive decline, components other than nutrition should be taken into 
account. The potential synergistic effects of  combined interventions, addressing multiple 
factors, might affect the process of  cognitive decline more than one factor alone.47-49 The 
combination of  nutrition and physical exercise, as we applied in Chapter 5 with protein 
supplementation and resistance-type exercise, is an example of  this type of  research. Another 
example of  a multi-domain intervention study is the MAPT (Multi-Domain Intervention 
in the Prevention of  Age-related Cognitive Decline) study in France, which investigates the 
combination of  nutrition (omega-3 fatty acids), and a combination of  cognitive training, 
nutritional advice and physical activity advice on cognitive decline.50 Performing a multi-
domain intervention trial is challenging, and preferably it includes groups with the single 
intervention as well as the combined intervention.  
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A broader perspective and health 
implications of the investigated 
nutrients 
Glucose and sucrose 
Effects on cognitive performance
To the best of  our knowledge, the literature review in Chapter 2 captured all studies (n = 20) 
performed in the field with acute effects of  glucose and sucrose on cognitive performance in 
non-demented older adults. We concluded that a glucose load may enhance episodic memory 
performance in the short-term in elderly people. This conclusion was in line with another 
review, which was conducted in younger and older adults, and patients with AD.51 In our 
intervention study (Chapter 3) we did not observe an effect on episodic memory, although 
we observed an effect of  sucrose on information processing speed, which was in accordance 
with the effect of  glucose in two other studies out of  eight that investigated this cognitive 
domain. 
Similar to other published studies, our study was performed when participants were in a 
fasted state, and the effects of  glucose or other food products might be different during the 
day when people are allowed to eat.52 Furthermore, not only does a glucose load seem to 
influence cognitive performance; enhancing effects were also observed after the intake of  
carbohydrates with a lower glycaemic index (barley and potato),53 and after a meal rich in 
protein and fat.54 This may suggest that beneficial effects are not limited to a high-glycaemic 
product, such as glucose or sucrose, but that it is the supply of  energy that is important for 
optimizing cognitive functions in the short-term. 
Health considerations 
Based on the available research, it seems that a rapid rise in glucose levels enhances episodic 
memory in the short-term. In the longer-term, however, stable blood glucose levels are 
preferred. Prolonged elevated blood glucose levels, insulin insensitivity and diabetes may 
harm vessel walls and induce neuronal brain death, and consequently increase the risk of  
cognitive decline and dementia.55 The consumption of  products containing a considerable 
amount of  refined sugar may be unfavourable for a person’s health in the long term. The 
Dutch guidelines for healthy nutrition state to be careful with sugar intake.56 In addition, a 
recent draft report of  the WHO proposes to reconsider the guidelines for free sugar use, as 
limiting the consumption of  free sugars may reduce the risk of  obesity and dental caries.57 
This makes it challenging to set a recommendation for the regular dietary use of  pure 
glucose, sucrose, or products containing high amounts of  added sugars to improve cognitive 
performance. 
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Protein supplementation and resistance-type exercise
Dietary protein and cognitive performance 
We have added an intervention study (Chapter 4) to the limited existing literature on dietary 
protein and cognitive performance, which mainly consisted of  observational studies and 
only a few RCTs.58 Although our findings were heterogeneous, our study does provide leads 
for future studies. Our positive finding on reaction time can be attributed to the effects 
of  extra supply of  precursors for neurotransmitters or may be related to a better physical 
performance as a result of  the protein supplementation.59 However, the finding could also 
be a chance finding, as no effects were observed on the associated domain of  information 
processing speed. Therefore, to unravel the possible role of  protein supplementation in 
cognition replication studies are warranted. 
Studies on the effects of  single amino acids, more particularly tyrosine and tryptophan, have 
shown acute effects on cognitive performance.58 Whether a change in amino acid supply 
impacts cognitive performance in the longer-term is unknown. Examining this hypothesis 
is challenging, as the uptake of  amino acids is modified by the presence of  other amino 
acids due to the competitive transport across the blood-brain barrier. Furthermore, when 
amino acids are consumed together with other dietary components, part of  the amino acids 
is absorbed by other body tissues, such as muscles. These crossing pathways complicate 
the prediction of  how much of  the amino acids will be taken up by the brain and can 
subsequently be used for neurotransmitter synthesis. It would be interesting to investigate 
changes in amino acid concentrations in CSF after a longer-term intervention of  amino 
acid or protein supplementation to unravel a part of  the mechanism. The optimal dose, 
supplementation method (protein drink vs. amino acid supplement), timing (during a meal, 
presence of  carbohydrates) and the burden of  measurements in CSF should be considered. 
Physical exercise and cognitive performance
Physical activity has been indicated as one of  the modifiable risk factors in the process of  
cognitive decline, but intervention studies with exercise programmes do not consistently 
observe beneficial effects.60, 61 Only one study has investigated the effects of  a combination 
of  aerobic and resistance-type exercise in a frail population, and observed beneficial effects 
on executive functions and processing speed, although the effects were not limited to the 
frail part of  the study group.24 We added to this that resistance-type exercise improved 
attention and working memory in a pre-frail and frail population of  older adults. Moreover, 
the combined exercise and protein supplementation revealed benefits on information 
processing speed. One would expect that the combination exercise and protein would, at 
least, be beneficial also for attention and working memory. We cannot explain this, but it may 
be that mechanisms are slightly different when a nutritional compound is added to exercise 
training. Imaging studies have already shown that exercise may influence prefrontal areas, 
white matter integrity, and functional connectivity,61 and this can relate to our findings on 
speed-related functions and working memory.
Other exercise types, including aerobic and flexibility training have been suggested to 
167
8Discussion
be good strategies to enhance cognitive performance, but especially the combination of  
different types of  exercise seems to be most beneficial.60 Results of  trials, however, are not 
totally equivocal. These mixed results may be a result of  differences in study design, follow-
up time, efficiency of  training, and study population. A challenge in physical exercise studies 
is a good control group, namely social interaction has been shown to be an important factor 
regarding cognitive function. This aspect of  social interaction is often lacking in a non-
exercise group. Social engagement has been shown to improve cognitive performance, and 
with training sessions twice a week this may interact with the much smaller social interaction 
contribution in the control group. In our study (Chapter 5), the control group visited the 
university on test days, which may already have had a beneficial effect on their well-being and 
social interactions, but for a perfect control group more social activities should have been 
included. Another aspect that needs to be considered is whether older adults, frail or non-
frail, can comply with extensive exercise training, for a longer period of  time. Future research 
preferably includes measures that can shine a light on the underlying mechanisms involved in 
physical exercise and cognitive performance. 
Vitamin B12 and folic acid 
Within the B-PROOF study, the role of  B-vitamins in brain health has been extensively 
investigated. Cross-sectional baseline data showed that higher methylmalonic acid (MMA) 
and homocysteine levels, but not serum vitamin B12 and holotranscobalamin, were associated 
with poorer performance on episodic memory (homocysteine and MMA) and information 
processing speed (homocysteine).62 In accordance, these biomarkers were also inversely 
associated with brain volume after two years supplementation with vitamin B12 and folic 
acid (Chapter 7). Higher folate concentrations at baseline were associated with better 
performance on episodic memory. In contrast, folate was also associated with lower brain 
volumes. Two-year supplementation with vitamin B12 and folic acid significantly decreased 
homocysteine and MMA levels. This did, however, not result in beneficial effects on 
cognitive domain performance (Chapter 6), whereas a small beneficial effect was observed 
on the incidence of  cerebrovascular events in women.63 In contrast to our hypothesis, 
brain volumes were slightly smaller in the group that received B-vitamin supplementation 
compared to those who did not. To put the somewhat heterogeneous results of  the 
B-PROOF study in perspective and to draw conclusions on the role of  B-vitamins in brain 
health, we have to look at evidence from other studies as well. 
Evidence for the role of  homocysteine and vitamin B12 and folate in brain health is mainly 
derived from pre-clinical 64, 65 and observational studies that examined cross-sectional 
and prospective associations between vitamin B12 markers and folate with cognitive 
performance,10, 66 brain volume 67-71 and brain integrity.72, 73 Our null-findings of  the two-year 
supplementation are in concordance with the conclusions of  different reviews,74, 75 a meta-
analysis of  studies conducted in elderly people,9 and with one other large study that was not 
yet included in the meta-analysis.76 Another study that was also not included in the meta-
analysis showed beneficial effects on cognitive performance in older adults with depressive 
symptoms,14 as well as a study in MCI patients showing beneficial effects on cognitive 
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performance and grey matter atrophy.77 
Wrapping up the evidence, we suggest that there is no strong evidence for the use of  vitamin 
B12 and folic acid supplementation to affect cognitive performance in healthy elderly adults 
who are not vitamin B12 or folate deficient. However, the observational data on vitamin B12 
and folate status on cognitive performance and brain parameters cannot be neglected, as well 
that in other populations, e.g. MCI and dementia patients, the effects may be different. This 
calls for further research.
Future perspectives 
In this chapter, various ideas are suggested as recommendations for the nutritional 
neurosciences field. In Box 1, a summary of  recommendations is given. Nutritional 
interventions should aim at prevention rather than treating cognitive impairment. Main 
messages are: 
1) There is a need for long-term prospective studies with multiple measurements over time 
with both neuropsychological tests and biomarkers that reflect risk factors for brain 
health; 
2) To confirm observational data, RCTs are needed in high-sensitive populations, such 
as MCI patients, people with suboptimal nutritional status, ApoE-ε4 carriers or family 
history of  dementia; 
3) To get a complete picture of  the influence of  lifestyle, not only single nutrients need to 
be investigated, also dietary patterns and combinations of  different domains should be 
studied. 
It should be taken into account that it is difficult to get people to change their lifestyle, 
including dietary habits. Taking a supplement in the form of  a tablet or capsule may be 
easy, but to change whole dietary patterns can be difficult. To be able to estimate the effects 
of  a change in lifestyle, it is important to study both the efficacy and effectiveness of  an 
intervention.
Concluding remarks
This thesis described the results of  a literature review, one cross-sectional study and four 
RCTs to investigate the role of  different nutrients in cognitive performance and brain 
volumes in healthy Dutch elderly people. In general, limited effects of  the different 
nutritional interventions, e.g. glucose and sucrose, protein and resistance-type exercise 
with and without extra protein, and vitamin B12 and folic acid, on cognitive performance 
were observed. Based on our results, we cannot yet recommend the use of  supplemental 
extra dietary protein, vitamin B12 and folic acid, or glucose or sucrose in the prevention of  
cognitive decline. Given the large problem of  dementia, research on modifiable risk factors, 
including nutrition, should continue. Future research should use well thought out research 
methods, including large and long-term observational and intervention studies with high-
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Box 1: Future perspectives for nutritional neurosciences
• There is a need for long-term, large-scale studies, both prospective cohorts and 
intervention studies. 
• Prospective cohorts should include multiple follow-up measurements, and preferably 
start as early as in midlife with a long follow-up time. Accurate assessments of  nutrient 
intake, total dietary intake, and patterns, are therefore needed.
• Especially populations high at risk should be included in studies, such as people with a 
family history of  dementia and people with ApoE-ε4 genotype. Those people who are 
at highest a priori risk, are also the most likely to benefit from risk reduction strategies.78 
This may be of  special interest when studies are done in younger participants. 
• In addition, it would be valuable to include patients with diagnosed MCI or self-reported 
memory complaints, especially in RCTs. Although brain damage may probably already 
be present, it is still possible that people return to normal again. This would be good 
for quality of  life and healthcare costs. Also people with a nutritional deficiency are of  
interest, as they have room to improve their nutritional status and cognitive performance. 
• RCTs should last at least 18 months, but preferably longer to be sure that the mechanism 
can induce its suggested effect. 
• For a better comparability of  studies, a standardized neuropsychological test battery is 
warranted and consensus is needed on the diagnosis of  normal cognitive decline, MCI 
and dementia. The use of  global measures, such as the MMSE, as an outcome measure is 
discouraged.
• Neuropsychological test batteries are suggested to be the primary outcome to define 
brain health, but it will be valuable to use other, earlier markers of  cognitive decline next 
to the cognitive tests. Early markers include imaging techniques as well as biomarkers in 
blood or cerebrospinal fluid, but the predictive value has not yet been established and 
further research is needed. 
• When multi-arm interventions are performed, combinations of  nutrients and single 
nutrients should be included to be able to disentangle the possible mechanisms. Also 
whole diet studies are needed, as synergy between nutrients seems to be important.12 
Long-term RCTs investigating the effects of  a whole dietary change, however, are 
expensive and difficult to perform.6
• Besides nutrition, other lifestyle factors can play a role in the development of  cognitive 
decline. In particular, physical activity may have synergic effects with nutrition. Other 
multi-domain options that may interfere with nutritional effects are cognitive and social 
engagement, and treatment of  diseases.61
sensitive study populations and early biomarkers (e.g. brain imaging techniques) for cognitive 
decline in combination with neuropsychological tests. In this way, nutrition can be added to 
the list of  lifestyle factors that can fight dementia.
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Summary
The age-related cognitive decline and the increase in dementia patients are large problems in 
societies with growing aging populations. No cure is present for dementia, while the available 
medication only focuses on alleviating symptoms. It is therefore of  major importance to find 
risk factors that can modify the development of  cognitive decline and dementia. Pre-clinical 
and observational studies suggest a role for nutrients. Evidence derived from randomized 
controlled trials (RCTs) is, however, limited and equivocal with most studies showing no 
effect and only a few studies showing a beneficial effect of  a nutritional intervention. In the 
current thesis, we investigated the acute and longer-term effects of  different nutrients, i.e. 
glucose and sucrose, protein, resistance-type exercise training with or without protein, and 
vitamin B12 and folic acid in order to optimize and preserve cognitive functions in non-
demented elderly people.
A comprehensive literature review was performed on the acute effects of  glucose and 
sucrose on cognitive performance (Chapter 2). Glucose is the most important fuel for the 
brain, and as such, manipulation of  the supply of  glucose may affect cognitive functions. 
The main conclusion of  our review was that a glucose load may have a short-term beneficial 
effect on episodic memory. Enhancing effects on other cognitive domains were less clear, 
partly due to the small number of  studies examining these effects. Limited research was also 
done on the possible effects of  sucrose on cognitive functions. Therefore, we investigated 
the acute effects of  50 g of  glucose and 100 g of  sucrose on a broad spectrum of  cognitive 
functions reflecting performance on episodic memory, working memory, attention and 
information processing speed, and executive functions (Chapter 3). This was done by a 
cross-over study in 43 elderly participants who had self-reported memory complaints. In 
contrast to the conclusion of  our review, we did not observe an effect of  glucose or sucrose 
on episodic memory, though we showed a beneficial effect of  sucrose on attention and 
information processing speed. 
Protein supplementation was the next nutritional intervention that was investigated. Several 
amino acids are precursors for neurotransmitters, and their supply may affect the synthesis 
and release of  these neurotransmitters, and may consequently affect cognitive performance. 
A 24-week randomized placebo-controlled trial was carried out in 65 frail and pre-frail elderly 
people (Chapter 4). The protein supplementation included twice a day 15 grams of  protein 
in the form of  a drink. Reaction time improved more in the protein group compared to the 
placebo group, but the scores on the cognitive domains, i.e. episodic memory, attention and 
working memory, information processing speed, and executive functions, or the other single 
test scores, did not differ between treatment groups. We furthermore investigated the effects 
of  24 weeks resistance-type exercise training with and without protein supplementation in 
pre-frail and frail elderly people (Chapter 5). Exercise training without extra protein (n = 
62) improved performance on the domain attention and working memory. Exercise training 
together with protein supplementation (n = 65) improved performance on information 
processing speed.  
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Last, the role of  vitamin B12 and foic acid on cognitive health was investigated. Low levels 
of  these nutrients can increase homocysteine levels, which is a suggested risk factor for 
cognitive decline. The effect of  daily supplementation with 500 µg vitamin B12 and 400 µg 
folic acid was investigated in 2,919 participants for two years (Chapter 6). Global cognitive 
function and episodic memory were assessed in the total study population, whereas 
extensive neuropsychological testing was done in a subpopulation (n = 856). B-vitamin 
supplementation did not improve cognitive domain scores. Only a small, though significant, 
effect was observed on global cognitive performance, measured by the Mini-Mental State 
Examination, but this was suggested to be due to chance. Brain MRI scans were made in a 
subgroup (n = 218) after two years of  intervention to obtain volumetric measures of  grey 
and white matter, and total brain volume (Chapter 7). We investigated the cross-sectional 
associations between follow-up levels of  folate, homocysteine and three vitamin B12 status 
biomarkers, i.e. methylmalonic acid, holotranscobalamin and serum vitamin B12, and brain 
volumes. Fully adjusted regression models showed a borderline significant association 
between plasma homocysteine and total brain volume, with a stronger association in the 
group that received B-vitamin supplementation. Serum B12 and holotranscobalamin were not 
associated with brain volumes, whereas high methylmalonic acid levels were associated with 
lower brain volumes in the group that received B-vitamins. In contrast, higher folate levels 
were associated with lower total brain volumes. In addition, when comparing the group that 
received two years of  B-vitamin supplementation and those who did not, we observed lower 
brain volumes in the B-vitamin group, which might be a result of  a difference in age between 
the two groups. 
To conclude, the nutritional intervention studies showed little evidence for a beneficial effect 
on cognitive performance in relatively healthy older adults. Given the large problem of  
dementia, research on modifiable risk factors, including nutrition, should continue, with well 
thought out research methods, including large and long-term observational and intervention 
studies with high-sensitive study populations and early biomarkers (e.g. imaging techniques) 
for cognitive decline in combination with neuropsychological tests. In this way, nutrition can 
be added to the list of  lifestyle factors that can fight dementia.
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Samenvatting
Met de toename van het aantal ouderen groeit ook het aantal patiënten met dementie. Omdat 
er nog geen genezing van dementie mogelijk is, is het belangrijk dat er leefstijlfactoren 
worden geïdentificeerd die van invloed zijn op het proces van cognitieve achteruitgang, 
zoals voeding. Preklinische en epidemiologische studies laten een mogelijke rol zien voor 
verschillende nutriënten. Bewijs van gerandomiseerde gecontroleerde onderzoeken is 
echter schaars en niet overtuigend, waarbij de meeste studies geen of  kleine effecten laten 
zien. Dit proefschrift richt zich op de acute en langere termijn effecten van verschillende 
nutriënten (glucose en sucrose, eiwit, krachttraining met en zonder eiwit, en vitamine 
B12 en foliumzuur), om nader te onderzoeken of  deze nutriënten een rol spelen in het 
optimaleseren en het behouden van cognitieve functies in gezonde ouderen.
In hoofdstuk 2 is er een uitgebreid literatuuronderzoek gedaan naar de acute effecten van 
glucose en sucrose op cognitieve functies. Glucose is de belangrijkste brandstof  voor de 
hersenen, en manipulatie van de glucosetoevoer zou daarom cognitieve functies kunnen 
beïnvloeden. De belangrijkste conclusie van deze literatuurstudie was dat de inname van 
een glucosedrank positieve effecten kan hebben op het episodisch geheugen op de korte 
termijn. Op de andere cognitieve domeinen was het effect van glucose minder duidelijk, wat 
gedeeltelijk verklaard zou kunnen worden door een kleiner aantal studies. Onderzoeken naar 
een mogelijk effect van sucrose op cognitieve functies waren ook schaars. In hoofdstuk 
3 hebben we daarom de effecten van 50 g glucose en 100 g sucrose op verschillende 
cognitieve functies onderzocht in een cross-over studie. De bestudeerde domeinen in deze 
studie waren episodisch geheugen, werkgeheugen, aandacht en informatieprocessnelheid, 
en uitvoerende functies. De onderzoekspopulatie bestond uit 43 oudere deelnemers met 
lichte zelf-gerapporteerde geheugenklachten. In tegenstelling tot de conclusie van het 
literatuuronderzoek werd er geen effect van glucose of  sucrose gevonden op episodisch 
geheugen. Wel was het cognitieve domein van aandacht en informatieprocessnelheid beter na 
de sucrosedrank vergeleken met de placebo.
In hoofdstuk 4 is het effect van eiwitsuppletie op cognitief  functioneren onderzocht. 
Verschillende aminozuren zijn nodig voor de aanmaak van neurotransmitters, en daarom 
suggereren studies dat extra toevoer van deze aminozuren mogelijk de aanmaak van 
neurotransmitters kan beïnvloeden. Dit zou effect kunnen hebben op cognitief  functioneren, 
maar dit is nog maar weinig onderzocht. In een gerandomiseerde, placebo-gecontroleerde 
studie van 24 weken kregen 65 kwetsbare ouderen tweemaal daags een eiwitdrank met 15 g 
eiwit, of  een placebodrank. Na 24 weken was de reactietijd in de eitwitgroep meer verbeterd 
dan in de placebogroep. Het functioneren op de andere cognitieve taken en domeinen 
(episodisch geheugen, aandacht en werkgeheugen, informatieprocessnelheid en uitvoerende 
functies) verschilde niet tussen de twee groepen. Ook werden de effecten van 24 weken 
krachttraining met en zonder eiwitsuppletie in kwetsbare ouderen onderzocht (hoofdstuk 5). 
Krachttraining zonder extra eiwit (n = 62) verbeterde de scores op het domein van aandacht 
en werkgeheugen. Daarnaast verbeterde krachttraining met eiwitsuppletie (n = 65) de 
informatieprocessnelheid.
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In hoofdstuk 6 en 7 is de rol van vitamine B12 en folaat onderzocht. Lage concentraties van 
deze nutriënten kunnen het homocysteïne gehalte in het bloed verhogen, wat een risicofactor 
is voor cognitieve achteruitgang. In ouderen met een verhoogde concentratie homocysteïne 
werd daarom onderzocht wat het effect was van dagelijkse suppletie van 500 µg vitamine 
B12 en 400 µg foliumzuur gedurende twee jaar, vergeleken met een placebo op cognitief  
functioneren (n = 856-2919) (hoofdstuk 6). Na twee jaar bleek er geen verschil te zijn in 
domeinscores (episodisch geheugen, aandacht en werkgeheugen, informatieprocessnelheid, 
en uitvoerende functies) tussen de B-vitaminegroep en de placebogroep. Wel was er een 
klein significant verschil op globaal cognitief  functioneren, gemeten met de Mini-Mental 
State Examination (MMSE, p = 0.05). Twee jaar na de start van de interventie zijn er in 
een subgroep (n = 218) MRI hersenscans gemaakt om volumes van grijze en witte stof  en 
totaal hersenvolume te bepalen (hoofdstuk 7). Middels regressieanalyses zijn de associaties 
onderzocht tussen bloedconcentraties van folaat, homocysteïne en drie markers voor 
vitamine B12 status (serum vitamine B12, methylmalonzuur, en holotranscobalamine) met 
hersenvolumes. Volledig gecorrigeerde regressiemodellen lieten een marginaal-significante 
associatie zien tussen plasma homocysteïne en totaal hersenvolume, waarbij de associatie 
sterker was in de groep die de B-vitaminesuppletie had ontvangen dan in de placebogroep. 
Serum vitamine B12 en holotranscobalamine waren niet geassocieerd met hersenvolumes, 
terwijl hoge concentraties methylmalonzuur geassocieerd waren met minder hersenvolume 
in de groep die B-vitaminen had gehad. Hogere folaatconcentraties bleken geassocieerd met 
een kleiner hersenvolume. Verder had de groep die B-vitaminen had gekregen een kleiner 
totaal hersenvolume dan de placebogroep, hetgeen mogelijk verklaard kan worden door het 
leeftijdsverschil van twee jaar tussen de groepen. 
De conclusie van dit proefschrift is dat de voedingsinterventies slechts kleine tot geen 
effecten op cognitief  functioneren laten zien in relatief  gezonde ouderen. Desalniettemin 
blijft onderzoek naar risicofactoren voor dementie, inclusief  voeding, belangrijk. Dit kan 
door middel van grote, lange-termijn observationele en interventiestudies, met gevoelige 
studiepopulaties en vroege biomarkers (bijvoorbeeld met MRI scans of  bloedmarkers) voor 
cognitieve achteruitgang in combinatie met neuropsychologische testen. Op deze manier zal 
duidelijk worden op welke manier voeding kan bijdragen aan de strijd tegen dementie. 
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Yes, het is af! Ik heb met veel plezier aan dit proefschrift gewerkt, maar ik had het zeker niet 
alleen kunnen doen; dankzij de bijdrage van vele anderen is het geworden zoals het nu is.
Allereerst wil ik mijn (co-)promotoren bedanken. Lisette, ik zag het een paar jaar geleden zelf  
misschien nog niet zo duidelijk voor me, een proefschrift, maar dankzij jouw vertrouwen is 
het gelukt. Bij verschillende keuzemomenten probeerde jij me aan het denken te zetten en 
uit te dagen tot het daadwerkelijk maken van een keuze. Ik vond je rustige en bedachtzame 
manier van werken en de vrijheid die je me gaf, erg prettig. Ondine, wat ontzettend fijn dat 
ik jou altijd alles kon vragen. Werd je nooit moe van mij als ik je deur weer eens plat liep 
of  je mailbox liet overlopen? Altijd kon je helpen en kwamen we tot een oplossing. De 
congresbezoeken waren nuttig en inspirerend, maar vooral ook erg gezellig. Ook jij wilt altijd 
alles tegelijk doen, soms was haasten om vanuit het zwembad op tijd aan tafel te zitten ;-). 
Rosalie, jouw levendigheid en interesse, en je instelling dat het allemaal wel goed kwam, was 
enorm fijn. (Onbewust?) gaf  je me soms net dat beetje meer vertrouwen om iets af  te maken 
en ergens tevreden mee te zijn, dank daarvoor. 
Edith, Monique en Marcel, bedankt dat jullie mijn proefschrift wilden lezen en beoordelen. 
Martha, thank you for coming all the way to the Netherlands to be part of  my thesis 
committee.
Marlou, wat is het alweer lang geleden dat wij als twee groentjes begonnen bij dat o zo 
drukke ProMuscle. Soms amper tijd om te ademen, maar gelukkig wel tijd voor teamuitjes, 
pubquizen, en het kijken van het Nederlands elftal (met een lekker bammetje erbij ;-)). 
Mikey-Mike, dank voor het vertrouwen dat je ons gaf  met alle verantwoordelijkheden die we 
kregen. Jij weet wel hoe je een goed team om je heen moet bouwen! Imre en Thomas, jullie 
hadden de sfeer er vanaf  het begin goed in, leuk om met jullie samen te werken!
B-PROOF was al up and running toen ik erbij kwam; Janneke, Paulette, Elske, en Rosalie, 
wat hadden jullie al een werk verzet! In de B-PROOF kamer als ontmoetingspunt hebben we 
heel wat uurtjes samen doorgebracht om al het werk rond te krijgen, en, oké, ook om heel 
veel (persoonlijke) dingen te bespreken. Livia en Anouk, gezellig om jullie ook een tijd bij 
het team gehad te hebben. De collega’s uit Rotterdam en Amsterdam: Karin, Anke, Suzanne, 
Annelies, en Evelien, dank voor de goede samenwerking. Elisa, leuk om samen een paper te 
schrijven. Ook natuurlijk dank aan Natasja, Nathalie, André en Paul voor de coördinatie van 
B-PROOF.
Zonder de hulp van alle studenten en vrijwilligers zouden de studies in dit proefschrift een 
stuk minder voorspoedig zijn verlopen, dank voor jullie hulp, toewijding en gezelligheid. 
Natuurlijk ook grote dank naar alle deelnemers; zonder u waren deze projecten nooit 
mogelijk geweest. Ik vond het ontzettend leuk en leerzaam om met u te werken.
Daarnaast wil ik alle co-auteurs bedanken voor hun input, suggesties en kritische blik. Roy, 
jij was mijn cognitievraagbaak. We hebben elkaar niet vaak gezien, maar des te meer gemaild 
en altijd was je enthousiast en behulpzaam, dank daarvoor. Frans, mede dankzij jou kon ik 
aan mijn proefschrift beginnen. Dank voor het vertrouwen en je interesse in het cognitie- en 
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hersenonderzoek. Paul Smeets, bedankt voor de hulp bij het opstarten van de MRI scans en 
voor het meedenken bij het analyseren van de scans. Mannen uit Maastricht, bedankt!
Met de hulp van het ondersteunend personeel werd een deel van het werk makkelijker 
gemaakt. Karen en Jacqueline, fijn dat ik altijd bij jullie kon binnenlopen voor allerhande 
vragen. Anita, Jantien, Diana, en Lucy; volgens de deelnemers waren jullie allemaal erg goede 
bloedprikkers. Bedankt voor jullie flexibiliteit en de hulp om de soms logistiek-uitdagende 
testdagen rond te krijgen.
De (epische) ouderencollega’s Elske, Anouk, Margot, Roland en Evelien: goeie matties voor 
de lunch, spelletjes en vrijdagmiddagborrels. Canan en Janne, jullie kritische blik tijdens de 
Epic-meetings was erg nuttig bij het MRI paper. Agnes, leuk dat je meeging naar de cognitie-
congressen! Anne, gezellig om jou het laatste jaar als kamergenootje te hebben. Alle andere 
afdelingsgenootjes, bedankt voor de gezellige tijd en jullie hulp bij van alles. 
Kippen (Eline, Maartje, Marjolein, Floor, Linda en Renske): Wat is het fijn om je hoofd leeg 
te maken door af  en toe een avondje te gaan dansen, en dank voor het meedenken over 
titels, covers, en mijn verdere carrière. Niels, naast gezellige etentjes op de Zuidas hielp je me 
ook verder met wat cognitieve zaken waar ik zelf  toch altijd net iets minder van wist dan jij 
(terwijl ik er ook op promoveer!). Wageningen-crew (Thijs, Bente, Thomas, Bart en Laura), 
onze dates zijn nog altijd ontzettend gezellig, en fijn dat jullie snappen waar ik mee bezig 
was. Psychotellers en andere vrienden, dank voor jullie interesse en de nodige balans aan te 
brengen tussen werk en vrije tijd.
Elske, wat een tijd hebben wij achter de rug! We leken wel een getrouwd stel als we elkaars 
zinnen weer eens afmaakten. Tof  dat je mijn paranimf  wilt zijn. Ik heb veel geleerd van jouw 
analytische blik en onze (werk)gesprekken. Onze reisjes naar de US, Dortmund en Milaan 
zullen niet snel overtroffen worden. En waarom eigenlijk altijd zo haasten; die metro wacht 
wel ;-).
Schoonfamilie, leuk dat jullie altijd zo geïnteresseerd en behulpzaam zijn! In die drukke 
laatste fase hebben we door de voedselaanvoer vanuit Hulst toch nog gezond kunnen eten 
;-). Ellen, jouw enorme enthousiasme is aanstekelijk! Ik kijk uit naar jouw boekje, succes de 
laatste maanden. 
Familie, dank voor jullie vertrouwen en interesse. Lieve omaatjes, jullie zijn schatten en ik vind 
het altijd erg leuk om met jullie over mijn onderzoek te praten. Paps en mams, jullie tweede 
dochter die promoveert! Dank voor jullie vertrouwen, steun, goede zorgen en de opbeurende 
woorden wanneer die nodig waren. Alex, leuk om te zien dat je als kleine broertje ook helemaal 
je eigen leven hebt nu. Carmen, de rollen zijn nu omgedraaid, wat fijn dat je mijn paranimf  
wilt zijn! Bedankt dat ik altijd bij jou terecht kan en voor je hulp bij de lay-out; dankzij jouw 
doorgehakte knopen en geperfectioneer is dit boekje zo mooi geworden.
Lieve Chris, dank dat jij er voor me bent en voor me gezorgd hebt tijdens die drukke 
periodes. Jouw vertrouwen in mij is oneindig! Je goede ideeën heb ik misschien niet altijd 
gebruikt, maar ik was blij dat je met me mee dacht en zo nu en dan de hele boel voor me 
relativeerde. En nu heb ik eindelijk weer alle tijd om na te denken over nieuwe mooie reizen 
met jou :-).
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